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Colorectal cancer
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and 
the second in females, with worldwide over 1.3 million new cancer cases and over 
650’000 deaths reported each year (Torre et al., 2015). The incidence of CRC is strongly 
age-dependent, increasing from the age of 40 years and reaching an average age of 
70 years in the general population (Haggar and Boushey, 2009). CRC is not a single 
disease, but rather a heterogeneous group of malignancies originating from precursor 
cells within the gastrointestinal tract between the cecum and the anus (Hamilton et 
al., 2000). Clinically, these malignancies can differ in (i) localization (e.g. proximal 
or distal), (ii) pathology/histology (e.g. adenocarcinoma/serrated adenocarcinoma) 
and (iii) invasiveness/metastatic behaviour (e.g. loco-regional or distant organ site) 
(Hamilton et al., 2000). About 90% of CRCs present as adenocarcinomas originating 
from the epithelial lining of the colon (Fleming et al., 2012). Other types of CRC 
include neuroendocrine, adenosquamous, signet ring cell, squamous cell, spindle cell 
and undifferentiated carcinomas (Fleming et al., 2012). Although every CRC is unique, 
it is generally believed that tumours with similar clinicopathologic characteristics arise 
and behave in a similar way (Ogino and Goel, 2008). Along with the increase in our 
understanding of the pathology and etiology of CRCs in recent decades, improved 
classification systems have been developed (Jass, 2007, Ogino and Goel, 2008). An 
example of this progress is the development of the pathological Dukes classification 
system (Dukes, 1932) to the TNM staging system that grades tumour growth and 
dissemination to lymph nodes and other organ sites (Sobin et al., 2009). Recently, 
high-resolution molecular profiling of somatic mutations has resulted in new insights 
in CRC sub-phenotyping (Cancer Genome Atlas, 2012). While the complete mutation 
profiles are, as yet, complex and not well enough understood to be used in routine 
clinical practice, classification systems have been introduced that primarily rely on 
specific mutation spectra (Jass, 2007).
Etiologic and pathologic hallmarks of CRC
A milestone in the classification of CRCs was achieved when it was first postulated 
in the late 1980’s that CRCs develop via a multistep process that is accompanied by 
the sequential accumulation of genetic mutations, often occurring over many years 
(Vogelstein et al., 1988). A more detailed comprehension of this multistep processes 
may provide a basis for understanding how various developmental and pathological 
characteristics of CRCs contribute to the apparent heterogeneous manifestation of 
this disease.
 
The first formulation of the multistep carcinogenic process was postulated by 









chromosomal instability (CIN) (Figure 1.1a) (Fearon and Vogelstein, 1990). The 
CIN pathway includes molecular events that occur during the development from 
hyperproliferative colon epithelium to adenomatous lesions and, finally, invasive 
adenocarcinoma. It has been put forward that mutations in so-called ‘gatekeeper 
genes’ are the major drivers of tumorigenesis (Vogelstein and Kinzler, 2004). Based 
on a genetic study of early adenomatous lesions it was found that the majority of the 
earliest lesions carry a mutated, inactive, APC gene (Powell et al., 1992). Concurrently, 
it was found that the frequency of inactivating APC mutations remained constant as 
tumours progressed from benign to malignant stages (Powell et al., 1992). Based on 
these findings, inactivation of APC was proposed to represent an initiating event of the 
CIN pathway. Another genetic event conferring neoplastic properties to colonic cells 
was found to occur in the KRAS proto-oncogene in intermediate adenomas (Fearon 
and Vogelstein, 1990, Vogelstein et al., 1988) (Figure 1.1a). Currently, it is thought 
that additional mutations that further propagate or ‘drive’ tumour development target 
genes and/or pathways that lead to various developmental and pathological hallmarks 
of cancer. These hallmarks include, for instance, the evasion from growth control 
(TGF-β signalling (Markowitz et al., 1995)), the acquisition of chromosomal/mitotic 
instability (spindle-assembly checkpoint (Cahill et al., 1998, Fodde et al., 2001)) and 
the loss of cell cycle control and apoptosis (P53 pathway (Baker et al., 1989)). As a 
consequence, mutations that are required for CRC development can affect any of the 
pathways mentioned, which hence may lead to molecular and genetic heterogeneity 
(Fearon, 2011). In addition to the CIN pathway, at least two alternative pathways have 
been proposed, i.e., the CpG island methylator phenotype (CIMP) pathway and the 
microsatellite instability (MSI) pathway (Figure 1.1B).
The CIMP and MSI pathways are characterized by different mutational mechanisms, 
but they also lead to the acquisition of cancer-specific features reminiscent to those 
seen in the CIN pathway (Figure 1.1B) (Fearon, 2011). The CIMP phenotype is related 
to widespread promoter CpG island methylation (Jass, 2007, Ogino and Goel, 2008). 
Tumours with a CIMP ‘high’ phenotype are thought to arise from sessile serrated 
adenomas and these tumours carry specific mutations in the BRAF gene reminiscent 
to those encountered in the KRAS gene in CIN tumours (Fearon, 2011). It has been 
suggested that the CpG island methylation observed may silence specific tumour-
related genes, including the mismatch repair gene MLH1, which may give rise to 
microsatellite instable tumours (Jass, 2007, Ogino and Goel, 2008). MSI-positive 
tumours tend to have stable karyotypes (CIN-negative). Instead, their genomes feature 
instability at e.g. mono- or dinucleotide repeats such as (A)n or (CA)n, referred to as 
microsatellites (Vilar and Gruber, 2010). The MSI phenotype can also manifest itself 
independent of CIMP. It has been shown that biallelic somatic mutations in the MLH1 
or MSH2 genes can explain a sizeable fraction of tumours that are characterized by 
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microsatellite instability (Carethers, 2014, Mensenkamp et al., 2014, Geurts-Giele et 
al., 2014). These tumours tend to feature KRAS mutations more frequently than CIMP 
tumours (Jass, 2007, Ogino and Goel, 2008). It should be noted, however, that the 
CIN, CIMP and MSI pathways are non-exclusive, and that alternative pathways and 
clinical entities are still being discovered as well (Al-Tassan et al., 2002, Jones et al., 
2002, Lipton et al., 2003, De Sousa et al., 2013, Palles et al., 2013, Nieminen et al., 
2014, Weren et al., 2015). In addition to somatic mutations, also, germline mutations 
may affect the ultimate tumour characteristics.
CRC predisposition syndromes
Concurrent with the formulation of the adenoma-carcinoma sequence in sporadic 
tumours, fine mapping of genomic lesions in the germline of patients with the familial 
adenomatous polyposis (FAP) syndrome has pointed at the same APC gene (Groden 
et al., 1991, Kinzler et al., 1991, Nishisho et al., 1991). It is assumed that in these 
patients germline inactivation of one APC allele markedly increases the chance of 
adenoma formation and that inactivation of the second APC allele is a critical (rate-
limiting) event in adenoma formation (Figure 1.1C) (Fearon, 2011). Presumably, once 
adenomas in FAP have developed, they progress at a rate akin to that seen in sporadic 
adenomas because of the need to acquire additional rate-limiting mutations for 
carcinoma development (Figure 1.1C) (Fearon, 2011).
Subsequently, the genes underlying the development of a second distinct group 
of familial tumours, now known as Lynch Syndrome, were identified. Patients with 
this syndrome differ from FAP patients in that they generally show a non-polyposis 
phenotype, with CRCs at a relatively young age and an excess of extra-colonic tumours 
(Lynch and de la Chapelle, 2003). The genes underlying Lynch Syndrome that were 
consecutively identified include MSH2 (Fishel et al., 1993, Leach et al., 1993), MLH1 
(Bronner et al., 1994, Papadopoulos et al., 1994), PMS2 (Nicolaides et al., 1994) and 
MSH6 (Miyaki et al., 1997). In addition, our group found that 3’ EPCAM deletions 
underlie a heritable form of epigenetic silencing of the MSH2 gene (Ligtenberg et 
al., 2009). It has been proposed that Lynch tumours result from major increases in 
mutation rates in the adenomatous lesions itself, thus leading to an accelerated 
progression towards carcinomas (Figure 1.1C) (Fearon, 2011).
To facilitate the identification of individuals at risk for CRC development, clinical 
guidelines have been issued (Stoffel and Boland, 2015), including (i) a strong family 
history of colorectal cancers or polyps, (ii) multiple primary cancers in a patient with 
CRC, (iii) the occurrence of other cancers within a kindred consistent with a known 
CRC causing syndrome, and (iv) a relatively young age at the initial time of diagnosis. 









FAP will generally be suspected in patients when at least 100 colonic adenomas are 
identified (Vasen et al., 2015), and the presence of microsatellite instability (MSI) in the 
tumour in combination with a positive family history may serve as hallmarks of Lynch 
syndrome (Umar et al., 2004). Besides the specific application to identify patients for 
example in FAP and Lynch syndrome such clinical guidelines have also been used to 
distinguish additional CRC predisposing syndromes from sporadic forms of CRC. 
 
Figure 1.1 Pathways underlying sporadic and hereditary forms of CrC. Carcinomas arise as a result of a multistep 
process. (A) The archetype of this model: the chromosomal instability (CIN) pathway. The initiating event in this pathway is 
loss of APC tumour suppressor activity due to biallelic mutations or deletions in APC. A second mutation in KRAS may lead 
to an intermediate stage, an adenomatous lesion. The acquisition of additional mutations may lead to the development 
of a full-blown carcinoma, including chromosome instability, after which the pathway is named. (B) Two conceptually 
similar formulations involving the microsatellite instability (MSI) pathway and the CpG island methylator phenotype (CIMP) 
pathway, respectively. Normally, the acquisition of the anomalies can take decennia. (C) In a subset of CRC patients, 
germline mutations in the APC gene (FAP) or the mismatch repair genes (Lynch (Syndrome)) may lead to accelerated 
progression along the CIN and MSI pathways, resulting in an average earlier onset of CRC. Figure modified from (Fearon, 
2011).
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Additional CRC predisposition syndromes
In addition to the most prevalent FAP and Lynch syndromes, germline mutations and 
aberrations in pathways relevant to cancer development have been identified in more 
rare highly penetrant Mendelian CRC predisposition syndromes (Table 1.1). Many 
of these genes were identified through targeted investigation of candidate genes. 
Among the first syndromes to be discovered this way were the hamartomatous 
polyposis syndromes Peutz-Jegher’s syndrome (PJS) and juvenile polyposis syndrome 
(JPS). These syndromes are characterized by mutations in the chromatin remodelling 
gene LBK1/STK11 (Hemminki et al., 1998, Jenne et al., 1998) and the TGF-β signalling 
genes SMAD4 and BMPR1A (Howe et al., 1998, Howe et al., 2001), respectively. In 
later studies autosomal recessively inherited mutations in the DNA repair gene MUTYH 
were found to give rise to a specific subtype of polyposis, referred to as MUTYH-
associated polyposis (MAP) (Al-Tassan et al., 2002). Recently, genome-wide screening 
efforts led to the identification of mutations affecting the expression of GREM1 as 
the cause of hereditary mixed polyposis syndrome (HMPS) (Jaeger et al., 2012) and 
mutations in the POLD1 and POLE genes as the cause of polymerase proofreading-
associated polyposis (PPAP) syndrome (Palles et al., 2013). In addition, our group very 
recently identified mutations in the NTHL1 gene as the cause of NTHL1-associated 
polyposis (NAP) syndrome (Weren et al., 2015).
 
Besides the above mentioned Mendelian CRC syndromes, CRC predisposition has also 
been observed in patients affected by various developmental syndromes (Table 1.1), 
including Bloom syndrome, which is caused by mutations in the BLM gene (Balci and 
Aktas, 1999). Also oligodontia-colorectal cancer syndrome, which is caused by defects 
in the AXIN2 gene, is associated with CRC predisposition (Lammi et al., 2004). In 
addition, an increased CRC risk has been reported in cases of Cowden syndrome 
(Pilarski, 2009) and Li-Fraumeni syndrome (Wong et al., 2006), which are caused 
by defects in the AKT signalling regulator PTEN and the cell cycle regulator TP53, 
respectively.
Missing heritability of CRC
Together, the above-mentioned Mendelian cancer syndromes account for ~5-10% of 
the total burden of CRC (Lynch and de la Chapelle, 2003) (Figure 1.2). Based on twin 
studies from the Swedish, Danish and Finnish twin registries the heritability of CRC was 
suggested to be on average ~30% (range: 15-45%) (Lichtenstein et al., 2000, Grady, 
2003, Mucci et al., 2016). The apparent discrepancy between the fraction accounted 
for by Mendelian cancer syndromes and the aforementioned estimates have led to 
the notion of ‘missing heritability’ (Risch, 2001, Czene et al., 2002, Jiao et al., 2014). 
It is thought that this missing heritability may be multifactorial in nature, i.e., may 









conjunction with environmental factors, may fail to give rise to clear-cut dominant 
or recessive inheritance patterns (Bodmer and Bonilla, 2008). These more common 
forms include high-risk Mendelian non-syndromic forms of CRC, intermediate familial 
risk forms of CRC and relatively low-risk forms of CRC that depend on interactions 
between genetic and environmental factors (de la Chapelle, 2004, Bodmer and Bonilla, 
2008) (Figure 1.2).
 
Table 1.1: Known CRC predisposition syndromes and CRC associated cancer syndromes, 
including the genes and pathways involved.
Syndromes Genes involved Pathways involved




Lynch syndrome MSH2, EPCAM, MLH1, MSH6, PMS2 Mismatch repair cascade
Peutz-Jegher’s syndrome STK11 Chromatin remodeling cascade






MUTYH-associated polyposis syndrome MUTYH Base-excision repair cascade
NTHL1- associated polyposis syndrome NTHL1 Base-excision repair cascade
other Mendelian syndromes associated with CrC
Bloom syndrome BLM RecQ-DNA helicase cascade




Li-Fraumeni syndrome TP53 Cell-cycle control cascade
In the search for this missing heritability, two contrasting hypotheses have been put 
forward: the common disease-common variant (CDCV) hypothesis and the common 
disease-rare variant (CDRV) hypothesis (Gibson, 2011). The CDCV hypothesis postulates 
that low-risk susceptibility variants occurring in >1% of the population may contribute 
to the development of CRC (Gibson, 2011). In contrast, the CDRV hypothesis postulates 
that many rare variants, with frequencies <1% in the population, may contribute to 
the development of CRC (Bodmer and Bonilla, 2008, Gibson, 2011). Most of the 
initial candidate gene studies lacked the power and genomic resolution to address 
this latter hypothesis (Ma et al., 2014) and high-throughput identification of variants 
found in more than 1% of the population only became feasible after the introduction 
of massively parallel genotyping techniques enabling genome-wide association studies 
(GWAS).
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Figure 1.2: distribution of CrC cases by familial background. Colorectal cancers can be divided into isolated cases, 
familial cases and hereditary cases. The latter are resulting from known predisposition syndromes, like Lynch syndrome and 
familial adenomatous polyposis (FAP) syndrome. Additional minor syndromes include polymerase proofreading-associated 
polyposis (PPAP), MUTYH-associated-polyposis (MAP), Peutz-Jegher’s syndrome (PJS), Juvenile Polyposis syndrome (JPS), 
NTHL1-associated polyposis (NAP), and other colorectal cancer associated syndromes as described in the main text. 
Currently, these forms of CRC predisposition account for 5%-10% of all cases. The black dots represent additional early-
onset cases below the age of 50, which were the subject of investigation in this thesis. About ~10% of CRC cases belong 
to this group. These cases can thus be familial or sporadic in origin and may result from variability in penetrance of the 
underlying risk alleles as described in the text. Modifi ed from (Burt, 2000, Lynch et al., 2004).
Genome-wide association studies
Since 2007, several genome-wide association studies (GWAS) have been conducted 
under the premise of the CDCV hypothesis for CRC (Broderick et al., 2007, Tomlinson 
et al., 2007, Zanke et al., 2007, Houlston et al., 2008, Tenesa et al., 2008, Tomlinson 
et al., 2008, Houlston et al., 2010, Lascorz et al., 2010, Cui et al., 2011, Figueiredo et 
al., 2011, Dunlop et al., 2012, Jiao et al., 2012, Fernandez-Rozadilla et al., 2013, Hong 
et al., 2013, Jia et al., 2013, Peters et al., 2013, Siegert et al., 2013, Figueiredo et al., 
2014, Whiffi n et al., 2014, Zhang et al., 2014b). These studies aimed to use unbiased 
genome-wide screens to identify non-random associations of alleles at nearby loci 
(linkage disequilibrium), which then served as proxies, or tagSNPs, for other nearby 
risk alleles (Stadler et al., 2010). To adequately power the detection of risk variants 









discovery phase have steadily been growing from roughly 1000 cases and controls 
included in the initial studies (Broderick et al., 2007, Tomlinson et al., 2007, Zanke 
et al., 2007) to (meta)analyses of several 10’000 samples in the more recent studies 
(Theodoratou et al., 2012, Peters et al., 2012, Peters et al., 2013). In addition to these 
large cohorts, recent studies have also started to address the involvement of multi-
ethnic disease loci (Schmit et al., 2014).
Together, GWAS have led to the identification of approximately 25 distinct CRC risk 
loci (Dunlop et al., 2013, Jiao et al., 2014). Some of the variants associated with CRC 
risk are in or near genes implicated in relevant functional pathways, such as the DNA 
repair (Dunlop et al., 2012), TGF-ß and MYC signalling pathways (Broderick et al., 
2007, Tenesa et al., 2008, Tomlinson et al., 2008, Houlston et al., 2008, Peters et al., 
2012, Peters et al., 2013). As yet, however, a major fraction of the associated variants 
cannot be placed within any functional context (Hindorff et al., 2009). Due to the 
small effect sizes of the loci identified in GWAS, the clinical utility of the outcome of 
these studies has so far been limited (Dunlop et al., 2013, Jiao et al., 2014). It has been 
estimated that individuals carrying multiple lowly penetrance risk loci may have a 1-2 
fold increase in their lifetime CRC risk (Dunlop et al., 2013). Together, these common 
variants, including those that remain to be discovered, may explain 5-10% of the 
heritability of CRC (Dunlop et al., 2013), suggesting that a substantial fraction of its 
heritability may still be missing.
Common disease - rare variant hypothesis
The remainder of the CRC risk may be due to rare variants causing common non-
Mendelian forms of CRC (CDRV paradigm) (Bodmer and Bonilla, 2008). Features 
reminiscent to those of Mendelian syndromes characterize these CRCs in that they 
may occur at relatively young ages and may be found as familial aggregates. They 
are, however, distinct from the above-mentioned Mendelian forms in that the CRC 
patients usually do not exhibit a clearly recognizable clinical phenotype. Examples of 
the latter are the identification of germline mutations in the EPHB2 and GALNT12 
genes through targeted screens of familial CRC patients (Zogopoulos et al., 2008, 
Guda et al., 2009, Clarke et al., 2012). Additionally, our group has previously 
implicated PTPRJ (Venkatachalam et al., 2010), and BUB1 and BUB3 (de Voer et al., 
2013) variants in familial and early-onset CRC cases without polyposis and/or loss of 
mismatch repair capacity, which is again indicative of a contribution of rare variants to 
CRC predisposition.
Based on current knowledge of CRC susceptibility, a model has been suggested and 
expectations about the remaining genetic risk factors have been formulated (depicted 
in Figure 1.3). According to this model, one side of the risk spectrum represents the 
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highly penetrant variants underlying e.g. Mendelian cancer syndromes, and the other 
side of the risk spectrum represents the common low-penetrance variants identified 
by GWAS (de la Chapelle, 2004, Manolio et al., 2009). It has been suggested that 
the majority of the missing heritability may involve variants with low minor allele 
frequencies (MAF), defined here as 0.5% < MAF < 5%, or rare variants (MAF <0.5%) 
(Manolio et al., 2009). Such variants are not frequent enough to be captured by 
current GWAS, nor do they exhibit sufficiently large effect-sizes to be detected by 
classical linkage analyses in families (Manolio et al., 2009). Indeed, many of the above-
mentioned examples of rare variants fall into this category (Manolio et al., 2009). 
Recently, the possibility has arisen to study more rare genomic variants through 
unbiased genome-wide screens using massively parallel sequencing (MPS) (Metzker, 
2010, Mardis, 2013) (Figure 1.3). Indeed, recent reports implicating variants in RPS20 
(Nieminen et al., 2014) and FAN1 (Segui et al., 2015b) in familial CRC predisposition 
support the potential of MPS to identify rare variants with a moderate penetrance.
Massively parallel sequencing and cancer predisposition
While it took almost 20 years for the first draft of the human genome to be completed 
(Lander et al., 2001, Venter et al., 2001), the recent application of MPS, and in 
particular whole-exome and whole-genome sequencing (WES and WGS, respectively), 
allows the generation of comparable data within a few days at highly reduced costs 
(Metzker, 2010, Geurts van Kessel, 2014, Sie et al., 2014). Particularly for Mendelian 
traits, MPS has allowed the identification of numerous disease genes (reviewed in 
(Bamshad et al., 2011, Gilissen et al., 2012, Chong et al., 2015, Taylor et al., 2015)) 
including a number of genes underlying rare highly penetrant well-phenotyped cancer 
predisposition syndromes. For CRC, this approach has resulted in the identification of 
distinct syndromes, such as PPAP (Palles et al., 2013) and NAP (Weren et al., 2015), 
which are caused by rare variants with a presumably high penetrance. Currently, it is 
unclear how many CRC cases these syndromes cause, as the exact frequencies of the 
underlying variants still have to be established.
Next to these highly penetrant risk factors, the identification of lowly to moderately 
penetrant CRC risk factors remains of major interest (Chang et al., 2012). Their 
identification, however, remains complex. Several factors may underlie the complexity 
and limited success of these studies. First, many large-scale sequencing projects have 
yielded the conclusion that the human genome harbours a plethora of non-causative, 
possibly detrimental, rare variants (Cooper and Shendure, 2011, Marth et al., 2011, 
Keinan and Clark, 2012, MacArthur et al., 2012a, Tennessen et al., 2012, Gudbjartsson 
et al., 2015). As a result, it has become a major interpretation challenge to point out 
the causative variants and genes within a vast number of candidates. Secondly, these 









on the phenotype may rely on an interplay with other genetic and/or environmental 
factors (de la Chapelle, 2004). Consequently, not all referral criteria used for the 
identification of high-risk syndromes as outlined above may apply. Conversely, the 
distinction from individuals with sporadic non-inherited tumours is not clear-cut, 
making it impossible to distinguish between cases with- or without predisposition on a 
case-by-case basis. Thirdly, since corroborative evidence is still missing for many novel 
candidates, and many variants and genes remain to be discovered, there is a lack of 
knowledge about the biological specifications of such variants. In conclusion, although 
there is a demand and potential for the identification of moderately penetrant risk 
factors, their identification is still challenging in lack of an a priory clear-cut strategy
Technology 
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Figure 1.3: Model explaining the penetrance of genetic risk factors for CrC. In the top panel, the genetic risk 
factors are shown. The risk factors that, according to current knowledge, do contribute most to CRC are shown in the grey 
shaded bar. Highly penetrant mutations, like those found in FAP syndrome, Lynch syndrome and other hereditary/familial 
conditions, are at the top left side of this plot. Usually, these syndromes are caused by very rare mutations. At the lower 
right side common low-penetrance risk factors are depicted. In between these two extremes rare moderately penetrant risk 
factors may exist that still await discovery. The bottom panel marks the technologies that have led to the discovery of the 
various genetic risk factors, i.e., the light grey bar marks highly penetrant risk factors that have been identified by linkage 
analysis, the black bar marks risk factors that have been identified by GWAS. In addition, massively parallel sequencing 
(MPS) may allow the identification of further moderately penetrant risk factors between these two extremes (dark grey bar).
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Aim and outline of the thesis
At the beginning of this work in 2010, massively parallel sequencing (MPS) emerged 
as a new promising approach for the identification of (novel) moderately to highly 
penetrant disease risk factors. The aim of the work described in this thesis was to 
apply this technique, in terms of whole-exome sequencing as well as targeted re-
sequencing, to the detection and characterization of rare genetic variants underlying 
CRC predisposition without a strong family history as discussed above. We, therefore, 
set out to investigate a large cohort of early-onset cases with and without a (suspected) 
family history of CRC (Supplementary Table 6.1). We performed whole-exome 
sequencing on these unexplained early-onset CRC patients (chapter 2 and (De Voer 
et al., 2016)). In doing so, we identified recurring variants in novel candidate CRC 
predisposing genes, including LRP6 and PTPN12. In addition, a recurrent carriership 
of BLM mutations was found. In chapter 3 (de Voer et al., 2015) we performed an 
extended study of pathogenic BLM mutations in early-onset CRC predisposition as 
compared to healthy controls, concluding that carriers of pathogenic BLM variants 
are at an increased risk to develop CRC, albeit small. In chapter 4 and chapter 5, we 
expand the application of targeted MPS to follow up on two of our previous studies 
(de Voer et al., 2013, Neveling et al., 2013) to assess the contribution of phenotypically 
heterogeneous conditions to early-onset CRC. In doing so, we identified hitherto 
unrecognized cases with biallelic MUTYH deficiencies and a lack of an overt polyposis 
phenotype in our cohort (chapter 4). In chapter 5 we only found two rare variants 
in BUB1B, which both of these seem to be benign, suggesting that BUB1B is not 
frequently mutated in early-onset CRC cases. Finally, in chapter 6 a perspective of 
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Approximately 30% of colorectal cancer (CRC) cases are expected to result from a 
genetic predisposition, but in only 5-10% of these cases highly penetrant germline 
mutations are found. The remaining CRC heritability is still unexplained, and may 
be caused by a hitherto-undefined set of rare variants with a moderately penetrant 
risk. Here we aimed to identify novel risk factors for early-onset CRC using whole-
exome sequencing, which was performed on a cohort of CRC individuals (n=55) with 
a disease onset before 45 years of age. We searched for genes that were recurrently 
affected by rare variants (minor allele frequency ≤0.001) with potentially damaging 
effects and, subsequently, re-sequenced the candidate genes in a replication cohort of 
174 early-onset or familial CRC individuals. Two functionally relevant genes with low 
frequency variants with potentially damaging effects, PTPN12 and LRP6, were found 
in at least three individuals. The protein tyrosine phosphatase PTP-PEST, encoded by 
PTPN12, is a regulator of cell motility and LRP6 is a component of the WNT-FZD-LRP5-
LRP6 complex that triggers WNT signalling. All variants in LRP6 were identified in 
individuals with an extremely early-onset of the disease (≤30 years of age), and two 
of the three variants showed increased WNT signalling activity in vitro. In conclusion, 
we present PTPN12 and LRP6 as novel candidates contributing to the heterogeneous 
susceptibility to CRC.
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Colorectal cancer (CRC) is a heterogeneous disease with an estimated heritable 
component in around 30%. About 5-10% of CRC cases are currently explained by 
germline mutations in genes that predispose to Mendelian cancer syndromes, such 
as Lynch syndrome, Familial Adomatous Polyposis, Peutz-Jegher’s syndrome, Juvenile 
Polyposis syndrome, MUTYH-associated polyposis, NTHL1-associated polyposis, and 
Polymerase Proofreading-associated Polyposis syndrome (Lynch and de la Chapelle, 
2003, de la Chapelle, 2004, Palles et al., 2013, Dunlop et al., 2013, Weren et al., 
2015). Typically, these CRC syndromes are marked by a strong family history, a high 
penetrance of the disease, and the development of multiple tumours at an early age 
(Lynch and de la Chapelle, 2003). An additional 10% of the heritability of CRC may 
be explained by a growing list of common, lowly penetrant risk factors (Theodoratou 
et al., 2012, Dunlop et al., 2012, Zhang et al., 2014a). In spite of this, a large part of 
the heritability of CRC still remains unexplained and may well result from the presence 
of rare variants with a moderate risk (Manolio et al., 2009).
Moderately penetrant risk factors do not necessarily result in dominant traits, since 
their phenotypic effects may rely on interplay with other genetic and/or environmental 
factors (de la Chapelle, 2004). However, these genetic factors may play a role in 
individuals with an early-onset of the disease, one of the hallmarks of hereditary cancer 
(Gryfe et al., 2000). In addition, unexplained early-onset CRC cases differ from late-
onset sporadic CRC cases based on their distinct clinical, molecular, and pathological 
etiology (Chang et al., 2012).
Here, we used whole-exome sequencing to identify novel moderately penetrant 
CRC risk factors. Since we expect such factors to follow non-Mendelian inheritance 
patterns, we focused specifically on individuals with an early-onset of the disease, 
which frequently manifests in the absence of a clear family history. We selected 
recurrent rare variants in genes with a low burden of comparable variants in controls, 
and identified PTPN12 and LRP6 as novel candidate risk factors for early-onset CRC.
Materials and Methods
Study samples
The discovery cohort used consists of 55 non-polyposis DNA mismatch repair 
(MMR)-proficient CRC cases, diagnosed at ≤45 years of age, which were referred to 
the Radboud university medical center, Nijmegen, the Netherlands (Table 2.1 and 
Supplementary Table S1) (Neveling et al., 2013, de Voer et al., 2013). The replication 
cohort used consists of 174 MMR-proficient CRC cases from both Nijmegen, The 
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Netherlands, and Dresden, Germany, that fulfilled one of the following two criteria: 
(i) diagnosed with CRC ≤40 years of age (n=90) regardless of family history, or (ii) 
diagnosed with CRC ≤50 years of age with at least two first-degree relatives with CRC 
(n=84). All individuals provided written informed consent. The study was approved by 
the CMO (study number 2009/256), Arnhem and Nijmegen, the Netherlands.
Whole-exome sequencing
Whole-exome sequencing was performed on genomic DNA extracted from peripheral 
blood cells of cases included in the CRC discovery cohort with SOLiD4 (n=10) and 
5500xl (n=45) sequencing platforms (Life technologies, Carlsbad, CA, USA) using 
the SOLiD-optimized SureSelect Human All Exon kit V1 (30Mb set, n=1), V2 (50Mb 
set, n=44) and V4 (50Mb set, n=10; Agilent Technologies, Santa Clara, CA, USA) as 
described previously (de Ligt et al., 2012, de Voer et al., 2013, Neveling et al., 2013). 
Sequencing reads were mapped to the hg19 reference genome using SOLiD LifeScope 
V2.1 software (Life technologies, Carlsbad, CA, USA).
Prioritization of variants
Variants were annotated using an in-house annotation pipeline, as described previously 
(de Ligt et al., 2012, de Voer et al., 2013, Neveling et al., 2013). High-confidence calls 
(i.e. ≥10 reads, ≥5 variant reads, ≥5 unique starts (available only for substitutions) 
and ≥28% variant reads) were filtered for non-synonymous variants that were absent 
in our in-house variant database. This in-house variant database consists of variants 
identified by exome sequencing in 2’037 individuals from mostly Western European 
Ancestry (>95%) that were sequenced using SureSelect Human All Exon kit V2 and 
SOLiD4 sequencers (~64% of exomes), Exon kit V4 and 5500xl sequencers (~25% of 
exomes), or Exon kit V4 and Illumina HiSeq 2500 sequencers (~11% of exomes). All 
SOLiD4 and 5500xl exomes were mapped and called with LifeScope V2.1 software and 
the Illumina exomes were mapped with BWA and called using GATK. All exomes were 
sequenced at a median coverage of at least 50-fold. Next, we removed all variants 
present with a MAF of >0.001 in The National Heart, Lung, and Blood Institute Exome 
Sequencing Project database (6’503 exomes) (Exome Variant Server, 2014), and genes 
that were described to be loss-of-function tolerant (MacArthur et al., 2012b).
Subsequently, variants that resulted in protein truncations (i.e. putative frameshifts, 
nonsense mutations and variants at canonical splice-sites), and non-synonymous 
variants with a PhyloP score ≥3.0 (missense mutations) were selected (Supplementary 
Table S2.3). The remaining list was analysed for variants in known CRC predisposing 
genes and genes that predispose to other types of cancer and/or cause recessive 
cancer syndromes (Neveling et al., 2013, Vogelstein et al., 2013, Rahman, 2014).
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Average age of onset (SD) 35 (4) 40.4 (4.5) 37.7 (5.6)
average age
≤25 yr 2 (4) 1 (1) 1 (1)
25-30 yr 8 (15) 2 (2) 12 (13)
31-35 yr 17 (31) 10 (12) 16 (17)
36-40 yr 26 (47) 21 (26) 27 (29)
40-45 yr 2 (4) 46 (56) 35 (38)
45-50 yr - 2 (2) 1 (1)
Family history for cancer
None 27 (49) 23 (28) 4 (4)
≥one first degree relative 10 (18) 33 (40) 37 (3)
≥one second degree relative 10 (18) 13 (16) 20 (22)
≥one third degree relatives 2 (4) 1 (1) 1 (1)
Unknown 6 (11) 12 (15) 30 (33)
Tumour location
Right colon 8 (15) 7 (9) 15 (16)
Transverse colon 4 (7) 8 (10) 9 (10)
Left colon 13 (24) 13 (16) 25 (27)
Rectum 25 (46) 32 (39) 33 (36)
Unknown 6 (11) 19 (23) 10 (11)
In the next filter step, all recurrent variants and genes recurrently affected were 
selected. This list of variants was subsequently filtered based on the occurrence of 
rare potentially pathogenic variants in a whole-exome sequence data set of 164 
anonymous healthy controls (Control dataset 1) that were extracted from a previous 
study (de Ligt et al., 2012). These exomes were sequenced using a SureSelect Human 
All Exon kit V2 and SOLiD4 sequencers, mapped and called using SOLiD LifeScope 
V2.1 software, after which a filtering approach identical to the one described for our 
CRC discovery cohort was applied. Analysis by a genotype-weighted metric described 
elsewere (Heinrich et al., 2013), revealed that the exomes of the CRC patients and 
those from ‘Control dataset 1’ were comparable, both in terms of genetic origin and 
sequencing performance (Supplementary Figure S2.1). Significance of differences 
between the frequencies of variants in our CRC discovery cohort and this dataset 
of 164 controls were calculated using the χ2 goodness of fit test and a Benjamini-
Hochberg (BH) correction for multiple testing was performed (corrected for 196 genes 
that harboured recurrent variants or were recurrently affected in our CRC discovery 
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cohort). A P-value of ≤0.05 was considered significant before correction. After 
correction a χ2 P-value less than the BH critical value was considered significant. None 
of the genes were significantly enriched in our CRC discovery cohort after correcting 
for multiple testing. Therefore, we continued with the genes that revealed a χ2 
goodness of fit P-value of ≤0.05 before multiple testing. This remaining list of variants 
was subjected to the following prioritization (Figure 2.1): (i) genes recurrently affected 
by protein-truncating variants solely; (ii) potential CRC driver genes (Supplementary 
Table S8) (Cancer Genome Atlas, 2012); (iii) genes identified in transposon-based CRC 
susceptibility studies in mice (Starr et al., 2009, March et al., 2011) and involved in 
CRC-related KEGG pathways [pathways hsa04310 (WNT signalling), hsa04350 (TGF-ß 
signalling), hsa03430 (mismatch repair), hsa03410 (base excision repair), hsa03420 
(nucleotide excision repair), map03450 (non-homologous end-joining), hsa03460 
(Fanconi anemia), and hsa05200 (pathways in cancer)] (Supplementary Table S9); 
and (iv) genes identified through GWAS studies (Dunlop et al., 2012, Theodoratou et 
al., 2012, Zhang et al., 2014a, Welter et al., 2014). Prioritized variants were further 
analysed in silico using software packages Align-GVGD, SIFT and Polyphen-2 integrated 
in the Alamut 2.0 software package (Interactive Biosoftware), and ‘HOPE’ (http://
www.cmbi.ru.nl/hope) was used to assess the structural effects of missense variants 
at the protein level (Venselaar et al., 2010). All selected variants were validated using 
Sanger sequencing.
Comparisons to control populations
To investigate whether the variants we identified were truly rare, we analysed their 
frequency in the dataset from the Exome Aggregation Consortium (Exome Aggregation 
Consortium, 2014) and in an independent exome data set from a cohort of individuals 
of mostly Western-European/Dutch ancestry (Control dataset 2; n=2’329) from which 
paired-end exome sequencing data were available with an average >90-fold coverage 
for our candidate genes (Agilent V4 kit; Illumina HiSeq 2500) (Supplementary Figure 
S2.2). This cohort did not contain any cases with a suspected hereditary form of 
cancer. In addition, we assessed the frequency of potentially pathogenic variants with 
a MAF ≤0.001 in our candidate genes in the latter dataset. Comparisons between the 
Discovery cohort and ‘Control dataset 2’ were performed using the Fisher’s exact test 
followed by a Benjamini-Hochberg correction for the three candidate genes and for 
exome-wide multiple testing. A P-value of ≤0.05 was considered significant.
Targeted re-sequencing
A multiplex AmpliSeq panel (Ion AmpliSeq Designer, Life technologies) was designed, 
targeting all coding exons of EMR3, PTPN12 and LRP6. For library preparation, four 
DNA samples from the replication cohort were equimolarly pooled and used for 
amplification. Libraries were barcoded using Ion Xpress Barcode adapters, run on 
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an OneTouch emulsion PCR system (Life Technologies), and sequenced using three 
Ion 318 chips (Life Technologies). Variant calling and annotation were performed 
using SeqNext (JSI Medical Systems, Kippenheim, Germany). Variants with a MAF of 
≤0.001 in the EVS that resulted in protein truncations, splice-site defects, or missense 
mutations with a PhyloP ≥3.0 were selected and validated by Sanger sequencing in 
the four samples of the subsequent pool. The frequencies of variants in this CRC 
replication cohort and the ‘Control dataset 2’ were calculated using the Fisher’s exact 
test, and a Benjamini-Hochberg correction for multiple testing was performed. A 
P-value of ≤0.05 was considered significant.
lrP6 localization and expression analyses
The human image clone IRCMp5012G1125D (Source BioScience, Nothingham, UK) 
was used to amplify the full-length cDNA of LRP6. This cDNA was subcloned into a 
cTAP vector in front of an in-frame C-terminal Flag-tag using the Gateway cloning 
system (Invitrogen, Carlsbad, CA, USA). Mutations were introduced using site-directed 
mutagenesis, and the open reading frames were confirmed by Sanger sequencing. For 
localization studies, CHO cells were grown on microscope glass slides and transfected 
with the wild-type or mutant LRP6 constructs using an X-tremeGENE transfection 
reagent (Invitrogen). After 48 hrs, cells were fixed, incubated with a rabbit polyclonal 
anti-Flag antibody (Sigma Aldrich, St. Louis, USA), embedded in Vectashield with DAPI, 
and analysed by fluorescence microscopy. Expression of wild-type or mutant LRP6 was 
compared by Western blot analyses using a rabbit polyclonal anti-Flag antibody and a 
goat polyclonal anti-actin antibody (Santa Cruz) and visualized using an Odyssey
infrared system (Li-cor Biosciences, NE, USA).
ToPflash reporter assay
CHO cells were transfected in 96-well plates with wild-type or mutant LRP6 
constructs together with TOP- or FOPflash reporter constructs (plasmid 12456 and 
12457; Addgene, Cambridge, MA, USA) using an X-tremeGENE transfection reagent 
(Invitrogen) (Veeman et al., 2003). The culture medium was refreshed 24 hrs post-
transfection with normal or WNT3a-conditioned medium, and luciferase activity was 
measured after 16 hrs using a Dual-Glo Luciferase kit (Promega) and an InfiniteM200-
Pro plate reader (Tecan). The expression of the reporter was normalized to co-
transfected Renilla luciferase. Differences between wild-type and mutant LRP6 were 
assessed using a student’s t-test. A P-value of ≤0.05 was considered significant. 
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Figure 2.1: Study design, variant fi ltering and candidate gene prioritization. 
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legend to Figure 2.1: Study design, variant filtering and candidate gene prioritization. Whole-exome sequencing 
was performed on germline DNA of 55 early-onset CRC cases. The exome data were first filtered for quality and frequency 
followed by filtering for protein truncating and highly conserved missense variants. Next, we removed all known loss-of-
function-tolerant genes from this list and searched for known and novel CRC predisposing gene variants (Neveling et al., 
2013, Vogelstein et al., 2013, Rahman, 2014). An additional filtering was applied to identify genes that were affected by 
two or more potentially pathogenic variants and to remove genes that are frequently affected by protein-truncating or 
highly conserved missense variants in healthy controls. The remaining set of recurrent variants was filtered for (i) genes 
recurrently affected by protein truncating variants; (ii) cancer driver genes in CRC (Cancer Genome Atlas, 2012); (iii) genes 
identified as CRC susceptibility genes in mice (Starr et al., 2009, March et al., 2011) and involved in cancer-related KEGG 
pathways [hsa04310 (WNT signalling), hsa04350 (TGF-ß signalling), hsa03430 (mismatch repair), hsa03410 (base excision 
repair), hsa03420 (nucleotide excision repair), map03450 (non-homologous end-joining), hsa03460 (Fanconi anemia), and 
hsa05200 (pathways in cancer)] (iv) genes identified in CRC GWAS studies (Dunlop et al., 2012, Theodoratou et al., 2012, 
Welter et al., 2014, Zhang et al., 2014a). Genes that remained after these filter steps were selected for re-sequencing in a 
replication cohort of 174 CRC cases. CRC: colorectal cancer; VUS: variant of unknown significance.
Results
Whole-exome sequencing of early-onset CrC cases
To identify rare genetic variants involved in CRC susceptibility, we performed whole-
exome sequencing on germline DNA from 55 CRC cases, diagnosed at age 45 years or 
younger. The average age at diagnosis was 35 years [range: 23-45] and 22 cases (40%) 
had a positive family history for cancer (Table 2.1 and Supplementary Table S2.1). 
The average coverage per target region was 76x [range: 46-127x] with on average 
43’124 identified variants [range: 29’040-49’929] per exome (detailed metrics per 
exome are listed in Supplementary Table S2.2). In total 2’381’720 variants were 
identified. After quality assessment, common variants were excluded, which were 
defined as variants that are present in our in-house database with 2’037 exomes from 
mostly Western-European ancestry or the Exome variant server (EVS) with minor allele 
frequencies (MAF) >0.001 (Exome Variant Server, 2014). Subsequently, we selected 
variants that result in protein truncation (i.e. frameshift or nonsense mutations and 
variants at canonical splice-sites) and missense substitutions at highly conserved 
positions (non-synonymous variants with a PhyloP score ≥3; see materials and methods 
for a detailed description). We identified on average 34 [range: 10-89] rare variants 
per sample, including on average 5 [range: 1-10] protein truncating variants and 29 
[range: 8-83] missense variants. In total, 279 protein truncating and 1’584 missense 
variants were identified (Supplementary Table S2.3). These potentially pathogenic 
variants were subjected to a subsequent filtering strategy to identify known and novel 
CRC predisposing gene variants (Figure 2.1).
variants in (colorectal) cancer predisposing genes
Within the list of potentially pathogenic variants, we analysed whether these variants 
were present in any of the known CRC predisposing genes, i.e., mismatch repair 
(MMR) genes, APC, POLD1, POLE, SMAD4, BMPR1A, MUTYH, NTHL1. In three 
individuals, variants in the MMR genes MSH2, MSH6 (three variants) and PMS2 were 
identified (Supplementary Table S2.4), but based on microsatellite instability or 
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immunohistochemistry analyses none of these variants resulted in MMR deficiency. 
Therefore, these variants were allocated to be of unknown significance. 
Next, we focused on variants in genes known to predispose to other types of cancer 
or to cause cancer syndromes when present in a biallelic state (Neveling et al., 2013, 
Rahman, 2014). We identified eight variants in six different genes (Supplementary 
Table S2.5). Two of these genes, BLM and ATM, were found to harbour rare variants in 
two patients. BLM encodes a RECQL-DNA helicase and is involved in the recessive Bloom 
syndrome, which predisposes to CRC. Although current literature on the risk of CRC 
development in carriers of pathogenic BLM alleles is contradictory (Gruber et al., 2002, 
Cleary et al., 2003, Baris et al., 2007), we recently found by targeted re-sequencing of 
a validation cohort that monoallelic pathogenic BLM variants were enriched in these 
cases (Chapter 3 and (de Voer et al., 2015)). ATM is involved in double-strand break 
repair and mutations in its encoding gene are associated with ataxia telangiectasia, 
another autosomal recessive disorder. Somatic nonsense mutations in ATM occur 
frequently in CRC, but monoallelic germline mutations have thus far only been shown 
to increase the risk for gastric, breast and pancreatic cancers, and mostly when they 
result in truncated proteins (Paglia et al., 2010, Roberts et al., 2012, Helgason et al., 
2015). Potentially pathogenic missense variants in ATM were also found twice in a 
cohort of 164 healthy individuals (Control dataset 1; see Materials and Methods of 
this chapter) and we, therefore, conclude that ATM is not enriched in our cohort of 
CRC cases. The remaining four variants represent highly conserved missense or protein 
truncating variants that occurred in four different genes: BRIP1, EGFR, ERCC3 and 
WRN (Supplementary Table S2.5). 
Identification of novel CrC susceptibility genes
To identify novel candidate CRC susceptibility genes, we first focused on genes with 
biallelic mutations (recessive inheritance pattern). Therefore, we analysed our list of 
potentially pathogenic variants for the presence of autosomal homozygous (≥95% 
variant reads) or compound heterozygous variants and, subsequently, performed 
Sanger validation. We identified biallelic variants in eight individuals, all affecting 
different genes (Figure 2.1 and Supplementary Table S2.6). However, these genes 
were either found to be be linked to other phenotypes, to contain many rare variants in 
the general population, or to have a function that remains to be elucidated. Therefore, 
these variants were excluded from further analysis. 
Subsequently, we filtered our list of potentially pathogenic variants for genes with 
at least two variants in unrelated individuals (see Material and Methods of this 
chapter for details). In total, we identified 445 rare potentially pathogenic variants 
in 196 recurrently affected genes. Some of these genes contain many rare variants 
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that occur in the general population and are, thus, unlikely to provoke an increased 
risk for CRC. Therefore, we selected an exome sequencing data set from healthy 
individuals (Control dataset 1; n=164) that were subjected to the same procedure 
as our CRC cohort and were found to be comparable based on genotyping accuracy 
and population (Supplementary Figure S2.1; see materials and methods for a 
detailed description). This ‘Control dataset 1’ was used to remove genes from our list 
that were not significantly enriched in the CRC cohort after a χ2 goodness of fit test 
(Supplementary Table S2.7; Materials and Methods of this chapter). The remaining 
variants, i.e., 347 variants in 150 genes, were subjected to a four-step prioritization as 
outlined below and depicted in Figure 2.1.
First, we investigated whether genes were recurrently affected by rare protein 
truncating variants. Only one gene, EMR3, was found to fulfil this criterion with two 
splice-site mutations (Table 2.2), each predicted to result in skipping of an exon. 
EMR3 belongs to the EGF-TM7 protein family of G-protein coupled receptors and 
is specifically expressed in granulocytes and data from ‘The Human Protein Atlas’ 
suggest that EMR3 is not or only very lowly expressed in colonic tissue (Matmati et al., 
2007, The Human Protein Atlas). EMR3 has been suggested to function as a mediator 
of invasive phenotypic variation in glioblastoma (Kane et al., 2010).
Second, we selected variants in genes that were identified as potential CRC driver 
genes (Supplementary Table S2.8)(Cancer Genome Atlas, 2012). We identified 16 
variants in three genes: MSH6 (3 variants), TTN (10 variants) and PTPN12 (3 variants). 
The tumours of the carriers of the MSH6 variants do not reveal MMR deficiency and 
TTN is known to harbour an excess of rare private variants, is mainly expressed in 
cardiac and skeletal muscle, and is associated with cardiomyopathies (MIM: 188840). 
Therefore, we investigated the three rare variants in PTPN12 in more detail (Table 
2.2). PTPN12 encodes the protein tyrosine phosphatase PTP-PEST that functions as a 
suppressor of epithelial cell motility in CRC cells and has been linked to breast cancer 
development (Espejo et al., 2010, Sun et al., 2011, Espejo et al., 2014). The identified 
variants p.S684L (2 cases, subjects PN045 and PN054) and p.R522K (1 case, subject 
PN014) were found to be located adjacent to the proline-rich regions of PTP-PEST 
(Figure 2.2), which have been shown to interfere with the kinase activity of PTP-
PEST (Streit et al., 2006, Espejo et al., 2010, Sun et al., 2011, Espejo et al., 2014). A 
data search in ‘The Human Protein Atlas’ revealed that PTPN12 is expressed at high 
levels in colonic tissue (The Human Protein Atlas). Somatic mutations that have been 
reported in PTPN12 were found to result in truncations of the protein or in amino acid 
substitutions (Figure 2.2a)(Cancer Genome Atlas, 2012).
Third, we filtered for variants in genes that were identified as mouse CRC susceptibility 
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genes in transposon-based studies (Starr et al., 2009, March et al., 2011). We identified 
18 variants in eight such genes (Supplementary Table S2.9). Since most of these 
genes did not exhibit a clear link to cancer development, we filtered our list for genes 
for those that are described in KEGG pathways implicated in CRC development. This 
resulted in one remaining candidate, namely LRP6. In three CRC patients diagnosed 
before the age of 30 highly conserved LRP6 missense variants with a predicted 
pathogenicity, p.W239L (subject PN002), p.N789S (subject PN001) and p.T867A 
(subject PN008), were identified (Table 2.2). LRP6 encodes a receptor of the WNT-
FZD-LRP5-LRP6 complex that triggers β-catenin signalling. The LRP6 protein consists 
of four β-propeller domains, a transmembrane domain, and a cytoplasmic domain. All 
variants were located in β-propeller domains (Figure 2.3a and Figure 2.3B), which 
are involved in the binding of WNT ligands and antagonists, such as WNT3a and 
Dickkopf-1, respectively (Cheng et al., 2011). Data from ‘The Human Protein Atlas’ 
revealed that LRP6 is expressed at high levels in colonic tissue. Interestingly, LRP6 has 
also been found to be affected by somatic mutations in colorectal adenocarcinomas 
(Cancer Genome Atlas, 2012), in which most of these mutations appear to occur 
within in the β-propeller domains (Figure 2.3a), thus supporting a role of missense 
variants in this gene in CRC development.
Fourth, we examined whether any of the genes that were previously identified in familial 
CRC genome-wide association studies (GWAS) (Welter et al., 2014) were present in 
our list of genes recurrently affected by rare variants, but none were identified.
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Figure 2.2: rare variants in PTPN12 encoding PTP-PEST in four cases. (A) Distribution of missense variants identified 
in the CRC discovery cohort (red dots) and CRC replication cohort (blue dots) in PTP-PEST. Somatic PTPN12 mutations 
identified in colorectal tumours (Cancer Genome Atlas, 2012) are indicated with black (missense) and green (protein 
truncating) dots. The kinase domain is shown in yellow and the proline-rich-regions are shown in orange. (B) Amino 
acid conservation of the three regions with missense variants (indicated with the red box) among 11 species, and the 3D 
protein structure of the kinase domain with the p.A105V variant. The close up shows the structural difference between 
the mutant (red) and wild-type (green) residue. The mutant residue at position 105 is bigger and may cause bumps during 
protein folding. The mutant residue at position 522 is smaller, which can result in loss of interactions. The mutant residue 
at position 684 is more hydrophobic than the wild-type residue; this may disturb correct protein folding.
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Figure 2.3: rare variants in LRP6 in three cases
 
 
legend to Figure 2.3: rare variants in LRP6 in three cases. (A) Distribution of missense LRP6 variants identified in the 
CRC discovery cohort (red dots). Somatic LRP6 mutations identified in colorectal tumours (Cancer Genome Atlas, 2012) 
are indicated with grey (missense) and black (protein truncating) dots. Structural domains include the β-propeller domains 
that are used to form the receptor complex (pink bars), and the transmembrane domain (purple). (B) 3D protein structure 
of the β-propeller domains of LRP6 with the positions of the identified missense variants in red. Insets show conservation 
of the region in which the missense variants (indicated with the red box) are located with, underneath, close ups of the 
local 3D protein structure with mutant (red) and wild-type (green) residues. The mutant residue at position 239 is predicted 
to disturb the protein structure (project HOPE; http://www.cmbi.ru.nl/hope/). The mutant residue at position 789 is much 
smaller than the wild-type residue and may disturb the binding of Dickkopf-1. Residue 867 is located on the surface of 
the protein and the mutant residues are not expected to disturb protein structure, but may influence protein binding. (C) 
Immunofluorescence analyses of LRP6 wild-type and mutant proteins showing similar subcellular localizations. (D) LRP6 
protein expression levels normalized to β-actin are similar between wild-type and mutant LRP6. (E) TOPflash analyses of 
wild-type and mutant LRP6 to determine their effects on the WNT signalling pathway. Luciferase activity was normalized to 
control and wild-type constructs. Both p.N789S and p.T867A mutants reveal a significant increase in activation compared 
to the wild-type LRP6 protein. Experiments were performed three times in triplicate. **P <0.001; error bars represent the 
standard error of the mean.
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Frequency of identified variants in control populations
We analysed the frequency of the potentially pathogenic variants that we identified in 
the EMR3, PTPN12 and LRP6 genes in an additional cohort of locally sequenced control 
individuals without any suspicion for hereditary cancer, and in data from the Exome 
Aggregation Consortium (Exome Aggregation Consortium, 2014). The local control 
individuals were sequenced at a high coverage and exhibited sufficient read depth for 
our three candidate genes (Control dataset 2; n=2’329; Supplementary Figure S2.2 
and Materials and Methods of this chapter for a detailed description). All variants 
that we identified in EMR3, PTPN12 and LRP6 were either absent or present at an 
extremely low frequency in both these data sets (MAF of ≤0.001; Table 2.1). Next, we 
determined the number of variants in these three genes with a similar predicted effect 
in ‘Control dataset 2’. This analysis revealed that protein-truncating variants in EMR3 
and missense variants with a PhyloP ≥3.0 in PTPN12 and LRP6 are indeed enriched in 
our cohort of CRC patients, which remained significant after correcting for multiple 
testing for three genes. After correcting for exome-wide multiple testing, none of the 
genes were significantly enriched (Supplementary Table S2.10).
resequencing of novel candidate CrC susceptibility genes
Next, we performed targeted resequencing of the novel candidate CRC susceptibility 
genes EMR3, PTPN12 and LRP6 using an Ion Ampliseq custom panel (Life technologies, 
see materials and methods for details) and a replication cohort of 174 CRC cases 
(Table 2.1). With an average read-depth of 530-fold per targeted region [range: 21-
1’852] per sample, one additional rare potentially damaging variant in the kinase 
domain of the PTPN12 protein was identified (p.A105V, subject RC204, age 45 
years) and confirmed by Sanger sequencing (Table 2.2 and Figure 2.2). This is not a 
significant increase compared to ‘Control dataset 2’ (Supplementary Table S2.10). 
No additional variants in EMR3 and LRP6 were identified.
Missense variants in lrP6 activate WnT signalling pathway
The three LRP6 variants identified were all encountered in individuals with a very early-
onset of the disease: 23, 24 and 29 years of age. To assess whether these LRP6 variants 
may have an effect on the WNT signalling pathway, we performed TOPflash assays 
with LRP6 wild-type (WT) and mutant proteins. Immunofluorescence and Western 
blot analyses revealed similar localization patterns and equal expression levels of the 
WT and mutant LRP6 proteins (Figure 2.3C and 2.3d). Overexpression of the mutant 
LRP6 proteins (p.N789S and p.T867A) induced 1.6-fold (P=0.0003) and 2.4-fold (P 
<0.0001) increases in WNT signalling activity in the TOPflash assay compared to the 
LRP6 WT protein, respectively (Figure 2.3E).
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Based on the availability of suitable material, a cosegregation analysis could only be 
performed for subject PN002 (p.W239L; age 24 years). PN002 did not have a clear 
family history of CRC, but her mother, two sisters and an aunt developed breast cancer. 
We found that the mother also carried the p.W239L variant. As we were unable to 
perform a complete cosegregation analysis in this family, or in any of the other PTPN12 
or LRP6 families, it remains to be established to what extend carriers of variants in 
these genes tend to develop cancer at a young age.
Discussion
In this study we have performed whole-exome sequencing on germline DNA from 55 
mismatch repair-proficient early-onset CRC cases and identified multiple potentially 
damaging variants in two colon-expressed genes: PTPN12 and LRP6. The germline 
variants identified in these genes appeared to affect highly conserved amino acids 
and were absent, or present at extremely low frequencies, in control populations. 
Targeted re-sequencing of a replication cohort of 174 individuals with early-onset 
CRC revealed one additional variant in PTPN12. We also found that two of the three 
missense variants in LRP6 can activate the WNT pathway in vitro. Based on these 
results, we propose that PTPN12 and LRP6 serve as novel moderately penetrant CRC 
susceptibility genes.
Within our discovery cohort, we focused on genes that were recurrently affected by 
rare potentially damaging variants. Rare variants represent the vast majority of normal 
variation in the human genome and they are unequally distributed between genes 
and between biological pathways (Marth et al., 2011, Abecasis et al., 2012, Keinan 
and Clark, 2012, Tennessen et al., 2012), illustrating that a comparison with exome 
sequence data from a geographically matched control cohort is crucial. We, therefore, 
selected only variants with a MAF ≤0.001 in locally sequenced control individuals, 
and applied the entire analysis pipeline to a dataset of 164 healthy controls that 
were sequenced using the same exome enrichment and sequencing procedures. This 
approach allowed us to reduce the risk of selecting locally common benign variants, to 
prevent the selection of false-positives by technical errors, and to focus only on genes 
that are protected from gathering pathogenic mutations in the normal population 
(MacArthur et al., 2014). Furthermore, we analysed an additional, more recent, high 
quality exome sequencing dataset from local individuals to confirm that our identified 
variants were indeed extremely rare. 
One of the candidate genes, PTPN12, encodes the widely expressed cytoplasmic 
protein tyrosine phosphatase PTP-PEST, which regulates epithelial cell adhesion and 
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migration (Mathew et al., 2008, Taieb et al., 2008, Zheng et al., 2009, Sun et al., 
2011). In colon carcinoma cells, PTP-PEST has been shown to control cell motility and 
adherence junction assembly by regulating the intracellular localization of p120 catenin 
and, consequently, its interaction with E-cadherin (Espejo et al., 2010). Therefore, PTP-
PEST may play a role in the tightly controlled migration of epithelial cells of the colonic 
crypts. The highly conserved variants identified in our study may result in diminished 
phosphatase activity, as has been demonstrated for comparable missense variants in 
the same domains (Streit et al., 2006, Espejo et al., 2014), resulting in aberrant crypt 
formation and possibly invasion.
LRP6 is a core-component of the WNT-FZD-LRP5-LRP6 receptor complex of the WNT 
signalling cascade, which is commonly activated in colon cancer (Clevers and Nusse, 
2012). Previously, this gene was also identified in a screen for mouse CRC susceptibility 
loci (March et al., 2011). Remarkably, we found that the rare LRP6 variants were present 
in three of the youngest diagnosed individuals in our cohorts (age 23, 24 and 29). 
Furthermore, two of the identified missense variants in LRP6 were found to be located 
at positions of the protein that interact with the WNT antagonist Dickkopf-1 (Mao et 
al., 2001) and to result in significantly increased activations of the WNT pathway in in 
vitro TOPflash reporter assays. This finding is intriguing, as it was recently shown that 
missense variants in LRP6 can abrogate activation of the WNT pathway (Massink et 
al., 2015).
Despite the fact that EMR3 is recurrently affected by rare protein truncating variants 
in our discovery cohort, we do not consider EMR3 a strong candidate gene for CRC 
susceptibility, since the protein is not or only very lowly expressed in tissue from 
colon and rectum, and we could not establish a functional link to CRC development 
(Matmati et al., 2007, Kane et al., 2010, The Human Protein Atlas).
Several recent whole-exome sequencing studies have revealed novel candidate CRC 
susceptibility genes and variants (DeRycke et al., 2013, Gylfe et al., 2013, Smith et 
al., 2013a, Schulz et al., 2014, Esteban-Jurado et al., 2015, Tanskanen et al., 2015, 
Zhang et al., 2015), but the concordance between these findings, including our own, 
is as yet limited, and statistical evidence for these correlations in case-control studies 
was not obtained. This limited concordance may be due to different patient inclusion 
criteria used, ranging from the selection of predominantly familial cases to individuals 
with isolated CRC at young age. In addition, it cannot be excluded that non-genetic 
(environmental) risk factors may have played a role in the development of CRC at a 
younger age in individual cases. Clearly, the genetic heterogeneity of CRC susceptibility 
may also, at least partly, explain the limited concordance between studies, and points 
out that statistical validation required very large case and control cohorts. Optimal 
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phenotypic pre-selection, including genetic or histologic abnormalities in the tumour, 
or even the presence of additional congenital features as we recently identified in 
individuals with BUB1 and BUB3 abnormalities (de Voer et al., 2013), may limit this 
heterogeneity. Furthermore, variant selection varies between studies. So far, most 
studies have put a primary focus on high-penetrance germline mutations by showing 
cosegregation within families and second-hit mutations in the tumour (DeRycke et al., 
2013, Gylfe et al., 2013, Smith et al., 2013a, Schulz et al., 2014, Esteban-Jurado et 
al., 2015, Tanskanen et al., 2015), but this approach may not be valid for predisposing 
variants with a moderate penetrance. 
The inclusion of missense variants as potential candidates is challenging, because their 
effect is difficult to predict, and can vary widely between variants in a particular gene. 
Nevertheless, the putative relevance of missense variants in functionally important 
domains should not be underestimated, as was recently illustrated by the discovery 
of missense POLE and POLD1 variants (Palles et al., 2013). Functionally important 
domains are conserved both at the nucleic acid and the amino acid level. Currently, 
there is no consensus on the best strategy to discriminate pathogenic missense 
variants from benign missense variants, which poses a challenge to this type of 
cohort studies. We have used PhyloP scores as the first prioritization cut-off in the 
pathogenicity assessments, as it was previously shown that pathogenic variants have 
higher scores than benign variants (Vissers et al., 2010). This prioritization step was 
followed by other in silico steps to predict pathogenicity based on the biophysical 
amino acid characteristics and multiple protein sequence alignments. Finally, essential 
evidence for the role of damaging variants in novel genes may results from the 
presence of these variants in independent families, but their frequency is expected 
to be low. Therefore, large replication series are needed that encompass comparable 
cases to replicate the findings. Additionally, more and better candidates are likely 
to be identified when datasets from different studies are merged and re-analysed. 
We did, however, identify several rare variants in single individuals in candidate CRC 
susceptibility genes previously reported by others (Supplementary Table S2.11). The 
same may, in reverse, turn out to be true for PTPN12 and LRP6. 
In conclusion, we and others have shown by whole-exome sequencing that the genetic 
susceptibility to CRC is heterogeneous. Our findings are in line with a polygenic model 
of CRC susceptibility in which multiple risk factors in known and novel CRC pathways 
may contribute to additive risks (Fletcher and Houlston, 2010). Future studies, such 
as functional assessments of the candidate genes and replications in larger CRC and 













Polyps location Tumour typeb
lnc 
Metastasis




NO Sigmoid Adeno (M) YES
PN003 Female 28 No FHC YES Rectum Adeno (NS) NO
PN004 Female 28 No FHC YES Sigmoid Adeno (M) YES
PN005 Male 28 No FHC NO Rectum Signetring cell (NS) YES
PN006 Female 28 Unknown NO Unknown Unknown NO




PN008 Female 29 No FHC YES Unknown Unknown NO
PN009 Female 29 Unknown NO Rectum Adeno (NS) YES
PN010 Female 30 2CRC80 NO Caecum Adeno (NS) YES
PN011 Male 31 No FHC NO Rectosigmoid Adeno (M) YES
PN012 Male 31 No FHC NO Rectum Adeno (NS) NO




PN014 Male 32 No FHC YES Unknown Unknown NO
PN015 Female 33 1OV39; 2CRC56; 2CRC80 NO Rectosigmoid Adeno (M) NO
PN016 Female 33 No FHC YES Rectum Adeno (M/W) YES
PN017 Male 33 No FHC NO Rectum Adeno (NS) YES
PN018 Male 33 No FHC NO Sigmoid Adeno (M) NO
PN019 Male 33 Unknown NO Rectum Adeno (NS) NO
PN020 Male 34 1CRC60; 2CRC70 NO Rectum Adeno (M) NO
PN021 Male 34 No FHC NO Appendix Adeno (NS) YES




PN023 Female 34 No FHC NO Rectum Adeno (P) YES
PN024 Female 34 No FHC NO Rectum Adeno (M) YES
PN025 Female 34 Unknown NO Rectum Adeno (NS) NO
PN026 Female 35 1CRC76 NO Sigmoid Adeno (M) NO
PN027 Female 35 No FHC NO Rectum Adeno (M) NO
PN028 Female 36 ?B35 NO Ascending Unknown NO
PN029 Female 36 1CRC71 NO Descending Adeno (NS) NO
PN030 Female 36 2CRC60 NO Sigmoid Adeno (M) YES
PN031 Female 36 2CRC74;2CRC70 NO Rectum Adeno (NS) NO
PN032 Female 36 3CRC45;3CRC50 NO Rectum Adeno (NS) NO
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Polyps location Tumour typeb
lnc 
Metastasis
PN033 Male 36 No FHC YES Rectum Adeno (W) NO
PN034 Male 37 1CRC63; 1CRC67 NO Sigmoid Adeno (M) NO
PN035 Male 37 2CRC81; 2CRC75 NO Sigmoid Adeno (NS) YES
PN036 Female 37 No FHC NO Descending Adeno (NS) NO




PN038 Female 37 No FHC NO Rectum Adeno (NS) NO
PN039 Female 37 No FHC NO Sigmoid Adeno (W) NO
PN040 Male 37 No FHC NO Sigmoid Adeno (NS) NO
PN041 Male 37 No FHC NO Sigmoid Adeno (W) NO
PN042 Female 37 No FHC NO Unknown Unknown NO
PN043 Female 38 1CRC70;2CRC80 NO Rectosigmoid Adeno (NS) NO
PN044 Male 38 2CRC80 YES Sigmoid Adeno (M) YES
PN045 Male 38 2EC79 NO Rectum Adeno (M) YES
PN046 Female 39 1SC30; 1SC>50 NO Ascending Adeno (W) YES
PN047 Male 39 2CRC? NO Rectum Adeno (NS) NO
PN048 Female 39 2CRC59 NO Unknown Adeno (NS) NO
PN049 Female 39 3CRC42 NO Rectosigmoid Adeno (NS) NO
PN050 Male 39 ?CRC53 NO Sigmoid Adeno (P) YES
PN051 Male 39 No FHC NO Transverse Adeno (P) YES




NO Transverse Adeno (M) NO
PN054 Male 43 No FHC YES Rectum Adeno (M/W) NO
PN055 Male 45 1CRC60; 3CRC30 NO Ascending Adeno (M) YES
aFamily history for cancer (FHC): 1, 2 or 3 indicate 1st, 2nd or 3rd degree relatives; B, breast cancer; 
CRC, colorectal cancer; EC, endometrium cancer; GC, gastric cancer; OV, ovarian cancer; SC, 
skin cancer; ?, degree of relative or age unknown; age of onset is indicated after the cancer 
type. bTumour type and differentiation: M, moderately differentiated; W, well differentiated; P, 
poorly differentiated; NS, differentiation not specified. cLN, Lymph node.
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PN001 V4-50Mb 6.33 4.74 75.14 55.00 92.02 82.85 49929
PN002 V4-50Mb 4.36 3.50 56.97 45.00 91.22 80.68 48581
PN003 V4-50Mb 4.39 3.62 58.41 45.00 91.08 79.96 49019
PN004 V2-50Mb 7.28 5.72 97.59 75.00 87.08 81.83 43114
PN005 V2-50Mb 7.94 5.92 99.60 75.50 86.80 81.13 43786
PN006 V2-50Mb 5.84 4.89 85.07 68.00 86.11 80.49 43601
PN007 V2-50Mb 6.79 4.00 67.51 52.00 83.37 75.44 39883
PN008 V2-50Mb 8.72 5.36 87.13 68.00 84.89 78.93 37792
PN009 V2-50Mb 6.47 3.85 65.37 51.00 82.57 74.55 38656
PN010 V2-50Mb 5.18 4.37 75.85 60.50 85.00 78.58 45053
PN011 V2-50Mb 6.66 5.37 92.20 70.50 88.54 83.44 40992
PN012 V2-50Mb 6.26 5.21 89.21 71.00 86.55 80.94 44788
PN013 V2-50Mb 6.12 3.35 56.43 42.50 80.71 71.48 29040
PN014 V2-50Mb 6.54 5.18 83.75 65.00 85.79 79.68 44146
PN015 V2-50Mb 5.87 4.55 77.65 60.00 83.39 76.65 41954
PN016 V2-50Mb 5.01 3.93 63.22 48.00 83.43 75.25 40174
PN017 V2-50Mb 6.90 4.06 69.18 54.00 84.58 76.85 39804
PN018 V2-50Mb 5.91 3.29 54.93 43.00 81.94 72.68 38176
PN019 V2-50Mb 6.62 5.54 95.66 77.00 86.51 81.13 44406
PN020 V2-50Mb 5.32 3.30 57.15 44.00 83.96 74.91 38551
PN021 V2-50Mb 7.06 4.24 70.27 53.00 84.91 77.66 40331
PN022 V2-50Mb 6.59 5.12 87.23 67.00 85.18 79.00 42542
PN023 V4-50Mb 5.79 4.52 76.15 60.00 92.89 85.59 47370
PN024 V2-50Mb 4.37 3.52 56.12 44.00 83.06 74.98 43396
PN025 V2-50Mb 9.49 6.00 101.65 77.00 87.63 82.61 39429
PN026 V2-50Mb N/A 4.46 74.74 57.50 85.02 78.49 38803
PN027 V2-50Mb 6.25 4.85 81.59 61.00 83.77 76.98 42404
PN028 V4-50Mb 4.60 3.76 60.80 48.00 92.05 82.15 49423
PN029 V2-50Mb 4.34 3.40 57.79 45.00 82.50 74.34 39716
PN030 V2-50Mb 6.85 5.78 101.89 82.00 87.99 83.28 44805
PN031 V4-50Mb 5.25 4.25 69.45 54.00 92.47 84.04 49502
PN032 V4-50Mb 6.24 5.06 81.03 63.00 93.99 87.15 49800
PN033 V1-30Mb N/A 2,78 46.68 48.50 73.47 65.36 36324
PN034 V2-50Mb 6.20 4.57 76.86 59.50 83.28 76.65 41507
PN035 V2-50Mb 6.98 5.74 98.44 78.00 87.47 82.36 45328
PN036 V2-50Mb 6.66 5.48 93.47 74.00 87.16 82.02 45973
PN037 V2-50Mb 8.86 6.76 114.35 87.00 86.94 81.87 43724
PN038 V2-50Mb 8.53 7.16 127.29 102.0 89.46 85.59 45725
PN039 V2-50Mb 6.90 5.37 91.72 72.00 86.39 80.92 42867
PN040 V2-50Mb 6.29 5.14 84.90 67.00 87.11 81.51 46267
PN041 V2-50Mb 7.18 6.03 105.27 84.00 87.58 82.60 45089
PN042 V2-50Mb 5.37 4.15 70.45 54.50 83.28 76.03 40257
PN043 V2-50Mb 6.15 4.94 78.50 62.00 85.73 79.92 44700
PN044 V2-50Mb 6.39 5.07 85.36 64.00 85.44 79.14 41855
PN045 V2-50Mb 6.13 4.73 81.03 62.00 83.48 76.65 41743
PN046 V2-50Mb 5.48 4.23 74.32 57.00 84.70 77.65 41289
PN047 V4-50Mb 4.66 3.70 57.02 41.00 89.08 75.98 47408
PN048 V2-50Mb 5.72 4.45 70.99 56.00 84.85 78.39 45070
PN049 V2-50Mb 6.71 5.40 86.62 68.00 86.89 81.73 45210
PN050 V2-50Mb 4.01 3.25 53.35 42.00 83.37 74.55 43623
PN051 V2-50Mb 4.38 3.26 53.54 42.00 80.43 71.11 40509
PN052 V2-50Mb 5.78 4.14 67.90 53.00 82.14 75.06 41337
PN053 V4-50Mb 3.83 3.03 47.44 35.00 87.42 72.12 46226
PN054 V2-50Mb 5.92 4.19 66.33 51.00 83.39 76.05 41973
PN055 V4-50Mb 4.29 3.46 56.71 44.00 90.56 79.20 48893 
Abbreviations: V1, Version 1; V2, Version 2; V4, Version 4 Agilent exome enrichment kits; N/A, 
not available.
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Supplementary Table S2.3: All high-confident protein truncating variants (i.e., putative 
frameshifts, nonsense mutations and variants at canonical splice-sites) and non-synonymous 
variants with a PhyloP score ≥3.0 (missense mutations) that were absent from an in-house 
variant database (n=2’037 exomes) and with a MAF of ≤0.001 in NHLBI-EVS database (n=6’503 
exomes). N/A: not applicable.
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Supplementary Table S2.7: Significance of differences between our CRC discovery cohort 
and ‘Control dataset 1’ (164 control exomes) were calculated using the χ2 goodness of fit test 
and a Benjamini-Hochberg (BH) correction for multiple testing was performed (correcting for 
196 genes that harboured recurrent variants or were recurrently affected in the CRC discovery 
cohort). A P-value of ≤0.05 (indicated by an asterisk) was considered significant before correction. 
After correction a χ2 P-value less than the BH critical value was considered significant. None of 
the genes were significantly enriched in our CRC discovery cohort after correcting for multiple 
testing (N.S.: not significant; *: significant P-value of ≤0.05 before correction).
Due to the size of this file this table can be viewed in the online edition of this chapter availbale 
at doi: 10.1371/journal.pgen.1005880.
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Supplementary Table S2.10: Enrichment analysis-based candidate genes in discovery cohort 



























P = 0.010839 P = 1 0
 
aTotal number of loss-of-function variants (e.g. nonsense, frameshift or splice-site variants) with 
a MAF of ≤0.001 in NHLBI-EVS database in ‘Control cohort 2’. bTotal number of highly conserved 
missense variants (PhyloP ≥3.0) with a MAF of ≤0.001 in NHLBI-EVS database in ‘Control cohort 
2’. cFisher’s exact test between Discovery cohort and ‘Control cohort 2’ not corrected for multiple 
testing. dP-values Fisher’s exact test between Discovery cohort and ‘Control cohort 2’ corrected 
for three genes. eP-values Fisher’s exact test between Discovery cohort and ‘Control cohort 2’ 
corrected for (exome-wide) multiple testing. fFisher’s exact test between Replication cohort and 
‘Control cohort 2’ was not significant. NHLBI-EVS: Exome variant server.
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Supplementary Figure S2.1: Similarities of exome samples. The similarity of the CRC cohort (n=55) and the control 
cohort (n=164) was analysed and compared to variant sets from the 1000 genomes project using a genotype frequency 
weighted metric described by (Heinrich et al., 2013). The results are visualized by non-metric multidimensional scaling. CRC 
exomes (red) and control exomes (black) cluster together, indicating similar genotyping accuracy.
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Supplementary Figure S2.2: average coverage per exon (A) EMR3, (B) PTPN12 and (C) LRP6 in a control cohort of 
exomes of mostly Western-European ancestry (n=2’329). The average coverage is based on a representative set of 50 
exomes. Error bars represent the minimal and maximal coverage per exon.
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Bloom syndrome is an autosomal recessive disorder characterized by chromosomal 
instability and increased cancer risk, caused by biallelic mutations in the RECQL-helicase 
gene BLM. Previous studies have led to conflicting conclusions as to whether carriers 
of heterozygous BLM mutations have an increased risk to develop colorectal cancer 
(CRC). We recently identified two carriers of a pathogenic BLM mutation in a cohort 
of 55 early-onset CRC patients (≤45 years of age), suggesting an overrepresentation 
compared to the normal population. Here, we performed targeted sequencing using 
molecular inversion probes to screen an additional cohort of 185 CRC patients (≤50 
years of age) and 532 population-matched controls for deleterious BLM mutations. In 
total, we identified three additional CRC patients (1.6%) and one control individual 
(0.2%) that carried a known pathogenic BLM mutation, suggesting that these mutations 
are enriched in early-onset CRC patients (P=0.05516). A comparison with local and 
publically available databases from individuals without suspicion for hereditary cancer 
confirmed this enrichment (P=0.003534). Analysis of family members of the five BLM 
mutation carriers with CRC suggests an incomplete penetrance for CRC development. 
Therefore, these data indicate that carriers of deleterious BLM mutations are at 
increased risk to develop CRC, albeit with a moderate-to-low penetrance.
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In autosomal recessive cancer predisposing syndromes such as Bloom syndrome 
(MIM2109000), Nijmegen breakage syndrome (MIM251260), and Fanconi anemia 
(MIM227650), the risk for cancer is age-dependent and varies between cancer types. 
Currently, evidence accumulates that also monoallelic mutations in the genes associated 
with these autosomal recessive syndromes, BLM, NBN and FANCC, respectively, may 
result in increased risks for cancer (Berwick et al., 2007, Seemanova et al., 2007, 
Thompson et al., 2012). Heterozygous deleterious mutations in the DNA RECQL-
helicase gene BLM have been associated with an increased risk for breast cancer 
(Thompson et al., 2012), but studies on the role of these mutations in susceptibility to 
CRC have been conflicting (Gruber et al., 2002, Cleary et al., 2003, Baris et al., 2007). 
In Bloom syndrome patients, the lifetime risk for developing CRC is approximately 
12% (Balci and Aktas, 1999). Previous research on heterozygous carriers of BLM 
mutations and CRC risk has mainly focused on the BLM founder mutation p.Y736fs 
(BLMAsh) in the Ashkenazi Jewish population. Whereas Gruber et al. (Gruber et al., 
2002) described that Ashkenazi Jews with CRC carry the BLMAsh allele more than 
twice as frequent as matched controls, Cleary et al. (Cleary et al., 2003) were unable 
to replicate these findings and Baris et al. (Baris et al., 2007) did not find an increased 
risk for CRC in BLMAsh mutation carriers.
Very recently, we performed whole-exome sequencing on a cohort of individuals 
diagnosed with CRC (n=55) before the age of 45 years, and we identified two individuals 
with heterozygous BLM mutations that are known to play a role in Bloom syndrome 
(Chapter 2 and (De Voer et al., 2016)). To reveal whether these mutations contribute 
to the risk for CRC development, we have performed a case-control sequencing study 
using targeted enrichment by molecular inversion probe technology (O’Roak et al., 
2012) followed by Ion semiconductor sequencing to compare the prevalence of Bloom 
syndrome-causing mutations in patients with CRC and healthy controls.
Materials and Methods
Study cohorts
The discovery cohort consisted of 55 CRC cases, diagnosed at ≤45 years of age, 
without polyposis or a mismatch repair deficiency (de Voer et al., 2013, Neveling et 
al., 2013), which were referred to the Radboud university medical center, Nijmegen, 
the Netherlands. The replication cohort was composed of 185 CRC cases without 
mismatch-repair deficiency from Nijmegen, The Netherlands and Dresden, Germany, 
diagnosed before the age of 50, either in the absence or presence of a family history 
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of CRC. All participants provided written informed consent. The study was approved 
by the Committee on Research involving Human Subjects of the region Arnhem-
Nijmegen (Commissie Mensgebonden Onderzoek (CMO) Regio Arnhem-Nijmegen; 
study number 2009/256), the Netherlands. The study was conducted in accordance 
with the approved guidelines.
Control cohorts and enrichment analysis
The control cohort for targeted resequencing consisted of 532 irreversibly anonymized 
DNA samples extracted from peripheral blood from individuals with European ancestry. 
In addition, we retrieved all known pathogenic BLM mutations reported in the Bloom’s 
syndrome registry (http://weill.cornell.edu/bsr/) (German et al., 2007) from the Exome 
Aggregation Consortium (ExAC) (Exome Aggregation Consortium, 2014), and from 
a cohort of 2,329 individuals of which in-house paired-end sequencing data were 
available with a >90-fold median coverage (Agilent V4 kit, Agilent Technologies, Santa 
Clara, CA, USA; Illumina HiSeq 2500; Illumina, San Diego, CA, USA). These latter 
exomes were sequenced as a part of routine diagnostic testing for multiple conditions, 
excluding hereditary cancers, at the department of Human Genetics, Nijmegen, the 
Netherlands (Neveling et al., 2013), and the data were analysed anonymously. We 
calculated that our replication study, with the above-mentioned CRC and control 
sample sizes, would result in a power of 70%. Power calculations and the Fisher’s 
exact test to calculate odds ratio’s (OR) and significance of differences between the 
CRC cohort and control cohorts were performed using the statistical software package 
R (http://www.R-project.org/).
Targeted resequencing by molecular inversion probes
Molecular inversion probes (MIPs) were designed as described by the procedure of 
O’Roak et al. (O’Roak et al., 2012) against the coding region and at least 20 nucleotide 
intronic sequences up- and downstream of each exon of the BLM gene. Aliquots of 
each 70-mer oligonucleotide probe (Integrated DNA Technologies, Coralville, IA, USA) 
were pooled at equimolar ratios and the 5’-end of each probe was phosphorylated 
using T4 polynucleotide Kinase (New England Biolabs, Ipswich, MA, USA). Genomic 
DNA was prepared from peripheral blood cells or paraffin embedded formalin-fixed 
(tumour or normal colonic) tissue using standard procedures. MIP-based target 
enrichment was performed as described previously with minor modifications (Hiatt et 
al., 2013, O’Roak et al., 2012). Briefly, 100ng of genomic DNA was used to capture 
the target regions. DNA, the phosphorylated MIP pool, dNTPs, polymerase and ligase 
were pooled, denatured for 10min at 95°C and MIP capture was performed for 22h at 
60°C. After an exonuclease treatment a PCR was performed to amplify the captured 
material together with forward and barcoded reverse primers suitable for Ion Torrent 
PGM sequencing: 5’-CCTCTCTATGGGCAGTCGGTGATATCGGGAAGCTGAAG-3’ 
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GTAGTGT-3’ (XXXXXXXX represents the 8 bp barcode). The resulting PCR products 
were pooled and purified twice using Ampure XP beads (Agencourt, Beckman Coulter, 
Pasadena, CA, USA) according to the manufacturer’s protocol. This final library was 
diluted for use in a 200 bp amplification run on an OneTouch emulsion PCR system 
(Life Technologies, Carlsbad, CA, USA). The resulting Ion spheres were run on an Ion 
Torrent PGM sequencing platform (Life Technologies). Reads were aligned to UCSC 
human genome assembly hg19 and called and annotated using SequencePilot (JSI 
medical systems, Ettenheim, Germany). All variants called with a minimal variant 
percentage of 20% and a minor allele frequency of <1% in dbSNP138 were selected 
for further analyses. Frameshift variants adjacent to homopolymeric nucleotide 
repeats that occurred in ≥10% of the samples were excluded as these were considered 
platform-specific artefacts. Variants predicted to be deleterious were validated using 
Sanger sequencing. 
loH and copy-number analyses
Locus-specific loss of heterozygosity (LOH) analyses were performed using DNA 
extracted from tumour material and adjacent normal tissue. The respective DNA 
fractions were used to perform PCRs generating small amplicons covering the patient-
specific mutations, which were sequenced by Sanger sequencing (primers and 
conditions available upon request). Genome-wide SNP array analysis of tumour DNA 
was performed using the OncoScan FFPE Express service (Affymetrix, Santa Clara, CA, 
USA). The SNP array data were analysed using the Nexus Copy Number software 
package (Biodiscovery, Hawthorne, CA, USA).
Results
Frequency of BLM mutations in the general population
We previously identified deleterious BLM mutations, a splice site mutation 
(c.3558+1G>T) and a nonsense mutation (c.2695C>T; p.R899*), in two individuals 
that were diagnosed with colorectal cancer at the age of 29 and 37 years, respectively 
(Figure 3.1a and Table 3.1; Chapter 2 and (De Voer et al., 2016)). Both mutations 
were reported in the Bloom’s syndrome registry, and are thus found in Bloom’s 
syndrome patients (German et al., 2007). Since there are no precise numbers on the 
frequency of pathogenic BLM mutations in the general population, we queried the 
data browser from the Exome Aggregation Consortium (ExAC; n=61’486) (Exome 
Aggregation Consortium, 2014), a publically available dataset containing exomes from 
individuals of European, African or Asian ancestry. We established an overall prevalence 
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of known deleterious BLM mutations of approximately one in 900 individuals (0.11%), 
suggesting that the prevalence of BLM mutations is enriched in our cohort of 55 
early-onset CRC patients. To determine whether we could validate these findings, we 
managed to collect and analyse a cohort of 185 CRC patients diagnosed with CRC 
before the age of 50 years originating from the Netherlands (n=105) and Germany 
(n=80), as well as a control cohort of 532 healthy individuals, for the presence of 
deleterious BLM mutations. 
Targeted re-sequencing of BLM in cases and controls
For the targeted enrichment of the entire coding sequence of the BLM locus, we 
used molecular inversion probes (MIPs) technology, a recently developed method that 
facilitates high-throughput, multiplex sequence analyses, with high specificity for 
the target sequence (O’Roak et al., 2012). The coding sequence of BLM, including 
the intron-exon boundaries, was targeted for 97.4% using 81 MIPs. The untargeted 
sequences involved two coding regions within exons 10 and 13, which do not 
overlap with known pathogenic mutations (Supplementary Figure 3.1). Sequencing 
of the MIP amplified regions was performed using Ion Torrent PGM sequencing in 
eight different runs, containing between 89 and 138 barcoded samples per run. On 
average, 99.2% of the target sequence of the CRC cohort had a coverage of ≥10-
fold (95.2% with ≥50-fold coverage), with a median coverage of 745-fold per probe 
(Supplementary Figure 3.2a). In the control cohort, on average, 98.7% of the target 
sequence was covered at least 10-fold (91.3% with ≥50-fold coverage), with a median 
coverage of 320-fold per probe (Supplementary Figure 3.2B). 
We identified heterozygous deleterious BLM mutations in three out of 185 CRC cases: 
one splice-site mutation (c.98+1G>A) and two nonsense mutations (c.1642C>T; 
p.Gln548* and c.2695C>T; p.Arg899* mutation, 1.6%; Figure 3.1a and Table 3.1), 
and in one out of 532 control samples (c.1642C>T; p.Q548*, 0.2%), which points 
towards an enrichment in early-onset CRC cases compared to controls with borderline 
significance (OR = 8.67; 95% CI, 0.69-455.36; P = 0.05516). In addition, we analysed 
an in-house cohort of individuals without a suspicion for hereditary cancer for which 
high-quality exome sequencing data were available (n=2’329; median exome coverage 
≥90-fold; see materials and methods). Two BLM mutations (0.1%) were found to be 
present in this dataset, which was significantly lower compared to our CRC cohort (P 
= 0.003534; Table 3.2).
Second-hit mutation analyses in tumours of BLM mutation carriers
BLM is thought to be a classical tumour suppressor gene (Payne and Hickson, 2009, 
Bernstein et al., 2010), suggesting that somatic events targeting the wild-type BLM 
allele may contribute to the development of CRC. Therefore, we analysed four 
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available tumours and matched normal colonic tissue for loss of heterozygosity (LOH) 
and mutations in the BLM locus (Table 3.1). In DNA from one tumour (PN034) a 
clear reduction of the wild-type allele compared to the normal tissue was observed, 
suggesting loss of the wild-type BLM allele in the tumour (Figure 3.2a). Subsequent 
genome-wide profiling of this tumour showed that multiple regions exhibited copy-
number neutral LOH, including the entire q-arm of chromosome 15 on which the BLM 
gene is located (Figure 3.2 and Supplementary Figure 3.2). On the remaining three 
tumours second-hit mutation analysis was performed using MIP-based sequencing of 
the entire coding region of BLM. However, due to poor quality and low quantity of the 
DNA this analysis was only successful for one tumour (PN057), which did not reveal 
additional somatic mutations in the coding region of BLM.
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Figure 3.1: deleterious missense mutations in BLM in individuals with early-onset CrC. (a) Distribution of deleterious 
mutations identified in the CRC discovery cohort (red dots) and replication cohort (black dots) in BLM. Structural domains 
of the protein are indicated in colours. (b) Pedigrees of the individuals with deleterious BLM mutations. An arrow indicates 
the proband. Individuals with cancer and their age at diagnosis (if known) are marked as follows: breast cancer (B), bladder 
cancer (BC), brain tumour (BT), colon cancer (C), endometrial cancer (Ed), leukaemia (Leu), liver cancer (LC), pancreas 
cancer (Pa), melanoma (Me), prostate cancer (PC) and cancer of unknown origin (Ca).
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Table 3.2: Enrichment analyses for known deleterious BLM mutations in early-onset CRC cases 
compared to a cohort of population-matched controls, in-house and public databases.













a In-house data set of sequenced exomes;  
b ExAC, Exome Aggregation consortium (Exome Aggregation Consortium, 2014); 
Abbreviations: OR, odds ratio; CI, confidence interval. 
 
risk for CrC in heterozygous BLM mutation carriers
Next, we collected clinical information from all five CRC patients in which we identified 
the BLM mutations, as well as from members of the corresponding families (Figure 
3.1B). Several first-degree relatives of index cases PN034 and PN056 have a history of 
CRC, and cases PN008, PN057 and PN058 have multiple second-degree relatives with 
CRC. The affected sister of case PN056 was found to be carrier of a pathogenic MSH2 
mutation (data not shown), which was not present in the BLM mutation-positive 
proband. We were unsuccessful in collecting DNA from the parents of the probands 
or other family members to perform cosegregation analyses. However, all identified 
BLM mutations have previously been described (German et al., 2007) and reported 
in the data from the ExAC browser, strongly suggesting that they are inherited from 
either one of the parents. 
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Figure 3.2: loss of heterozygosity analyses of the deleterious BLM mutation in the tumour of Pn034. (a) Sanger 
sequencing results of the region around the variants in reference DNA, DNA from normal- and tumour tissue from the 
patient, showing a loss of the wild-type C-allele in the tumour. (b) B-allele frequency plot of chromosome 15 showing the 
loss of heterozygosity along the entire chromosome 15 in the tumour of individual PN034 (top) as compared to a reference 
(bottom). A blue arrow on the top ideogram marks the BLM locus.
Discussion
Using exome sequencing we previously identified two individuals with early-onset 
CRC (≤45 years of age) that carried a deleterious BLM mutation in a cohort of 55 CRC 
cases (Chapter 2 and (De Voer et al., 2016)). We estimated that on average only one 
in every 900 individuals in the general population is a carrier of a known deleterious 
BLM mutation, indicating an enrichment of BLM mutation carriers amongst individuals 
that develop CRC at an early age. Targeted re-sequencing of the BLM locus in an 
additional cohort of cases and controls confirmed this enrichment in individuals with 
early-onset CRC. In the tumour of one of these individuals, the BLM gene was found 
to be completely inactivated by somatic loss of the wild-type allele. Analyses of the 
familial histories for cancer revealed that carriers of a heterozygous deleterious BLM 
mutation most likely have a low-to-moderate penetrant risk for developing CRC. 
As yet, precise estimations of the carrier rate of pathogenic BLM mutations in the 
general population have not been reported. Based on data from the Exome Aggregation 
Consortium (Exome Aggregation Consortium, 2014), the prevalence of pathogenic 
BLM mutations is 0.11%. However, in certain populations, such as in people from 
Ashkenazi Jewish ancestry, carrier frequencies may be as high as 1% (Gruber et al., 
2002). Previous research on the risk for developing CRC in carriers with a pathologic 
BLM mutation has mainly focused on this latter group. Studies in mice have shown that 
the genetic background and levels of BLM protein may have an effect on the degree 
of tumour susceptibility (Luo et al., 2000, Goss et al., 2002, McDaniel et al., 2003), 
which suggests that other genetic and/or environmental factors may influence the 
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penetrance of mutant BLM alleles. This observation may explain why previous studies, 
which only focused on the Ashkenazi founder mutation (Gruber et al., 2002, Cleary 
et al., 2003, Baris et al., 2007), have not been able to provide conclusive evidence of 
such an association. 
Approximately 45% of registered Bloom syndrome patients have developed one or 
multiple malignancies. In approximately 12% of Bloom syndrome patients CRC was 
diagnosed (Balci and Aktas, 1999). Unfortunately, there are no reports on the incidence 
of CRC in family members of patients with BLM syndrome that have developed CRC. 
However, based on the incidence of CRC in Bloom syndrome patients, the penetrance 
for carriers will likely be even lower, and a pronounced family history for CRC in these 
individuals is not expected. Next to CRC, heterozygous truncating mutations in BLM 
have also been associated with an increased risk for breast cancer (Thompson et al., 
2012). In two of the five families in which we identified BLM mutations one or more 
female relatives were indeed diagnosed with breast cancer. Unfortunately, we were 
unable to perform segregation analyses, so it therefore remains to be established 
whether these family members were also carriers of BLM mutations. However, as not 
all carriers of deleterious BLM mutations develop CRC or breast cancer, additional 
moderate penetrant risk factors or modifiers most likely influence cancer risk in these 
carriers. This latter hypothesis is in line with the idea that the risk for CRC at an early 
age is the result of an interplay between multiple moderate-to-low penetrant genetic 
and/or environmental risk factors. 
Whether complete loss of BLM is necessary for the development of CRC in these 
heterozygous carriers is currently unclear. Studies in mice have suggested that 
monoallelic BLM mutations can induce tumorigenesis due to haploinsufficiency (Goss 
et al., 2002), which suggests that additional loss of the wild-type allele is not strictly 
required for tumour initiation. In line with this, a recent study revealed that breast 
cancers from BLM mutation carriers did not show somatic inactivation of the wild-
type BLM allele (Suspitsin et al., 2014). Analyses of a larger group of tumours from 
BLM mutation carriers is needed to establish the exact molecular mechanism by which 
heterozygous BLM mutations initiate tumorigenesis.
So far, deleterious BLM mutations have not been described in other whole-exome 
sequencing studies focusing on the identification of novel genetic risk factors for CRC. 
A possible explanation for this discordance is that these studies focused on families 
in which the index patient had at least one first degree relative affected by CRC or 
families in which the onset of the disease occurred at a later age, rather than on the 
group of early-onset non-familial cases that we present in this study (DeRycke et al., 
2013, Gylfe et al., 2013, Smith et al., 2013a). Our study is slightly underpowered 
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due to the limiting number of early-onset CRC cases that were available for mutation 
analyses. However, all comparisons between our discovery and replication cohorts 
and the publically and in-house available control cohorts reveal an enrichment of 
deleterious BLM mutation in early-onset CRC cases. Validation of our findings in 
another non-Ashkenazi population will substantiate the role of heterozygous BLM 
mutations and the risk for CRC.
In conclusion, carriers of deleterious BLM mutations may have an increased risk 
for developing CRC at an early age, and this risk is most likely influenced by other 
moderate-to-low penetrant risk factors. Further knowledge of whether BLM acts as 
a classical tumour suppressor gene and/or whether other risk factors are necessary 
to initiate tumorigenesis, will allow for a more precise estimation of the CRC risk of 
heterozygous BLM mutation carriers.
67
dElETErIouS GErMlInE BLM MuTaTIonS and THE 









Supplementary Figure 3.1: Distribution of known pathogenic BLM mutations as reported in the Bloom’s Syndrome 
Registry (http://weill.cornell.edu/bsr/). Regions that were not properly covered by our molecular inversion probe design 
(<10-fold) are indicated in orange. These regions, located in exons 10 and 13, represent ~ 2.6% of the total coding 
sequence and they do not overlap with known pathogenic mutations.
Supplementary Figure 3.2: Box plots of the coverage per molecular inversion probe. (a) Coverage per probe for the CRC 
samples (n=185). (B) Coverage per probe for the population-matched control cohort (n=532).
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Supplementary Figure 3.3: Overview of the genomic profiling of the tumour of individual PN034. Analysis was performed 
using Nexus Copy Number, version 6. To accommodate for a noisy signal a smoothing of 0.8 was applied. Significance 
thresholds were set to 1x10-15, allelic balance calls ignored and minimal length of loss of heterozygosity (LOH) areas defined 
as greater than 1 Mb to assure genomic significance. (a) The top graph showing the copy number profile. Note the copy 
number loss of 8pter, 18 and 22 and the gain of 8qter and 16qter (blue bars). For chromosomes 15, 17, and 1q the B-allele 
frequency plot shows a copy-neutral loss-of-heterozygosity. (B) Diagram showing the genomic profiling results of the 
tumour of individual P034 as determined by Affymetrix Oncoscan array analysis. Copy-neutral LOH of chromosomes 15, 
17, and 1q is depicted by yellow shading, deletion of 8pter, 18 and 22 by red bars, and duplication of 8qter and 16qter by 
blue bars. The location of the BLM locus on chromosome 15 is indicated by an arrowhead.
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MUTYH-associated polyposis (MAP) is an autosomal recessive colorectal cancer (CRC) 
predisposition syndrome caused by biallelic germline mutations in the MUTYH gene. 
A medical indication typically used for MAP testing is the presence of ten to a few 
hundred colonic adenomatous polyps before the age of 70 years and indications for a 
recessive inheritance pattern. However, the absence of a positive family history makes 
the clinical recognition challenging and, therefore, MAP cases may sometimes be 
overlooked. Here, we report the use of a targeted sequencing approach to screen the 
coding region of the MUTYH gene for the presence of mutations in a cohort of 192 
early-onset CRC patients without a clear familial suspicion of polyposis. Biallelic MUTYH 
mutations with a known pathogenicity were found in one individual, and an additional 
individual was found to carry one pathogenic variant and a second variant (p.D161H) 
of which the pathogenicity still needs to be established. This report illustrates that the 
identification of actionable MAP mutations by targeted next generation sequencing 
is feasible, and provides additional insight into the frequency of MAP among patients 
with early-onset CRC without an overt familial polyposis phenotype.
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Currently, approximately 5-10% of the colorectal cancer (CRC) cases are known to 
be caused by established Mendelian cancer predisposition syndromes, which usually 
lead to CRC development at relatively young ages (Jasperson et al., 2010). The 
clinical recognition of these syndromes relies on distinct clinical phenotypes, such as 
microsatellite instability (MSI) originating from mutations in the mismatch repair genes 
in Lynch syndrome, or the presence of multiple colonic polyps in familial adenomatous 
polyposis (FAP) caused by mutations in the APC gene (Vasen et al., 2015). For some of 
these syndromes, however, the clinical recognition may be challenging as they exhibit 
heterogeneous phenotypic characteristics (Hampel, 2009, Gallagher et al., 2010, 
Hampel et al., 2015). One example of such a syndrome is MUTYH-associated polyposis 
(MAP), an autosomal recessive inherited cancer syndrome resulting from deficiency of 
the base excision repair glycosylase MUTYH (Mazzei et al., 2013). Compared to FAP, 
MAP typically exhibits a later age of onset, and it usually presents with relatively less 
polyps and/or adenomas (Lipton et al., 2003, Aretz et al., 2006). The guidelines from 
the Dutch society of clinical genetics (VKGN, 2010) recommend screening for MUTYH 
mutations if a patient has a positive family history of familial polyposis, i.e., at least 
10 adenomas with or without CRC, or more than 3 adenomas with CRC before the 
age of 30 years. Through several studies, however, it has become apparent that in a 
subset of MAP patients the polyposis phenotype as outlined above may not be that 
clear, thereby impeding its distinction from other CRC syndromes (Croitoru et al., 
2004, Wang et al., 2004, Riegert-Johnson et al., 2007, Giraldez et al., 2010, Casper 
et al., 2012).
Massively parallel sequencing (MPS) has been shown to be cost-effective for paralell 
sequencing of multiple genes in large sets of patients, independent of the phenotypic 
diagnosis (Gallego et al., 2015). In addition, MPS allows an unbiased screening for 
the presence of pathogenic gene mutations in patients with less overt phenotypes. 
This is important, as the complexity of all known variants as catalogued in the Leiden 
Open Variation Database (LOVD) (Out et al., 2010) is continuously increasing, as well 
as the fact that about 20% of European cases are missed by only screening for the 
most common founder mutations p.Y179C (c.536A>G) and p.G396D (c.1187G>A), 
respectively (Aretz et al., 2006). In a recent study (Neveling et al., 2013), in which we 
assessed the utility of exome sequencing for the diagnosis of heterogeneous diseases 
including cancer-associated syndromes, we identified a patient with biallelic MUTYH 
mutations without a prominent polyposis phenotype. Since individuals with MAP 
can be offered established surveillance strategies to facilitate early cancer detection 
and prevention, the potential of MPS to identify such individuals is of major clinical 
relevance.
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To explore the prevalence of MAP among CRC patients without a pronouced polyposis 
phenotype, we performed a targeted MPS of MUTYH in 192 patients diagnosed 
before the age of 50 (i.e., early-onset) with microsatellite stable CRCs. Through the 
identification of two patients with biallelic MUTYH mutations, we show the feasibility 
of MPS to identify patients with uncharacteristic MAP phenotypes.
Materials and Methods
Patients
Patients with CRC before the age of 50 that were referred to the department of Human 
Genetics of the Radboud university medical center between 1996 and 2014 (n=108) 
and the Universitätsklinikum Carl Gustav Carus at the TU Dresden between 1998 and 
2010 (n=84) were included. From these patients at least one tumour was tested for 
the presence of microsatellite instability, and found to be stable. An overview of the 
patients enrolled in this study, and other studies presented in this thesis, is provided in 
Supplementary Table 6.1. From previous studies, two patients were known to carry 
biallelic MUTYH mutations. In one patient (PN108), the mutations p.P405L (c.1214C>T) 
and p.A385fs (c.1147del) were identified by diagnostic whole-exome sequencing 
(Neveling et al., 2013), which was performed in parallel to our study. The second 
patient (PN227) carried two commonly encountered MUTYH founder mutations, 
i.e., p.Y179C (c.536A>G) and p.G396D (c.1187G>A). These two patients were used 
as positive controls in our current targeted next generation sequencing effort. DNA 
was isolated from peripheral blood leukocytes following standard procedures. All 
patients provided written informed consent and the study was approved by the ethics 
committee Arnhem and Nijmegen (CMO study number 2009/256), the Netherlands.
Targeted resequencing and detection of variants
To reduce sequencing and library preparation costs, patient DNAs were pooled in 
equimolar amounts to pools of 6 based on Qbit measurements. From these pools, 
PCR amplicons were generated representing all exons of MUTYH (Table 4.1). After 
PCR amplification, amplicons were mixed in pools with equimolar quantities based 
on band intensities and product sizes after gel electrophoresis. Next, the resulting 
product pools were concatemerized according to the SOLiD 2.0 library preparation 
protocol (Life Technologies, Rijswijk, The Netherlands). The concatemerized DNA 
was sheared by sonication to obtain fragments of ~200 bp in size using a Covaris E 
sonicator (Covaris Inc., USA), after which libraries were prepared using an Ion Xpress 
Fragment Library preparation kit in conjunction with Ion Xpress Barcode adapters (Life 
Technologies). The libraries were mixed according to the manufacturer’s instructions 
and clonally amplified on Ion Sphere particles using the Ion OneTouch system (Life 
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Technologies). The resulting Ion spheres were run on an Ion 316 chip (first 16 pools) 
and an Ion 318 chip (last 16 pools) using an Ion Torrent PGM sequencing platform (Life 
Technologies). Base calling was performed using the Ion server 3.0 software package 
(Ion Torrent) and reads were aligned to the NCBI hg19 reference assembly using Next 
Gene version 2.3.1 (Softgenetics, USA). 
Since each pool contains 12 alleles, variants are expected to be called with allele 
frequencies of approximately 8.3%. Considering the previously reported IonPGM error 
rate between 0.48% and 2.84% (Liu et al., 2012, Quail et al., 2012, Bragg et al., 
2013, Ross et al., 2013, Junemann et al., 2013), variant calling thresholds were set at 
3% variant calls, >3 variant reads and a read strand imbalance of ≤0.1. Positions where 
pathogenic mutations were reported in the LOVD (Leiden Open Variant Database 
[v2.0 Build 35])(Out et al., 2010) were visually inspected in the alignments using the 
Integrative Genome viewer (Robinson et al., 2011, Thorvaldsdottir et al., 2013). Ion 
PGM sequencing results in relatively high error-rates in homopolymeric stretches of 
especially more than 3 mononucleotide repeats. Therefore, indel calls located in these 
regions were excluded from validation. In the coding sequence (CDS) of MUTYH 84 
homopolymeric stretches can be found comprising a total of 292 bp (~18% CDS).
Table 4.1: Primers used to target the MUTYH gene locus.
Exon(s) targeted directionality a Sequence b
01 R caggaaacagctatgaccgacgtctgaacggaagttcg 
01 F tgtaaaacgacggccagtacgctcaatccactccactg 
02 R caggaaacagctatgacccgtatcacaatcccttcccag 
02 F tgtaaaacgacggccagtgatgagagggagatagctatc 
03 R caggaaacagctatgaccgatgaggagttagggtggagg 
03 F tgtaaaacgacggccagttctgactccagctccaaagc 
04-05 R caggaaacagctatgacctctctacacccaccccaaag 
04-05 F tgtaaaacgacggccagtgagcagggacagtgggtg 
06-08 R caggaaacagctatgaccagaggggccaaagagttagc 
06-08 F tgtaaaacgacggccagtgagcctctactttggggtgg 
09-10 R caggaaacagctatgaccctgagaggcacagggttgag 
09-10 F tgtaaaacgacggccagtcaggtgatctcacagcccac 
11-12 R caggaaacagctatgacccagctgccgattccctc 
11-12 F tgtaaaacgacggccagtgtaagcctactggggaaggg 
13-14 R caggaaacagctatgaccgtagaacatgtaggaaacacaagg 
13-14 F tgtaaaacgacggccagtagggcagtggcatgagtaac 
15 R caggaaacagctatgacccagtgaagcctggagtggag 
15 F tgtaaaacgacggccagtggacatgaagttaagggcag 
16 R caggaaacagctatgacccacttgaggccagaatcacc 
16 F tgtaaaacgacggccagtggggaaagggagagaggac 
a F: forward; R: reverse 
b M13 tags are indicated in italics
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Quality assessment of next generation sequencing and variant 
prioritization
To assess the quality of the alignments, we used BedTools Version 0.1.0 (Quinlan and 
Hall, 2010). The coverage of the open reading frame of NM_001128425.1 (MUTYH) 
was assessed and the functional impact of the called variants at the protein level were 
predicted using Alamut Visual Version 2.5 (Interactive Biosoftware, Rouen, France), 
including annotations with SIFT (Ng and Henikoff, 2001) and PolyPhen-2 predictions 
(Adzhubei et al., 2010). To establish whether a variant is common, rare or novel, the 
frequency of each variant was assessed using an in-house database containing 1,302 
non-cancer exomes and data from the Washington exome variant server (Exome 
Variant Server, 2014). As a first filtering step, all synonymous and non-coding variants 
were excluded from further analysis. Next, we excluded variants present in our in-
house and private databases with an allele frequency >1%, which is well above the 
frequency of the hotspot mutations (max 0.8% as reported in the ExAC database 
available at http://exac.broadinstitute.org (Exome Aggregation Consortium, 2014)). 
Since most novel variant calls that are encountered in more than 3 pools likely represent 
platform-dependent artefacts, they were neglected. The remaining variant calls were 
validated by Sanger sequencing of the 6 individual DNAs present in the respective 
barcoded pools. To affirm, that we did not miss a second mutation in the patient, 
carriership of pathogenic variants in patients was confirmed by Sanger sequencing of 
PCR amplicons spanning the coding region of MUTYH (Table 4.1). For the analysis of 
additional effects of the validated mutations on the encoded protein structure, project 
HOPE at http://www.cmbi.ru.nl/hope/ was consulted (Venselaar et al., 2010).
Results
Performance of targeted sequencing and variant selection
First, we sought to identify and prioritize potentially pathogenic variants in the MUTYH 
locus. The average coverage per exon was 1’542-fold [range: 159-10’502]. The 
coverage obtained in the two runs differed slightly [1’463 vs. 1’620 average coverage], 
but in both runs at least 99% of the open reading frame (ORF) was covered >200x and 
at least 60% was covered more than >500x, indicating sufficient coverage for variant 
calling. In total 64 substitution variants and 42 insertion-deletion (indel) variants were 
called (Table 4.2). Of these, in total 64 substitutions and 16 indel variant calls were 
located in the coding regions of MUTYH. We excluded one synonymous substitution 
variant call (Table 4.2). Filtering for rare variants reduced the amount to 14 substitution 
and 16 indel calls. From these, 12 indel calls were excluded as they were called in 
several different pools (Table 4.2). Finally, 18 variant calls were selected for validation 
77
MUTYH MuTaTIonS In a CoHorT oF 








by Sanger sequencing, i.e., 14 substitutions and 4 indels (Table 4.2). We were able to 
confirm 13 out of 14 substitutions, but none of the indels (Table 4.2). Consistent with 
these results, the variant read percentages of the substitution calls varied between 4.4 
and 10.2%, which approximates the expected allele frequency of 8.3%, whereas for 
the indel variant calls the variant read percentages were considerably lower (i.e. 3-6%) 
(data not shown). 
To assess the performance of our variant calling and selection procedures, the 
pathogenic variants present in the two positive controls that we included in this 
screening effort (see materials and methods) were checked for their occurrence in the 
list of confirmed variants (Table 4.3 and Figure 4.1). The two variants from positive 
control patient PN227 (p.G396D and p.Y179C) were readily identified in pool 6, with 
variant read frequencies of 9.2% for both calls. From the second positive control 
patient that was included (PN108; pool 4) (Neveling et al., 2013), one variant was 
called (p.P405L; variant read percentage 4.4%), whereas the second variant (p.A385fs) 
was not called due to a low number of variant reads present in the raw data (3 variant 
reads out of 1’603 reads)
Figure 4.1: validation of Ion torrent PGM reads using Sanger sequencing. Shown are the two positive controls 
(PN108 and PN227) in the top panel, and two further patients with biallelic mutations (PN169 and PN077) in the bottom 
panel. The position of the respective variants as compared to the reference sequence is marked by red vertical bars.
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Identification of novel patients carrying MUTYH mutations
Next, we set out to identify novel patients carrying pathogenic MUTYH variants that 
were included in the 10 remaining validated high-quality calls. We found that these 10 
variant calls could be assigned to 7 patients (Table 4.3). One of these patients, PN077 
(Figure 4.1), turned out to be a compound heterozygote, carrying two variants that 
were also reported in the LOVD (p.D161H and p.P405L), whereas a second patient 
(PN169) was homozygous for another variant (p.Y179C; Figure 4.1). The remaining 7 
variants were present heterozygously.
Based on these results, we continued to collect clinical information from the two 
patients with homozygous or compound heterozygous MUTYH mutations (PN169 
and PN077, Table 4.4). Patient PN169 (homozygous) underwent surgery for a cecum 
carcinoma at the age of 29 and developed polyps at the age of 32. No known 
record of a family history was available for this patient. The second patient, PN077, 
carried a pathogenic MUTYH mutation (p.P405L) and a MUTYH variant of unknown 
significance (p.Asp161His). Assessments of the latter by SIFT and Polyphen yielded 
predictions denoted as tolerated and probably damaging, respectively. A further 
structural analysis of this protein revealed that the mutated residue is located within 
its DNA glycosylase domain, a domain that is important for the activity of the protein 
(Figure 4.2). The wild-type residue forms a hydrogen bond with threonine at position 
158 and a salt bridge with arginine at position 125. Both interactions are predicted 
to be lost due to the size difference and the lack of charge of the mutant residue. 
Therefore, this mutation may alter the function of the protein. Since this variant was 
reported twice in the LOVD, once in a patient from the Netherlands and once in a 
patient from France, its pathogenicity should be considered. Patient PN077 developed 
a rectal adenocarcinoma at the age of 43 and, in addition, some polyps. There was no 
indication of a family history of CRC.
 
Table 4.2: Filtering of variant calls.
Selection step Substitutions Indels
Total number of variant calls 64 42
Variant calls in coding sequence and splice-sites 64 16
Non-synonymous variant calls 63 16
Variants calls with allele frequency <1% in public databases 14 16
Variant calls found in less than 3 pools 14 4
Validated variant calls 13 0
Novel variant calls (not found in controls) 10 0
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In addition to the above-mentioned patients with biallelic mutations, 7 patients carried 
one validated MUTYH variant each. Three of these patients carried known pathogenic 
mutations, i.e., p.Y179C (patient PN112), p.G396D (patient PN150) and p.P405L 
(patient PN151) (Table 4.4). Another patient (PN223) carried a p.I223V variant, which 
has been described as being potentially pathogenic in the LOVD. SIFT and Polyphen 
rank this latter variant as tolerated and probably damaging, respectively (Table 4.4). 
To exclude the option that we may have missed relevant MUTYH variants in the 
aforementioned 4 patients we screened all its coding exons using Sanger sequencing 
in the respective germline DNAs. By doing so, no additional pathogenic variants were 
found in either one of these patients. Three variants, p.D105N, p.R426C and p.D530Y 
were found in patients PN057, PN216, and PN186, respectively, and were reported 
to be of unknown significance in public databases. Both p.D105N and p.N530Y, 
but not p.R426C, were predicted to be damaging to the protein function by SIFT 
and Polyphen. To double-check whether we may have missed additional pathogenic 
variants, we went back to the raw data and searched for the presence of low-confident 
variants that are reported as pathogenic in the LOVD. Except for the variants shown 
in Table 4.2, no significant observations could be made below 1.7% of the variant 
reads because of loss of sensitivity due to background noise (data not shown). Taken 
together, we conclude that ~1-2% of the patients included in our early-onset CRC 




Figure 4.2: Conservation and structural analysis of the p.asp161His variant. (A) Amino acid conservation of the three 
regions with missense variants (indicated between the red vertical bars) among 8 species, and (B) the 3D protein structure 
of the kinase domain with the p.D161H variant. The close-up shows the structural difference between the mutant (red) 
and wild-type (green) residue. The mutant residue at position 161 is bigger and contains no charge as compared to the 
reference, which may affect protein folding.
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Pn112 unknown unknown unknown unknown unknown c.536a>G p.Tyr179Cys Monoallelic
Pn057 unknown 38 unknown Colon Positive c.313G>a p.asp105asn Monoallelic
Pn223 unknown 44 unknown
Sigmoid 
Colon
unknown c.667a>G p.Ile223val Monoallelic
Pn150 unknown 42 unknown rectum unknown c.1187G>a p.Gly396asp Monoallelic
Pn151 unknown 43 unknown rectum unknown c.1214C>T p.Pro405leu Monoallelic
Pn216 unknown 41 unknown Colon Positive c.1276C>T p.arg426Cys Monoallelic
Pn186 unknown 35 unknown rectum Positive c.1588G>T p.asp530Tyr Monoallelic
Discussion
In this study we aimed to identify MAP patients without a prominent polyposis 
phenotype, using a cohort of CRC patients with microsatellite stable tumours diagnosed 
before the age of 50. Through the use of pooled-template massively parallel sequencing 
(MPS) we identified two novel patients with biallelic MUTYH mutations, one with a 
homozygous p.Y179C mutation and another one that was compound heterozygous 
for two known and a likely pathogenic mutations. In addition, we identified several 
carriers of monoallelic pathogenic variants whose pathogenic significance is still under 
debate. Together, our findings suggest that at least a small fraction of under-diagnosed 
MAP cases can be identified using MPS.
In recent years, targeted MPS has emerged as a potent methodology for studies 
focusing on heterogeneous conditions, such as CRC (Pritchard et al., 2012, Domchek 
et al., 2013). Targeted MPS and the concurrent drop in sequencing costs continuously 
make it easier to screen patient cohorts for mutations in clinically conclusive genes 
(Pritchard et al., 2012, Domchek et al., 2013). In this study we applied a targeted 
MPS approach to MUTYH, as it is a relatively compact gene causing a heterogeneous 
phenotype. As such, the MUTYH gene may serve as a good candidate to exemplify 
unbiased sequencing of disease genes in less stringently selected clinical cohorts to 
identify more patients and to assess the heterogeneity of the associated phenotypes.
We used a pooling strategy of patient DNAs in order to reduce the costs of the library 
preparation and the targeted MPS procedure (Schlotterer et al., 2014). Several studies 
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have shown that by using pooled samples an increase in error rate occurs due to 
the unequal contributions of patients in the DNA pools, variations in DNA quality, 
variations in sequencing depth and enrichment methodologies, and error rate biases, 
particularly for indels (Out et al., 2009, Cutler and Jensen, 2010, Chen et al., 2012). 
Also our study has indicated that the template-pooling approach was not optimal, 
given the fact that we have missed an indel variant in one of our positive controls. 
Conversely, we were able to validate 13 out of 14 substitution variant calls, but none 
of the 4 indel variant calls, indicating that the specificity of our approach was high. The 
high error rate of the Ion Torrent PGM system prompted us to perform an extra check 
for variants reported in the LOVD. We found that almost every position reported in the 
LOVD was covered by 3 variant reads or more, suggesting that a high degree of false 
positive calls may have occluded some variants in the background noise. However, 
only few indel mutations have been observed in the West European population with 
an additive frequency of roughly ~8% in MAP cases (Nielsen et al., 2009, Out et al., 
2010). Therefore, statistically the effect of missing indels due to the pooling design of 
our study is likely to be marginal. Importantly, the current developments in sequencing 
technologies and platforms no longer require the use of these pooling strategies as 
sequencing of individually barcoded samples has become a cost-efficient reality and 
has significantly improved error rates. Therefore, we anticipate that MPS will become 
a reliable method to identify additional (phenotypically ambiguous) MAP patients. 
This will allow a further assessment of the cancer risk and the establishment of the 
(polyposis) phenotype in MAP patients.
Indeed recent findings and observations of more comprehensive and optimized panels 
for the testing of cancer predisposition, including MAP, have been reported in the 
literature (Kurian et al., 2014, LaDuca et al., 2014, Selkirk et al., 2014, Cragun et al., 
2014, Yurgelun et al., 2015). Three of these studies (LaDuca et al., 2014, Cragun et al., 
2014, Yurgelun et al., 2015) reported the application of gene panels in a diagnostic 
setting to patients with a suspected CRC predisposition syndrome. It was found that 
these gene panels could be successfully used to identify MUTYH mutations, including 
frameshift mutations, in unselected patient cohorts. These studies thus demonstrate 
that MPS is a powerful tool to resolve unrecognized MAP patients.
The existence of MAP patients without a family history and a lack of a clear polyposis 
phenotype, as observed in patients PN169 and PN077, has also been noticed by 
others. Casper et al. for example reported the identification of a similar case after 
screening a cohort of 352 early-onset CRC patients (Casper et al., 2012). This patient 
was 44 years old when diagnosed with CRC without polyposis, but developed more 
than 107 colonic adenomas in the 14 years of follow-up (Casper et al., 2012). Wang 
et al. identified 2 MAP cases among 984 CRC patients without a polyposis phenotype 
84 CHaPTEr 4
(Wang et al., 2004). In a larger study (Croitoru et al., 2004) 12 patients were identified 
with biallelic MUTYH mutations in a cohort of 1’238 CRC cases. 3 out of these 12 
cases were reported without a polyposis phenotype and a relatively late age of onset, 
i.e., beyond 45 years (Croitoru et al., 2004). Similarly, Farrington et al. reported that 
36% of MAP patients identified in a cohort of 1’222 CRC patients had no polyps 
(Farrington et al., 2005). Also, Cleary and colleagues found that 9 out of 26 MAP 
patients identified in a cohort of 3’811 CRC cases had no, or only a few polyps (Cleary 
et al., 2009). The exact prevalence of these MAP cases is difficult to estimate, due to 
the large variation among the studies reported (Riegert-Johnson et al., 2007, Giraldez 
et al., 2010, Knopperts et al., 2013). In a recent study by Landon it was reported 
that MAP patients without polyps can phenocopy other CRC syndromes, like Lynch 
syndrome, and are thus under-ascertained by current referral practices (Landon et al., 
2015). Our results are in line with the suggestion that biallelic MUTYH mutations are 
rare but probably underdiagnosed in Western European patients with early-onset CRC 
not fulfilling the clinical genetic referral criteria for MUTYH testing. Since referral criteria 
are motivated by the optimal follow up of patients through the health care system, it is 
likely that with the further development of screening technologies solutions to identify 
such patients can be provided without relying solely on the phenotype.
In contrast to patients with biallelic MUTYH mutations, there are still no clear clinical 
guidelines concerning carriers of monoallelic MUTYH mutations. Although recent 
reports allude to a somewhat elevated risk (Win et al., 2014, Rosner et al., 2015), 
other studies do not support these findings (Webb et al., 2006, Theodoratou et al., 
2010). An extensive meta-analysis of the literature suggested that the CRC risk may 
be particularly elevated in monoallelic carriers with a positive family history of CRC 
(Win et al., 2011). Only large case-control studies are sufficiently powered to detect 
such effects. In the largest analysis reported thus far, which studied 2’332 individuals 
with monoallelic mutations in MUTYH among 9’504 relatives of 264 CRC cases with 
a pathogenic MUTYH mutation, it was estimated that the cancer risk was 2.5-fold 
increased compared to that in the general population (Win et al., 2014). In line with 
these findings, the carrier frequency observed in our cohort does not differ from that 
of the general population, which is 1-2% (Al-Tassan et al., 2002, Cleary et al., 2009).
Besides patients harbouring known pathogenic MUTYH variants, we also observed 
carriers of rare variants whose clinical significance is still unknown. p.D105N (Niessen 
et al., 2006, Nielsen et al., 2009) and p.R426C (Aceto et al., 2005, Kanter-Smoler 
et al., 2006, Aretz et al., 2006, Gomez-Fernandez et al., 2009) have been observed 
in patients with CRC in a monoallelic state, but as yet no firm evidence for their 
pathogenicity is available. Also p.I223V has been observed in a monoallelic state in CRC 
patients (Sieber et al., 2003, Russell et al., 2006, Olschwang et al., 2007). Interestingly, 
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p.I223V has been reported to reduce the DNA glycosylase activity of MUTYH in vitro 
(Goto et al., 2010). To the best of our knowledge, p.D530Y has not been reported 
as a CRC risk factor before. Some of the patients with these variants had a polyposis 
phenotype, but it is unclear whether this observation is due to ascertainment bias, 
since the evidence for a risk of MUTYH mutation carriers is still inconclusive. Further 
research will be necessary to reveal the clinical and functional importance of such 
variants.
In conclusion, our results indicate that MAP patients without an overt polyposis 
phenotype account for a small fraction of the currently unexplained early-onset CRC 
patients. Although our study is limited by its size and its approach, other studies also 
reported MAP patients that do not fulfil the current clinical recruitment criteria. It is 
likely that with the further application of MPS and the extended study of MUTYH 
variants a refinement of the MAP phenotype and its concurrent differential diagnosis 
will be possible.
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Germline mutations in BUB1B, encoding BUBR1, one of the crucial components of the 
spindle assembly checkpoint (SAC), have been shown to cause variable phenotypes, 
including the recessive mosaic variegated aneuploidy (MVA) syndrome which 
predisposes to cancer. Reduced levels of the wild-type BUBR1 protein have been linked 
to the development of gastrointestinal neoplasms. To determine whether mutations in 
BUB1B occur more frequently in individuals with colorectal cancer (CRC), we performed 
amplicon-based targeted next-generation sequencing of BUB1B on germline DNA of 
192 individuals with early-onset CRC (≤50 years). None of the individuals was found 
to be homozygous or compound heterozygous for mutations in BUB1B. However, we 
did identify two rare heterozygous variants, p.E390del and p.C945Y, in patients who 
developed CRC at the ages of 41 and 43 years, respectively. Since the p.E390del variant 
is located in the BUB3-binding domain, we examined whether this variant affects the 
binding of BUB1 or BUB3 to BUBR1 by immunoprecipitation, but the p.E390del variant 
did not affect the binding for these other components of the SAC, compared to wild-
type BUBR1. Our data suggest that mutations in BUB1B do not occur frequently in 
the germline of individuals with CRC and that BUB1B only rarely plays a role in the 
predisposition to early-onset CRC. Whether carriers of pathogenic BUB1B mutations, 
such as the parents of MVA syndrome patients, have an increased risk for cancer or 
not remains of interest, as studies in mice have suggested that haploinsufficiency of 
BUB1B may cause an increase in carcinogen-induced tumours.
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Correct chromosome segregation during mitosis is essential to prevent aneuploidy, a 
hallmark of cancer. The main checkpoint controlling chromosome segregation during 
mitosis is the spindle assembly checkpoint (SAC) (Lara-Gonzalez et al., 2012). The 
SAC delays the onset of the anaphase until bipolar spindle attachments are achieved 
and all chromosomes are aligned and under tension at the metaphase plate. The best 
studied SAC component is BUBR1, encoded by BUB1B. Congenital defects of BUB1B 
have been shown to cause variable phenotypes, including developmental anomalies 
and intellectual impairment (Hanks and Rahman, 2005). Individuals with heterozygous 
mutations in BUB1B show premature sister chromatid separation (PSCS, OMIM 
#176430), but otherwise appear to be asymptomatic (Garcia-Castillo et al., 2008). The 
mosaic variegated aneuploidy (MVA) syndrome (OMIM #257300) represents a more 
severe condition in which biallelic BUB1B mutations can cause constitutional mosaic 
variegated aneuploidies in multiple tissues, and these patients frequently exhibit 
microcephaly, intellectual impairment, growth deficiency, and some milder dysmorphic 
features (Hanks et al., 2004). Interestingly, these individuals also show a predisposition 
to develop cancer at a very young age, with Wilms’ tumour and rhabdomyosarcoma 
being most prevalent (Hanks et al., 2004, Garcia-Castillo et al., 2008). In addition, 
a patient has been reported with a homozygous splice-site germline mutation in 
BUB1B, resulting in reduced levels of the wild-type BUBR1 protein, mosaic variegated 
aneuploidy and multiple gastrointestinal neoplasms, but no intellectual impairment or 
growth deficiency as observed in the classical MVA syndrome (Rio Frio et al., 2010).
Detailed studies in mice have shown that proper functioning of the SAC is highly 
dependent on a strictly orchestrated expression of its different components, and 
that an imbalance of one of these components can lead to chromosome segregation 
defects, senescence, and tumour formation (Sotillo et al., 2007, Baker et al., 2009, 
Ricke et al., 2011). In line with these studies, we have recently shown that germline 
mutations in two other SAC components, BUB1 and BUB3, may confer an increased 
risk to develop early-onset colorectal cancer (CRC) (de Voer et al., 2013). 
So far, most human studies on BUB1B have focused on the prevalence of somatic 
mutations in malignancies with severe chromosomal instability (Sato et al., 2000, Reis 
et al., 2001). Therefore, in this study we investigated whether germline mutations in 
BUB1B occur more frequently in the germline of individuals with early-onset CRC. 
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Materials and Methods
Study and control cohorts
We used an anonymized cohort of 192 patients with mismatch-repair proficient 
colorectal cancer (CRC) without obvious polyposis (i.e. ≤10 polyps), who were 
diagnosed at the age of 50 years or younger, and were referred to the Department of 
Human Genetics of the Radboud university medical center, Nijmegen, the Netherlands 
(n=109; Table 1), or the Department of Surgical Research of the Carl Gustav Carus 
University Hospital, Dresden, Germany (n=83; Table 1). All patients provided written 
informed consent. The study was approved by the CMO (study number 2009/256), 
Arnhem and Nijmegen, the Netherlands. 
Ion torrent sequencing 
Genomic DNA was extracted from peripheral blood cells and combined into 32 pools 
of DNA. Each pool contained the DNA of 6 patients from the CRC cohort. The full 
coding sequence of BUB1B (Refseq. accession: NM_001211.5), including the intron-
exon boundaries, was amplified using 5 ng input DNA from each pool with Ready-
mix Taq PCR Reaction Mix (Sigma-Aldrich, Saint Louis, MO, USA; primer sequences 
available upon request). PCR products were quantified using GeneTools software 
(Syngene, Cambridge, UK), and pooled based on their intensities and sizes after gel 
electrophoreses and Bioanalyzer (Agilent, Santa Carla, USA) measurements. Next, 
the samples were purified and then end-repaired using a Fast DNA End Repair Kit 
(Thermoscientific, UK), concatenated using a Quick Ligation Kit (New England Biolabs, 
Ipswich, MA, USA) and sheared using the Covaris E series (Covaris, Woburn, MA, USA). 
After shearing, the fragmented DNA was end-repaired using an Ion Plus Fragment 
Library kit (Life Technologies, Carlsbad, CA, USA). Ligation of barcode adapters was 
performed using an Ion Xpress Barcode Adapters Kit (Life Technologies). DNA was 
eluted and samples were size selected using E-Gel® EX SizeSelect™ agarose gels (Life 
Technologies). A final amplification was performed using a Platinum PCR SuperMix High 
Fidelity and Library Amplification Primer Mix from the Ion Plus Fragment Library kit (Life 
Technologies). After shearing and end-repair, adapter-ligation and amplification, DNA 
was purified using Agencourt AMPure XP Reagent beads (Beckman Coulter, Pasadena, 
CA, USA), according to the manufacturer’s instructions. DNA concentrations were 
measured using a Qubit 2.0 Fluorometer. We used an Ion OneTouch™ Instrument 
(Life Technologies) for emulsion PCR on the final library and subsequent Ion sphere 
particle enrichment. After amplification and enrichment, sequencing was performed 
on an Ion Torrent PGM™ Sequencer (Life Technologies). Obtained reads were aligned 
to UCSC human genome assembly hg19 using SeqNext software (JSI medical systems, 
Ettenheim, Germany).
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Ion Torrent sequencing reads were mapped and variants were called and analysed 
using SeqNext software (JSI medical systems). Variant calling thresholds were set at 
>3 variant reads, a read strand imbalance of ≤0.1, and a variant read percentage 
of ≥3% (substitutions) or ≥4% (indels). All variants within coding regions and +/-
20 bp of canonical splice-sites were selected for further analysis. Variants that were 
present with a frequency of ≤1% in an in-house variant database (2,329 exomes with 
a >90-fold median coverage without a suspected hereditary cancer syndrome mostly 
from European ancestry) were analysed in silico using Alamut software (Interactive 
Biosoftware, Rouen, France) and integrated software packages (Align GVGD, SIFT, 
Polyphen-2 and Mutation taster). In addition, ‘HOPE’ (http://www.cmbi.ru.nl/hope) 
was used to predict the structural effect of a missense variant (Venselaar et al., 2010). 
Missense variants predicted to be damaging by two or more pathogenicity predictors 
and indels were validated by Sanger sequencing.
Validated variants were checked for their presence in the Human Gene Mutation 
Database (HGMD) (Stenson et al., 2014), The National Heart, Lung, and Blood 
Institute Exome Sequencing Project (NHLBI-EVS; 6’503 exomes), Exome Aggregation 
Consortium (ExAC; 60’706 exomes) and Genome of the Netherlands (GoNL; 498 
exomes).
real-time quantitative rT-PCr
Total mRNA was extracted from lymphoblastoid cell lines using an RNeasy mini kit 
(Qiagen, Valencia, CA, USA) and cDNA was synthesized using a RNA LA PCR kit (AMV; 
Takara Bio Inc, Shiga, Japan). Real-time quantification was performed on a 7500 Fast 
Real-Time PCR system (Applied Biosystems) using SYBR Green-based quantification 
(Applied Biosystems). All experiments were performed in duplicate and data were 
normalized using expression of the housekeeping genes GAPDH and HPRT (primer 
sequences available upon request).
Cloning and co-immunoprecipitation
Full-length BUB1B cDNA (I.M.A.G.E. clone 4649881; BioScience, Nothingham, UK) 
was cloned into the mammalian expression vector C-TAP-FLAG using the Gateway 
cloning system (Invitrogen), resulting in a C-terminal FLAG-tagged BUBR1 protein 
(FLAG-BUBR1). Two variants were introduced into FLAG-BUBR1 by site-directed 
mutagenesis, the p.E390del variant identified in this study and a p.E413K variant, a 
positive control for BUBR1-BUB3 interaction (Taylor et al., 1998). Sanger sequencing 
was used to confirm both variants. For immunoprecipitation studies, HEK293 cells 
were cultured in DMEM (Invitrogen) with 10% foetal calf serum, penicillin (100 U/
ml) and streptomycin (100 µg/ml) at 37°C and 7.5% CO2. Cells were transiently 
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transfected with the FLAG-BUBR1 constructs using polyethyleneimine. After 24 hours 
nocodazole (500 ng/ml) was added and cells were synchronized overnight (16 hours). 
After this, cells were washed three times in ice-cold PBS and scraped from the tissue 
culture dishes in 500 µl lysis buffer (TBS, 0.5% NP-40, protease inhibitors), kept on ice 
for 30 min and centrifuged for 10 min at 21’000 × g at 4°C. Immunoprecipitations 
were performed using anti-FLAG M2 affi nity gel (Sigma Aldrich) for 2 h at 4°C. The 
bound immune complexes were washed three times using TBS and antigens were 
released by heating at 95°C for 5 min in NuPAGE sample buffer (Life technologies). 
Western blotting was performed as described previously (De Voer et al., 2013) using 
anti-BUBR1 (BD Transduction Laboratories; #612503), anti-BUB3 (BD Transduction 
Laboratories; #611731) and anti-BUB1 (kindly provided by Jan van Deursen) murine 
primary antibodies. Signals were visualized using an Odyssey infrared system (Li-cor 
Biosciences, NE, USA) and a pre-stained Molecular Weight Marker (Bio-Rad, Hercules, 
CA, USA) was used for size comparison.
Results
Ion torrent PGM sequencing was performed to detect sequence variants in BUB1B 
in germline DNA from 192 individuals with early-onset CRC (Table 5.1). Using this 
approach, we were able to target the full coding sequence of BUB1B, with an overall 
average coverage of 4’426x [range: 1’440-10’421x]. After quality assessment we 
identifi ed six sequence variants, of which two were validated with Sanger sequencing. 
One of these variants was a heterozygous 3 base pair deletion in the BUB3-binding 
domain of BUBR1 (p.E390del) in a patient who developed CRC at the age of 41 years 
(Case 1; PN063). A second variant (p.C945Y) was identifi ed in the kinase domain 
of BUBR1 in a patient who developed CRC at the age of 43 years (Case 2; PN076) 
(Figure 5.1).
Figure 5.1: location of rare variants identifi ed in BuBr1 (encoded by the gene BUB1B) in two individuals with 
CrC. Structural domains of BUBR1 include the MAD3-BUB1 homology domain (pink), the BUB3-binding domain (yellow) 
and the protein kinase domain (purple). The p.E390del variant (black dot) is located in the BUB3-binding domain of BUBR1. 
The p.C945Y variant (red dot) is located in the protein kinase domain (Protein Painter, Pediatric Cancer Genome Project).
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The p.E390del variant was detected four times (MAF 0.00086) in our in-house 
database of exome sequencing data from 2’329 control individuals (see Materials and 
Methods of this chapter). The variant is not reported in the HGMD, NHLBI-EVS and 
the GoNL databases, but is reported 26 times in the ExAC database (MAF 0.00021). 
The index patient did not have any first-degree relatives with CRC, but she had one 
sister who developed breast cancer and several siblings with polyps (Figure 5.2a). 
Segregation analysis in seven out of eight of her siblings revealed that a non-affected 
brother and the sister with breast cancer carried the p.E390del variant (Figure 5.2B). 
In tumour tissue from the index patient, as well as in tumour tissue from the sister with 
breast cancer, the variant was found to be present in a heterozygous state (Figure 
5.2B). The p.E390del variant is located in the BUB3-binding domain of BUBR1 (Figure 
5.1). To determine whether this p.E390del variant affects BUB3 protein binding, we 
performed a co-immunoprecipitation assay with a known mutant with BUB3 binding 
deficiency (p.E413K) as a control (Taylor et al., 1998)(Figure 5.3a). We found that the 
p.E390del variant did not have any effect on the binding of BUB3 nor BUB1 to BUBR1, 
in contrast to the control mutant p.E413K (Figure 5.3B). In addition, mRNA analyses 
of BUB1B in lymphoblastoid cells from the seven siblings did not reveal any differences 
in expression, irrespective of the p.E390del variant carrier status (data not shown). 
The second variant that we identified is located in the kinase domain of BUBR1, 
p.C945Y, and is not reported in the HGMD, NHLBI-EVS, GoNL or ExAC databases. 
The variant affects a moderately conserved amino acid predicted to be damaging by 
Polyphen-2 and Mutation taster (Table 5.2). Protein modelling using the online tool 
‘HOPE’ (as described above) predicted the variant to be damaging to the protein. The 
patient had nine siblings, of which one was diagnosed with a brain tumour at the 
age of 33 years. None of the siblings was diagnosed with colon cancer. The father of 
the index patient developed colon cancer at the age of 83 years. Unfortunately, no 
DNA or vital cells from family members or the index patient were available to perform 
segregation analyses and/or follow-up studies.
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Table 5.1: Age distribution and familial history for cancer for individuals analysed for BUB1B 
germline DNA sequence variants.
Characteristic dutch German
number 109 83
average age of onset (Sd) 39.7 (5.1) 36.6 (5.4)
age of onset (%)
≤25 yr 1 (0.9) 2 (2.4)
25-30 yr 6 (5.5) 12 (14.5)
31-35 yr 14 (12.8) 17 (20.5)
36-40 yr 31 (28.4) 26 (31.3)
40-45 yr 51 (46.8) 26 (31.3)
45-50 yr 5 (4.6) -
Family history for cancer 
None/Unknown 52 34
≥one first degree relative 36 24
≥one second degree relative 18 25
≥one third degree relatives 3 -
Discussion
Based on a previous study from our group showing that mutations in the spindle 
assembly checkpoint genes BUB1 and BUB3 are associated with an increased CRC 
risk, and a recent study reporting a homozygous BUB1B splice-site mutation in a 
patient with multiple gastrointestinal malignancies, we investigated whether BUB1B 
germline mutations are more frequently present in individuals that are diagnosed with 
CRC at a young age. No individuals were identified with biallelic BUB1B mutations, 
and we found no indication that BUB1B mutations are enriched in the germline of 
individuals who developed CRC. In a cohort of 192 cases with CRC we did identify two 
heterozygous rare variants (1%) in BUB1B, but strong evidence to support a damaging 
effect of these variants could not be obtained. 
One of these rare variants involved a deletion of one amino acid (p.E390del) in the 
BUB3-binding site of the protein. This domain has been shown to be important for 
correct localization of BUBR1 at the kinetochores via interaction with BUB3 (Taylor et 
al., 1998). Using an immunoprecipitation assay we have shown that the p.E390del 
variant does not affect the binding of BUB3 or BUB1 to BUBR1, and it is therefore 
unlikely that this particular variant has a major pathogenic effect on BUBR1 protein 
function.
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Figure 5.2: Pedigree and co-segregation analysis of Pn063 (p.E390del). (a) The index case is indicated by an arrow. 
Tumours are diagnosed in each family member at indicated ages. BC: breast cancer; CRC: colorectal cancer; LC: Lung 
cancer; TC: Testis cancer. (B) Cosegregation analysis of the p.E390del variant in the germline of seven siblings of the index 
case and in the tumour of the index case and a younger sister. The position of the variant is indicated by yellow shading.
 
The other variant, p.C945Y, located in the kinase domain of BUBR1, is not reported in 
any of the control datasets that we have assessed. It has been described that missense 
mutations in the kinase domain of BUBR1 may result in a higher protein turnover, 
resulting in decreased protein levels (Suijkerbuijk et al., 2010). In addition, it has also 
been shown that levels of BUBR1 may decrease during life due to natural aging (Baker 
et al., 2004). Therefore, individuals that carry protein truncating or protein turnover 
acceleration variants may reach critical protein levels of BUBR1 at a later age in life. 
Unfortunately, no vital cells from the index patient with the p.C945Y variant were 
available to determine whether the BUB1B mRNA or BUBR1 protein levels had reached 
a critical level in this individual.
Previous studies in mice have shown that BUBR1 protein levels need to drop to low 
levels, due to hypomorphic or loss of function alleles, in order to cause chromosome 
missegregation and subsequently initiate tumorigenesis (Dai et al., 2004, Baker et al., 
2009). In humans, this also seems to be the case, but the resulting phenotype can still 
be very heterogeneous (Garcia-Castillo et al., 2008). So far, only one individual with 
gastrointestinal cancer and biallelic BUB1B mutations has been described (Rio Frio et 
al., 2010). In this individual, levels of BUB1B mRNA and BUBR1 protein were even more 
reduced than in several of the patients described with MVA, but the phenotype was 
less severe. This difference in phenotype cannot solely be explained by the fact that 
residual protein in the patient described by Rio Frio et al. was similar to that of the wild-
type allele, due to a partial splicing defect. Ochiai et al. (Ochiai et al., 2014), reported 
a patient with MVA syndrome who harboured a homozygous intergenic mutation 44-
Kb upstream of BUB1B that also resulted in a low expression of the wild-type protein, 
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but the phenotype of this patient was far more severe. Therefore, it is likely that other 
factors may influence the phenotype, such as genetic modifiers or the environment. 
Heterozygous mutations in BUB1B have been shown to result in premature sister 
chromatid separation, but not in aneuploidy (Bohers et al., 2008, Garcia-Castillo et al., 
2008), and heterozygous BUB1B mouse models have revealed accelerated age-related 
phenotypes or increased carcinogen-induced tumours compared to wild-type mice 
(Dai et al., 2004, Wijshake et al., 2012). Together, these data suggest that for BUB1B 
to cause a phenotype - either MVA syndrome or cancer - both alleles of BUB1B need 
to be affected, and that it is likely that also other (non) genetic factors may influence 
the outcome of the phenotype. 
 
Figure 5.3: Co-immunoprecipitation of BuBr1 wild-type (WT) and mutant proteins with BuB1 and BuB3. (a) 
Western blot analyses of the immunoprecipitation of BUBR1-WT, BUBR1-p.E390del and BUBR1-p.E413K with BUB1 
and BUB3. (B) Relative binding of BUB1 and BUB3 to BUBR1-WT, BUBR1-p.E390del and BUBR1-p.Glu413Lys. Data were 
normalized to binding of BUBR1-WT with BUB1 or BUB3, respectively.
In conclusion, our data suggest that BUB1B only rarely plays a role in the predisposition 
to early-onset CRC, since mutations in BUB1B do not occur frequently in the 
germline of individuals with CRC. However, as mouse studies have indicated that 
haploinsufficiency of BUB1B may cause a mild disease phenotype and an increase in 
carcinogen-induced tumours, it will be of interest to collect and study more individuals 
with heterozygous variants in BUB1B, such as the parents of MVA syndrome patients, 
to ultimately determine whether or not they present with a clinical phenotype and 
have an increased risk for developing cancer during their life.
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A search for the missing heritability
In spite of extensive efforts in previous years, including linkage studies in large 
families, candidate gene analyses and genome-wide association studies (GWAS) in 
large patient-control cohorts, still a major fraction of the heritability of CRC remains 
unexplained. The term heritability is not absolute, but rather refers to a continuous 
spectrum of CRC predisposition, which includes the extreme forms of rare early-onset 
hereditary cancer syndromes to cases that result from moderately and lowly penetrant 
risk factors (chapter 1). In fact, such mutations are likely to be responsible for the 
major part of CRC heritability, since individuals with high-penetrance mutations would 
tend to be extinguished through purifying selection (Gibson, 2011). Moderately to 
lowly penetrant genetic risk factors do not per se result in disease in each individual 
that carries them, but they may underlie CRC predisposition in cases that lack a 
positive family history but, instead, show an early age of onset which is also suggestive 
of heritability (chapter 1). The aim of this thesis was to identify moderately penetrant 
risk factors for CRC. To this end, a selection was made of early-onset CRC cases. 
Although this selection criterion most likely led to an enrichment for cases with a 
genetic susceptibility, it is impossible to make such statements on a case-by-case basis. 
Nevertheless, we found known and novel candidate risk factors in a subset of these 
cases. Most of these risk factors are suspected to exhibit a moderate penetrance and, 
thus, may not explain all cases. In this chapter, I will discuss our findings in a broader 
perspective, outline the impact and suggest possible approaches for future research.
In chapter 2 (De Voer et al., 2016) we applied whole-exome sequencing (WES) to 55 
stringently selected patients with early-onset CRC, followed by replication of the initial 
findings in an extended patient cohort of more than 180 early-onset CRC patients. 
Among the most interesting candidate CRC risk factors, we identified recurrent 
mutations in the WNT-signalling gene LRP6 and the cell migration regulator PTPN12. 
In addition, we identified recurrent carriership of BLM mutations. In chapter 3 (de 
Voer et al., 2015) we performed a follow-up investigation on BLM mutations as a risk 
factor for early-onset CRC. Using a case-control study, we found an enrichment of 
carriership of pathogenic BLM mutations in a large cohort of early-onset CRC patients 
as compared to the general population. These data lend support to the notion that BLM 
mutations may serve as risk factors for an oligogenic inheritance model. In chapters 4 
and 5 we used candidate gene approaches to analyse our cohort of unresolved early-
onset CRC cases. In chapter 4 we report the identification of hitherto unrecognized 
MUTYH-associated polyposis patients (MAP, recessive inheritance model). These results 
suggest that MAP may at least in part contribute to early-onset CRC cases with an 
unexplained (missing) heritability. In chapter 5 we used a similar approach to screen 
for BUB1B mutations. In doing so, we identified and further characterized two rare 









correlation between these rare variants and CRC.
These findings, together with what was previously known about CRC predisposition 
(chapter 1), reveal a heterogeneous picture of the genetic susceptibility of CRC 
(Figure 6.1). Besides patients with highly penetrant cancer syndromes, such as MAP, 
most of the candidate genes identified here will moderately contribute to the risk 
to develop CRC. Previous studies have revealed several biological functions and 
pathways that are recurrently linked to CRC. These include the DNA repair cascade, 
the WNT signalling cascade, the cell adhesion signalling cascade, the spindle assembly 
checkpoint (SAC) cascade, the cell cycle control cascade, epimutations, chromatin 
modifiers and the TGF-β signalling cascade (all described in chapter 1), as well as 
potentially other functions which have not been elucidated yet, such as for example 
the recently identified candidate gene RPS20 which encodes a component of the 
small ribosomal subunit (Nieminen et al., 2014) (Figure 6.1). We have identified and 
investigated several candidate genes along the lines of Figure 6.1, including LRP6, 
PTPN12, EMR3, BLM, MUTYH, and BUB1B. An overview of the cohort with all the 
rare and pathogenic variants can be found in Supplementary Table 6.1. Except for 
the patients with biallelic pathogenic MUTYH mutations, none of the other variants 
are likely to fully explain CRC development by themselves. Instead, a complex and 
heterogeneous picture emerges, in which variants are spread over a heterogeneous 
patient population. Similar to our findings, recent investigations by others have 
revealed novel candidate CRC predisposing genes (DeRycke et al., 2013, Gylfe et al., 
2013, Palles et al., 2013, Smith et al., 2013a, Nieminen et al., 2014, Weren et al., 
2015, Esteban-Jurado et al., 2015, Zhang et al., 2015, Segui et al., 2015a, Spier et 
al., 2016). Given the increased availability of massively parallel sequencing (MPS) data, 
including whole-genome sequencing (WGS) data, a further understanding of the 
implications of these findings is anticipated in the future.
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Figure 6.1: The functional landscape of CrC predisposition genes/mechanisms. Shown are seven known functional 
modules of CRC predisposition. As described in the text these modules include genes featuring highly penetrant (bold), 
moderately penetrant (black) and low penetrant (grey) risk factors.
Main ﬁ ndings in comparison with others
In the past, it was perceived that genetic variants involved in CRC predisposition might 
fall under discrete strata such as highly penetrant Mendelian traits, the common 
disease-rare variant (CDRV) and the common disease-common variant (CDCV) 
hypothesis (chapter 1). An explanation put forward for this was that most highly 
penetrant germline mutations can be found in ‘gatekeepers’ of important pathways 
involved in CRC tumorigenesis (Vogelstein and Kinzler, 2004). Among the same lines, it 
was postulated that loci identifi ed by GWAS may contribute to CRC risk in an additive 
way, either through the same pathways or through additional pathways not previously 
found to be involved, as discussed in chapter 1. Candidates identifi ed by WES in 
patients with a likely CRC predisposition, including the early-onset patients presented 
in this thesis, further fi t into this model. However, due to the rare frequency and 
the unconfi rmed status of many of these candidate variants, a highly heterogeneous 









conducted on cases with a suspected predisposition that may be assigned to different 
categories: (i) well-defined phenotypes and distinct large families (Palles et al., 2013, 
Nieminen et al., 2014, Weren et al., 2015), (ii) familial CRC (DeRycke et al., 2013, 
Gylfe et al., 2013, Esteban-Jurado et al., 2015, Segui et al., 2015a), (iii) sporadic early-
onset CRC (Smith et al., 2013a, Tanskanen et al., 2015) and (iv) combinations of such 
categories as presented in this thesis and in our other work (Zhang et al., 2015).
In particular, studies focusing on very rare, local cases have successfully led to the 
identification of distinct syndromes, such as NTHL1-associated polyposis (NAP) 
(Weren et al., 2015) and polymerase-proofreading associated polyposis (PPAP) (Palles 
et al., 2013), which are caused by exceedingly rare variants with a presumably high 
penetrance. Another candidate, RPS20 was identified by studying the exomes of a 
single pedigree (Nieminen et al., 2014). Currently, it is unclear, how many CRC cases 
are caused by these syndromes, as the exact frequencies of the underlying variants still 
have to be established. Moreover, to determine the absolute risk of carriers of these 
variants in the absence of ascertainment bias, further studies will be necessary.
Four published studies focused on the identification of CRC risk factors using multi-
case families to identify moderately penetrant risk variants. DeRycke and colleagues 
(DeRycke et al., 2013) performed WES on 40 affected persons from 16 multi-case 
families to identify novel susceptibility loci. Variants from several cases in each family 
were filtered in order to exclude common variants and single-nucleotide variants 
predicted to be benign, before overlap analysis. This led to the identification of CENPE 
and KIF23 as predisposing candidates (DeRycke et al., 2013). Gylfe and colleagues 
(Gylfe et al., 2013) focused on genes affected by recurrent private truncating variants 
in 96 familial CRC patients with no previous diagnosis of a hereditary CRC syndrome. 
This study yielded another eleven candidates, i.e., UACA, SFXN4, TWSG1, PSPH, 
NUDT7, ZNF490, PRSS37, CCDC18, PRADC1, MRPL3, and AKR1C4. Additionally, loss 
of heterozygosity (LOH) analyses and genotyping of variants in candidate genes were 
performed to validate the initial results (Gylfe et al., 2013). Another study of 43 patients 
with CRC from 29 families with multiple cases implicated CDKN1B, XRCC4, EPHX1, 
NFKBIZ, SMARCA4 and BARD1 as candidate genes (Esteban-Jurado et al., 2015). This 
study focused mainly on gene function, in conjunction with cosegregation and LOH 
analyses, but the authors did not replicate the candidates emerging from this approach 
in an independent cohort (Esteban-Jurado et al., 2015). Lately, studies focusing on 
rare multi-case families, who had mismatch proficient tumours but for the remainder 
fulfilled Amsterdam I criteria for Lynch syndrome, have reported and replicated FAN1 
(Segui et al., 2015a) and SEMA4A (Schulz et al., 2014) as novel CRC candidate genes. 
Some authors have suggested that the high number of genetic variants encountered 
may have led to biases in the filtering (DeRycke et al., 2013, Gylfe et al., 2013). In 
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addition, many of the cases included were diagnosed at a relatively old age, making 
it likely that further studies will have to be performed to address the biases that are 
intrinsic to such sample selections.
Another approach was employed in three studies (Smith et al., 2013a, Tanskanen 
et al., 2015, Spier et al., 2016) to identify risk alleles in patients with a presumed 
CRC predisposition. Smith and colleagues (Smith et al., 2013a) selected rare or novel 
truncating variants in genes likely to play a role in CRC susceptibility from exome 
data of 50 patients with sporadic tumours in the absence of a positive family history. 
To substantiate their initial results, the authors performed second-hit analyses in 
the respective tumours, revealing biallelic inactivation of FANCM, LAMB4, PTCHD3, 
LAMC3 and TREX2 (Smith et al., 2013a). Spier and colleagues studied the exomes of 
DNA from leukocytes and a total of 12 colorectal adenomas from 7 unrelated patients 
with unexplained sporadic adenomatous polyposis and replicated the candidates in an 
additional cohort of 192 patients (Spier et al., 2016). In doing so, they identified and 
replicated DSC2 and PIEZO1 as CRC candidate genes (Spier et al., 2016). Tanskanen 
and colleagues sequenced the exomes of 22 early-onset sporadic CRC patients 
diagnosed before the age of 40. Subsequently, they prioritized extremely rare variants, 
found in <0.1% of a matched (Finnish) population, in genes with heterozygous loss-
of-function (LoF) or missense variants and genes with homozygous nonsynonymous 
variants. ADAMTS4, CYTL1 and SYNE1 were found to harbour rare LoF variants, and 
homozygous variants were found in MCTP2, ARHGAP12, ATM, DONSON and ROS1 
(Tanskanen et al., 2015). The pathogenic relevance of these latter mutations still has to 
be established, as for instance ATM associated clinical phenotypes were not reported 
in these patients (Tanskanen et al., 2015). The authors concluded that there was very 
little overlap in the early-onset CRC cases and the previously reported familial cases 









Figure 6.2: Pathways and networks of moderately penetrant CrC candidate genes. Network visualization and an 
evidence-based network model are presented as a screenshot from the STRING database (Szklarczyk et al., 2015) based 
on the selection of candidate genes found in studies addressing moderately penetrant CRC risk variants. The confidence 
within the network is presented by the thickness of the lines connecting the genes. The insets mark the DNA repair, spindle 
assembly and TGF-ß signalling.
In line with the conclusions of others, the results presented in this thesis and reported 
in our earlier publications on sporadic and familial cancer cases reveal a heterogeneous 
picture in which most variants and genes are limited to a few cases with rare overlaps 
(Table 6.1 and (Zhang et al., 2015)). This makes the interpretation of such studies 
difficult, particularly since they are primarily based on relatively small (discovery) patient 
cohorts. Nevertheless, we noted overlap between the different pathways involved. 
For moderately penetrant CRC candidates, a search in the STRING protein-protein 
interaction network database (Szklarczyk et al., 2015) highlights direct and indirect 
molecular links between the candidates (Figure 6.2). Some of these interactions 
fall within established CRC pathways, as outlined in Figure 6.1. Examples of this 
include pathways involved in stem cell signalling (e.g. the MYC and MAX genes in 
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the MAPK signalling pathway), breast cancer DNA repair signalling (e.g. ATM, BRCA2, 
BLM, FANCD2 and FANCM) and spindle assembly checkpoint (SAC) components (e.g. 
KIF23 and CENPE). Although this conceptual approach may be biased towards the 
selection of candidate genes from known predisposition pathways, it is in line with our 
as yet limited knowledge of cancer-associated pathways (Figure 6.1). Next to these 
established interactions, a large number of candidates remains, whose exact function 
and contribution to CRC risk awaits further analysis. To follow up on this, current 
strategies aimed at the identification of Mendelian risk factors may be illustrative. 
 
Emerging insights and future directions
Lessons learned from Mendelian cancer syndromes
In 2009, PALB2 was reported as the first candidate cancer predisposition gene discovered 
by MPS (Jones et al., 2009). Since then MPS has been spearheading identification 
strategies for novel cancer predisposition genes. Especially the discovery of novel 
Mendelian forms of cancer predisposition from well-selected cohorts of patients by 
WES and WGS appeared to be successful. This notion is exemplified by studies that 
have led to the first identification of various novel candidate cancer predisposing 
genes, including GATA2, MAX, PALB2, SMARCE1, BAP1 and ERCC4, which predispose 
to the clinically well-defined entities Emberger-syndrome (Ostergaard et al., 2011), 
pheochromocytoma (Comino-Mendez et al., 2011), multiple spinal meningioma 
(Smith et al., 2013b), melanocytic tumours (Wiesner et al., 2011) and Fanconi anemia 
(Bogliolo et al., 2013), respectively. 
Beyond the successful identification of novel candidate genes for the rare cancer 
syndromes mentioned above, the methodologies and guidelines applied to these 
syndromes have benefited largely from those used in syndromes with Mendelian 
inheritance patterns (MacArthur et al., 2014, Chong et al., 2015, Taylor et al., 2015). 
As such, the success rates appear to be similar to the ~0.5 genes identified per disease 
studied with a Mendelian inheritance pattern (Chong et al., 2015). The methodologies 
and criteria used to study these diseases encompass a couple of distinct entities, 
i.e., (1) patient and cohort selection, (2) candidate gene and variant selection and 
(3) corroborative evidence to support causality, including cosegregation, recurrence, 
functional and somatic evidence (Figure 6.3).
Patient and cohort selection
A well-designed study starts with a carefully selected cohort of patients and/or 
families, which will increase the chance to discover rare disease-causing candidate 









to select well-phenotyped cases. For some cancer syndromes, which are genetically 
homogeneous, this may not be a problem since candidate variants will be implicated 
through frequency if the number of cases included is large enough. This has recently 
been demonstrated e.g. by the finding of germline CTR9 mutations in 3 out of 35 
patients with Wilms tumour (Hanks et al., 2014). However, for conditions such as CRC, 
the current cohorts of early-onset and familial cases appear to be too heterogeneous to 
use such strategies. It may, therefore, be necessary to apply more stringent definitions 
by e.g. performing endophenotyping (see below) of tumours or by focusing on rare 
phenotypes such as the occurrence of childhood CRC. In this way, germline mutations 
in the RPS20 gene could be identified using only a single four-generation family, which 
is probably unique since similar mutations have so far not been reported in other 
families (Nieminen et al., 2014).
Another strategy may be a search for founder mutations. The recruitment of families 
with similar phenotypes from local populations may be of help for such strategies. This 
approach has e.g. led to the identification of POT1 mutations in cutaneous melanoma 
(Shi et al., 2014) and an NTHL1 variant in patients with hereditary polyposis by our 
group (Weren et al., 2015).
Studies of Mendelian disorders suggest that the patient selection step may be crucial 
for increasing the power of the studies to reveal rare alleles with a high to moderate 
penetrance. This is especially so since in a cohort of resembling patients it is more likely 
that a single gene or a few genes with similar function underlie a specific phenotype. 
This in turn would then be more obvious in a plethora of non-causative rare variants 
(Cooper and Shendure, 2011, Marth et al., 2011, Tennessen et al., 2012, Keinan 
and Clark, 2012, MacArthur et al., 2012a, Gudbjartsson et al., 2015) than would 
be the identification of a candidate gene identification by mere prioritization on an 
ad hoc hypothesis with the exclusion of common variants. Possibly, some CRC risk 
factors may be too rare (e.g. RPS20) or their penetrance may be too low to give rise 
to a distinctly recognizable phenotype. Nevertheless, the advantages of unravelling 
Mendelian or near-Mendelian CRC conditions are two-fold. First, they may reveal 
novel pathways involved in CRC predisposition that can be used in further candidate 
gene identification approaches. Second, the removal of resolved cases from cohorts 
will increase the specificity of novel searches for the underlying genes and/or pathways 
(Figure 6.3).
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Figure 6.3: Strategy for (colorectal) cancer predisposition gene identifi cation. Commonalities of recently published 
successful MPS studies to identify cancer predisposition genes in hereditary CRC, and potential improvements as described 









Candidate gene and variant selection
The bottleneck in the MPS study design is rapidly moving away from the performance 
of genome-wide screens towards the development of bioinformatic tools for the 
selection of variants and the introduction of comprehensive pipelines for sequence 
analysis (see for detailed reviews (Bao et al., 2011, Goldstein et al., 2013)). Particularly, 
the variant and gene selection step by which the vast number of identified variants is 
reduced is important (Figure 6.3). The approach chosen for prioritization depends on 
prior knowledge of the patient selection criteria (as described above), the damaging 
effect of variants encountered in the genes, the inheritance model and the function 
of the genes affected (MacArthur et al., 2014). Such approaches are not trivial as they 
are based on selecting one or two causative variants from several million variants that 
usually result from genome-wide sequencing efforts (Cooper and Shendure, 2011, 
Marth et al., 2011, Keinan and Clark, 2012, Tennessen et al., 2012, MacArthur et al., 
2012a, Gudbjartsson et al., 2015). Overlap, linkage, trio-based sequencing (i.e., patient 
and parents) and shared homozygosity can be used to augment the prioritization of 
variants and genes in the exomes of patients with Mendelian conditions (Gilissen et 
al., 2012, Chong et al., 2015). The application of such strategies is not limited to WES 
but can also be used for WGS (Gilissen et al., 2014, Taylor et al., 2015). 
For oligogenic disorders, detailed knowledge of gene and variant function remains 
important. A thorough understanding of the underlying biology can be of help to 
specify pathways and gene functions. Gala and colleagues focused in a recent sessile 
serrated polyposis study, which also give rise to an increased CRC risk, on truncating 
variants in oncogene-induced senescence pathways. In doing so, they found several 
variants in five genes that were enriched in 20 patient-derived exomes as compared 
to 4’500 exomes from healthy individuals deposited in a public database (Gala et 
al., 2014). Although at least one of these variants (p.E49* in PIF1) appears to be 
more common in the healthy population than originally assumed and, therefore, is less 
likely to be causative (Weren and Herwaarden, personal communication), the study 
illustrates how insight into the genetic and functional interplay between different 
genes can assist in variant prioritization. Obviously, such a selection may also introduce 
biases since it is limited to known pathways. Therefore, further corroborative evidence 
is required to establish the causality of particular genes and variants.
Corroborative evidence to support causality
In order to establish a causal relationship between a variant and its predisposition to 
cancer, additional evidence is usually required (Figure 6.3). This evidence may include 
(1) recurrence in cases versus controls, (2) cosegregation in families, (3) second-hit 
mutations in tumours and (4) modelling functional effects.
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Recurrence in cases versus controls- One of the best ways to proof that a rare variant, or 
a rarely mutated gene, plays a role in a Mendelian disease is by independent replication 
in a validation cohort. Such a replication is considered to be a strong indication that 
a candidate variant is not the product of an ascertainment bias (MacArthur et al., 
2014). Most recent studies that utilized MPS to identify the cause of Mendelian cancer 
predisposition syndromes aimed at addressing this point (Jones et al., 2009, Comino-
Mendez et al., 2011, Goudie et al., 2011, Wiesner et al., 2011, Bogliolo et al., 2013, 
Palles et al., 2013, Ruark et al., 2013, Smith et al., 2013b, Hanks et al., 2014). Also, 
for moderately penetrant variants such a replication is considered to be one of the key 
requirements to demonstrate that a specific or comparable variant recurrently occurs 
in other patients. To really proof an association, and to assess the variation in the 
normal population, screening of a large control cohort is needed, the size of which 
depends on the size of the effect to be investigated. As discussed below, however, 
further considerations to lend adequate statistical power to such screens will become 
increasingly important. In cases where replication turns out to be difficult beyond the 
initial discovery cohort, additional functional evidence or familial co-segregation may 
be employed to underscore pathogenicity.
Cosegregation in families- To further assess the penetrance of a candidate risk allele 
and to check whether the anticipated inheritance model is correct, an assessment 
of the presence or absence of the candidate risk allele in respectively affected and 
unaffected family members should be performed. As most Mendelian cancer 
predisposition syndromes by definition feature either a dominant or a recessive 
pattern, this step can be very informative. Cosegregation analysis has, for instance, 
been used to substantiate the implication of POLD1, POLE and NTHL1 in CRC (Palles 
et al., 2013, Weren et al., 2015). Although there may be considerable ascertainment 
biases in the selection of families, and cancer syndromes may not exhibit complete 
penetrance due to a multifactorial etiology, a familial risk is expected to contribute to 
our understanding of CRC development.
Translating this approach to moderately penetrant risk variants will, therefore, be 
important for an accurate risk assessment. A mutation may be significantly associated 
with early-onset CRC, but may not per se lead to a strong family history of CRC. This 
notion may be explained by the ‘genetic background’ in such families. Current study 
designs are not suited to detect polygenic inheritance in cancer. Indeed, as of today, 
only a few reports have been published that describe interactions between known 
predisposition genes, including MUTYH and OGG1 (Morak et al., 2011), MSH6 and 
APC (Okkels et al., 2006), and APC and MSH2 (Uhrhammer and Bignon, 2008).









support the causality of mutations was based on Knudson’s two-hit hypothesis 
(Knudson, 1971). Indeed, many of the well-established cancer predisposition genes, 
such as those underlying FAP and Lynch syndrome follow this scenario, as described 
above. Also, some of the recently discovered cancer predisposing genes appear to 
act in accordance with this scenario, such as for instance the MAX (Comino-Mendez 
et al., 2011), SMARCE1 (Smith et al., 2013b) and BAP1 (Wiesner et al., 2011) genes. 
Subsequent elaborate work on this scenario has revealed that (partial) deregulation 
of tumour suppressor genes and/or proto-oncogenes may add to the risk of tumour 
formation (Berger et al., 2011). Therefore, this scenario should not be regarded as 
absolute. Perhaps, moderately penetrant risk factors may not exhibit second hits, as 
their effects are less prominently associated with gene dosage.
Instead of limiting mutation analyses to hits in the second allele of a candidate 
gene, more insight may be gained from genome-wide profiling through MPS. It is 
well-established now that specific cancer syndromes may follow distinct mutational 
pathways as has, for instance, been observed in Lynch syndrome (see above), and 
MUTYH-associated polyposis (MAP) (Al-Tassan et al., 2002). Also, recent studies on 
CRC predisposition syndromes such as PPAP (Palles et al., 2013) and NAP (Weren et 
al., 2015) have revealed mutation profiles that are specifically associated with defects 
in DNA repair pathways. Given that MPS continuously improves the ease at which 
mutations can be detected, the generation of mutation profiles may become a cost-
effective way to phenotype heritable tumours (Seshagiri et al., 2012, Cancer Genome 
Atlas, 2012, Cancer Genome Atlas Research et al., 2013). This concept, also known as 
endophenotyping, may make a difference in the study of CRC predisposition.
Modelling functional effects- As novel genes and variants continue to be implicated in 
cancer predisposition, it is becoming increasingly imperative to unravel the functional 
consequences of such genes and variants. Well-established models, such as mouse 
models, are available for at least some of the currently known cancer predisposition 
syndromes. Existing knockout models of the POLE and NTHL1 genes have for instance 
been used to support their implication in CRC predisposition (Palles et al., 2013, 
Weren et al., 2015). In the absence of such in vivo models, in silico models can be 
used to make an educated guess of the functional consequences of specific variants. 
Ultimately, proof can be delivered by in vitro modelling. For variants in e.g. DNA repair 
genes this can be done through their exogenous expression in mammalian or yeast 
cells and assessment whether the sensitivity to DNA damaging agents has increased, 
as has been shown for ERCC4 (Bogliolo et al., 2013) and POLE (Palles et al., 2013). 
Also, the effects of variants on downstream signalling can be investigated. This has 
e.g. been done to show the effect of TGFBR1 variants on TGF-β signalling through 
SMAD2/3 (Goudie et al., 2011). Another example represents the influence of RHBDF2 
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variants on EGFR signalling (Blaydon et al., 2012). In the case of SASH1 mutations, 
wound-healing assays on control and patient-derived fibroblasts were performed 
to reveal alterations in pathways governing cell migration (Courcet et al., 2015). 
It is anticipated that functional evidence will play an increasingly important role in 
CRC research. Indeed, in the recent literature, functional analyses have been used 
to implicate genes in gastrointestinal predisposition syndromes when other criteria 
such as replication could not be met due to the rarity of pathogenic mutations in the 
underlying genes. The implication of RPS20 in a single family with CRC (see above) 
was for instance supported by showing a defect in pre-rRNA maturation in patients 
with mutations in this gene (Nieminen et al., 2014). Also, germline mutations in the 
IPMK gene were found to increase the resistance to apoptosis in cell lines derived from 
a single family with small intestinal carcinoids (Sei et al., 2015).
Beyond Mendelian disease gene identification
As alluded to above, novel insights gained from MPS approaches for Mendelian 
conditions may be limited in what they can contribute to our understanding of CRC 
predisposition. There are three possible reasons for this: (i) the underlying risk models 
may not be applicable to CRC, (ii) a significant part of the heritability may result from 
non-coding variants and (iii) not all familial CRC cases may result from genetic defects.
Firstly, few moderately penetrant genetic risk variants have been studied so far, and 
their contribution may deviate from currently known inheritance models. Most of our 
knowledge of moderately penetrant CRC risk variants stems from candidate gene 
approaches, of which only a few have significantly contributed to novel insights 
(Ma et al., 2014). Interestingly, risk variants may act as modifiers, which affect the 
penetrance, dominance, expressivity and pleiotropy of inherited traits (Nadeau, 2001). 
An early example of a role of modifiers in CRC came from an FAP model in mice: 
APCmin (Moser et al., 1992). These mice have a lifespan on average 120 days in which 
they develop multiple polyps and CRC (Moser et al., 1992). Through crossing with 
another mouse strain, a novel strain was obtained of which the mice lived disease-free 
for almost 300 days, suggesting that the APCmin locus was influenced by a modifier 
(Moser et al., 1992). Subsequently, the genetic locus for this modifier was mapped 
and named modifier of min (mom) (Dietrich et al., 1993). In recent years several 
additional modifiers have been identified and mapped, indicating that modification 
is a recurring theme, particularly in the WNT signalling cascade (McCart et al., 2008, 
Starr et al., 2009, March et al., 2011). Similar observations have been made in mouse 
models for DNA repair genes. For instance, in a model reminiscent of heterozygous 
BLMAsh carriers, in which CRC predisposition is only found in an APCmin background 
(Goss et al., 2002), the overall predisposition effect depends both on BLM ablation 









2003). Such effects are generally not accounted for in Mendelian disease gene and 
GWAS studies. As a consequence, care should be taken when applying Mendelian 
prioritization guidelines to detect moderately penetrant CRC risk variants.
Secondly, the criteria used for Mendelian disease genetics are mostly based on the 
protein-coding regions of the genome (i.e., the exome). While human exome itself 
seems to still be ill-defined (Ezkurdia et al., 2014), another significant part of the 
heritability may still reside outside these regions of the genome. Many of the variants 
identified by GWAS are in fact located outside coding regions (Hindorff et al., 2009). 
Also, variants implicated in Mendelian cancer syndromes may not necessarily be 
coding, examples of which include mutations in the MLH1 5’UTR region associated 
with CRC (Kwok et al., 2014, Hesson et al., 2015) and presumed enhancers that 
may affect the expression of EPCAM-MSH2 read-through transcripts associated with 
CRC in EPCAM deletion carriers (Kempers et al., 2011). Likewise, a 40-kb upstream 
duplication of GREM1 has been linked to hereditary mixed polyposis syndrome by 
effecting an increased and ectopic expression of the BMP antagonist GREM1 (Jaeger 
et al., 2012). Consequently, it is reasonable to assume that many additional, also 
moderately penetrant, risk factors reside in non-coding regions. Therefore, care has to 
be taken to not overrate the utility of exomes.
Thirdly, not all CRC cases with a suspected heritability may be caused by genetic 
variants. Recent work of Tomasetti and Vogelstein suggest that only a few mutations 
are required for CRC to become manifest (Tomasetti and Vogelstein, 2015, Tomasetti 
et al., 2015). Their propositions raise some concern about how much of the CRC 
heritability still remains to be discovered. Furthermore, mere chance together with 
the above-mentioned modifying effects have not been taken into account in current 
heritability estimates (Zuk et al., 2012, Witte et al., 2014). Therefore, it is difficult to 
provide an accurate estimate of the remaining heritability of CRC and how much of it 
may be attributed to which class of variants.
Although the above limitations may appear challenging, some promising strategies 
and developments have been outlined in the current literature, i.e., (1) rare variant 
association studies, (2) whole-genome sequencing, (3) functional genomics and (4) 
somatic and germline mutations overlap (see Figure 6.3).
rare variant association studies to power discoveries
Most of the studies presented in the survey above have sought to prioritize variants 
under the premise that they would be similar to Mendelian conditions. As already 
pointed out, the insights gained by these approaches have been limited. A particular 
shortcoming is the strong signal-to-noise ratios in WES and WGS experiments (Zuk et 
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al., 2014). One way to filter out causative variants from ‘noise’, such as large numbers 
of neutral variants, may be to enhance the power of associations in large groups of 
cases and controls. Simulations have indicated that studies in which several thousand 
samples are included may be adequately powered to detect loci explaining ~1% of 
the phenotypic variance underlying a common dichotomous trait in WES screens 
(Moutsianas et al., 2015). It has been proposed that the power of such approaches 
could be enhanced by focusing on isolated populations, de novo mutations and/or 
specific genomic regions (Zuk et al., 2014). For WGS, probably much more cases and 
controls are needed, demanding cohort sizes similar or even larger than those used in 
recent GWAS. As GWAS consortia have already collected such cohorts, these may also 
be used for WGS. This notion may be a basis for future patient recruitment (Figure 
6.3).
WGS and the elucidation of non-coding and complex variation
From studies comparing WES with WGS, it has been concluded that WGS is much 
more sensitive than WES in calling single-nucleotide variants and short insertions/
deletions (indels) at a comparable coverage (Meynert et al., 2014, Belkadi et al., 2015). 
Moreover, it was found that WGS avoids the biases intrinsic to enrichment, thereby 
delivering improved uniformity of read coverage and reduced bias of allele ratios 
across the entire genome (Meynert et al., 2014). This also translates into a greater 
ease in the detection of copy number variation across the genome by WGS (Meynert 
et al., 2014). It is considered likely that with further improvements in the technology 
towards applications of ‘third generation sequencing’, such as the Nanopore (Schadt 
et al., 2010, Schneider and Dekker, 2012) or PacBio platforms (Chaisson et al., 2015), 
increasing read lengths will allow the delineation of complex structural rearrangements 
and the phasing of variants by a single WGS experiment (Figure 6.3). Currently, 
however, our understanding of non-coding variation is still limited. Therefore, a further 
development of conceptualized data interpretation approaches (Khurana et al., 2013, 
Kircher et al., 2014, Lee et al., 2015), as well as functional genomics, will be required.
High-throughput functional genomics 
Recently, high-throughput functional technologies have become available to study 
specific gene functions and to develop human disease models through the application 
of genomic engineering via nuclease-induced genome modifications (Carroll, 2014). 
These technologies allow forward as well as reverse genetic screens (Carroll, 2014). In 
particular, the CRISPR/Cas9 system has become a popular option based on its simplicity 
and versatility (Jinek et al., 2012). Findlay and colleagues already used the CRISPR/
Cas9 system to e.g. mutagenize a region of 6 nucleotides in exon 18 of the BRCA1 
gene with all possible hexamers and compared their impact on nonsense-mediated 









Besides the recapitulation of specific variants, functional genetic analyses have become 
feasible in a much broader context in both in vitro and in vivo models. Promising 
models include organoids, which represent in vitro culture systems to grow cells in 
a three-dimensional (3D) organ-like fashion, such as intestinal epithelial structures 
derived from Lgr5-positive colonic crypt stem cells (Sato et al., 2009). Importantly, 
these organoids are amenable to high-throughput genetic manipulation. Recently, 
the utility of these organoids was demonstrated by introducing mutations in the 
key driver tumour suppressor genes APC, SMAD4 and TP53, and the oncogenes 
KRAS and PIK3CA, in colonic organoids via a knock-out/knock-in approach to mimic 
tumorigenesis according to the classical adenoma-carcinoma sequence model (Drost 
et al., 2015, Matano et al., 2015). When comparing the tumorigenic and metastatic 
properties of these organoids, it was found that ‘driver’ pathway mutations are 
sufficient for clonal expansion and features of invasive carcinomas, but that additional 
molecular lesions are required for invasive behaviour (Drost et al., 2015, Matano et al., 
2015). These findings underscore the notion that knowledge on genetic background 
and environmental variation may be important for our understanding of CRC 
development. As such, recent efforts to build organoid biobanks from CRC patients 
may hold promise for the elucidation of individual genetic and environmental risk 
factors (van de Wetering et al., 2015) in a high-throughput setting. Last but not least, 
the findings may be translated into animal models and, ultimately, humans.
Using somatic driver mutations to identify novel predisposition 
genes
An interesting feature of many of the CRC predisposing variants is the apparent overlap 
between the corresponding pathways that drive cancer development somatically and 
those that predispose genetically. This notion is not new, as the very first models 
of cancer development such as the Knudson’s two-hit hypothesis discussed above 
originated from these parallels. Recent large-scale profiling efforts of cancer genomes 
have revealed genes frequently affected by somatic mutations in CRC (Seshagiri et 
al., 2012, Cancer Genome Atlas, 2012, Cancer Genome Atlas Research et al., 2013). 
These efforts were motivated by the aim to identify driver mutations. In a recent 
review, a comparison was made between drivers in the COSMIC (Catalogue of Somatic 
Mutations in Cancer) database featuring 468 genes that are somatically mutated in 
cancers, and known germline predisposition genes (Rahman, 2014). The result was 
that ~10% of somatically mutated cancer genes also confer susceptibility to cancer 
when present as mutant variants in the germline, but that 40% of the germline-
mutated predisposition genes can also be mutated somatically in tumours (Rahman, 
2014). The author suggested that this discrepancy may at least in part represent 
a bias due to the scarcity of studies on germline-associated mutations in tumours 
(Rahman, 2014). Indeed, holistic studies of somatic and germline variants in tumour 
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material to reveal oncogenic drivers are getting increasingly popular (Feigelson et al., 
2014). Most of the current studies are limited because of their small numbers and the 
resulting lack of power. Therefore, more systematic screens of tumour and matched 
germline material using large patient cohorts will be needed. Since the screening for 
somatic mutations in cancer cells has been among the first fields to harness the power 
of MPS, and especially WGS (Pon and Marra, 2015), the methods used to identify 
driver mutations are better established than those to identify germline variants. 
Consequently, although missing driver variants have been reported, the identification 
of driver variants in (non-)coding regions (Peng et al., 2015) may lead to the discovery 
and improved prioritization of germline variants (Figure 6.3).
Conclusions and prospects
With the advent of MPS, expectations have been high that this technology may be able 
to reveal much of the missing heritability of CRC. Motivated by this in the beginning 
of 2010 we initiated a search for moderately penetrant risk factors for early-onset 
CRC. In due time, however, we and others found that the predisposition to CRC is 
rather heterogeneous and may involve various genetic and/or environmental factors. 
In this chapter, I have outlined how further adjustments of experimental approaches 
and strategies may be of help to obtain final evidence on true CRC risk factors as 
also on their clinical relevance. Knowledge of known (highly penetrant) genetic risk 
factors may be rewarding in this respect, as they may reveal novel pathways involved 
in cancer predisposition. In the end, it is anticipated that the availability of large multi-
centre datasets from clinically well-defined patients and controls will yield enough 
power to perform independent comprehensive meta-analyses, which may unravel 
the complex interplay between common and rare variants within genes or intergenic 
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Zusammenfassung
Darmkrebs gehören zu den häufigsten Todesursachen in den Industrienationen. 
Zwischen 10 und 45  % der Darmkrebsfälle stehen im Verdacht, erblich bedingt 
zu sein, jedoch verursachen hoch penetrante Keimbahnmutationen in jediglich 
5-10% der Fälle . Diese Keimbahnmutationen führen in bestimmten Familien zu 
einer Häufung der Krankheit und/oder zu einem Ausbruch der Krankheit in einem 
relativ jungen Alter. In weiteren 5-10  % der CRC-Fälle wurden niedrig penetrante 
Risikofaktoren durch genomweite Assoziationsstudien (GWAS) identifiziert. Hieraus 
ergibt sich, dass ein großer Teil der erwarteten Vererbung von Darmkrebs nicht zu 
erklären ist (auch als „Missing Hertitability“ bekannt). Kapitel 1 gibt einen Überblick 
über die bekannten Formen der Vererbung in CRC und führt Strategien zum Studium 
der „Missing Hertitability“ auf. Ein Teil der „Missing Hertitability“ könnte auf die 
Anwesenheit von seltenen, moderat penetranten, genomischen Varianten und 
Mutationen zurückzuführen sein. Die Einführung von Massively Parallel-Sequencing 
(MPS) als technologische Neuentwicklung hat die erforschung solcher Varianten  sehr 
erleichtert: sowohl in  genomweiten Studien als auch in einer Gruppe ausgewählter 
Gene (z.B. Exomsequenzierung (WES) bzw. targeted-MPS). In dieser Arbeit konzentriere 
ich mich auf die Identifizierung von mäßig penetranten genetischen Risikofaktoren in 
der Annahme, dass solche Varianten vor allem bei Patienten mit CRC in jungem Alter 
eine Rolle spielen könnten.
In Kapitel 2 wird WES zum Studium von Keimbahnvarianten in der DNA niederländischer 
Patienten mit Diagnose Darmkrebs vor Erreichen des 45. Lebensjahres durchgeführt, 
mit dem Ziel neue Darmkrebsrisikovarianten zu identifizieren. Hierbei wurden vor 
allem sehr seltene (MAF<0,001), potentiell pathogene Varianten berücksichtigt. Die 
Gene, die besonders häufig von solchen Varianten in Darmkrebspatienten betroffen 
waren im verglichen mit einer gesunden Kontrollgruppe und bei Prozessen in den 
Tumorentwicklungen eine Rolle spielten, wurden für die weitere Untersuchung 
ausgewählt. Hierzu haben wir die kodierenden Gebiete dieser Gene auf weitere 
Mutationen in einer separaten Gruppe von 181 CRC-Patienten gescreent. In zwei 
Genen - LRP6 und PTPN12 - wurden Mutationen in mindestens drei Patienten 
gefunden. Eine zusätzlich funktionelle Analyse der Varianten zeigte, dass mindestens 
zwei der drei Varianten in LRP6 die WNT-Aktivität in vitro erhöhten. Diese Ergebnisse 
legen nahe, dass LRP6 und PTPN12 neue Kandidatengene für die erbliche Veranlagung 
für CRC sein könnten. Weitere Forschung ist erforderlich, um die exakte Rolle dieser 
Gene bei der Entwicklung von Darmkrebs zu bestätigen.
Da mit Hilfe von WES auch zwei Patienten mit pathogenen BLM-Mutationen (siehe 
Kapitel 2) gefunden wurden, haben wir die Häufigkeit von BLM-Mutationsträgern 
mit CRC weiter in Kapitel3 untersucht. Durch targeted-MPS, die den kodierenden 




























Regionen des BLM-Locus folgt, untersuchten wir eine Gruppe von 185 Patienten 
(mit Diagnose Darmkrebs vor Erreichen des 50. Lebensjahres) und verglichen diese 
mit einer gleichaltrigen Kontrolle aus 532 Personen. In diesen Kohorten wurden 
3 CRC-Patienten (1,6  %) und ein Kontrollindividuum (0,2  %) mit pathogenen 
BLM-Mutationen gefunden. Aus diesem Resultat schlossen wir, dass Träger von 
pathogenen BLM-Mutationen häufiger in der Gruppe der Darmkrebspatienten als in 
den Kontrollengruppe vorkommen. Folglich könnten Träger von pathogenen BLM-
Mutationen ein erhöhtes Risiko für die Entwicklung von Darmkrebs haben, allerdings 
mit mäßiger bis niedriger Penetranz.
In Kapitel 4 verwendeten wir MPS, um Patienten mit biallelischen MUTYH-
Mutationen in unserer Kohorte zu identifizieren, die vorher aufgrund eines fehlenden 
charakteristischen Phänotyps nicht erkannt wurden. Zu diesem Zweck wurde die 
kodierende Sequenz des MUTYH Gens auf das Vorhandensein von pathogenen 
Mutationen in einer Kohorte von 192 early-onset CRC-Patienten ohne Polyposis 
gescreent. Biallelische pathogene MUTYH-Mutationen wurden in der Tat in einem 
Patienten gefunden. Darüber hinaus fanden wir einen CRC-Patienten mit einer 
pathogenen-Variante und einer zweiten Variante, p.D161H, deren Pathogenität 
noch weiter untersucht werden muss. Aus dieser Studie ergibt sich, dass MUTYH-
Mutationen bei Patienten mit nicht eindeutigen Phänotypen mittels MPS identifiziert 
werden können. Folglich bietet sich MPS als Methode an, um auch bei heterogenen 
Erkrankungen, wie CRC, ähnliche Gene zu untersuchen.
In Kapitel 5 konzentriere ich mich auf eine mögliche Rolle des „Spindel assembly 
Checkpoint“ (SAC)-Proteins BUBR1 - kodiert durch das Gen BUB1B - bei jungen 
Darmkrebs-Patienten. Zuvor hatten wir andere Keimbahnmutationen in verschiedenen 
Komponenten des SAC Proteinen mit einer erblichen Veranlagung für CRC in Verbindung 
gebracht. Um zu untersuchen, ob Mutationen in BUB1B wiederholt in jungen CRC-
Patienten auftreten, benutzten wir in diesem Kapitel einen methodologischen Ansatz, 
der dem in Kapitel 4 verwendeten ähnelt. Hierbei fanden wir zwei seltene heterozygote 
Varianten, p.E390del und p.C945Y. Beide Varianten haben jedoch keinen Einfluss 
auf die Interaktion von BUBR1 mit anderen Spindelassembly Checkpoint-Proteinen 
in vitro. Dies legt nahe, dass Mutationen in BUB1B keine wichtige Rolle bei jungen 
Darmkrebspatienten spielen.
Schließlich diskutiere ich in Kapitel 6 die Auswirkungen dieser Ergebnisse auf 
die Forschung zur erblichen Veranlagung für CRC. Basierend auf der Arbeit in 
dieser Dissertation sowie auf ähnlichen Forschungen in der Literatur, kann davon 
ausgegangen werden, dass die Erforschung der erwartete verbleibende „Missing 
Heritability“ von Darmkrebs eine Herausforderung darsetllen wird. Obwohl MPS in 
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der Praxis für die Untersuchung von Mutationen in bekannten Prädispositions-Genen 
wie BLM und MUTYH nützlich ist, stellt die Masse der identifizierten Kandidatengene 
eine zunehmende Herausforderung dar. Um Kandidatengene in so heterogenen 
Krankheiten, wie beispielsweise CRC zu bestätigen, ist eine effektive und integrative 
Forschung erforderlich. In Kapitel 6 mache ich einige Vorschläge, wie dies erreicht 
werden kann, vor allem auf der Basis von Vergleichen mit anderen Formen erblicher 
Veranlagung für Krebs. Letztendlich ist noch weitere umfangreiche Forschungsarbeit 
nötig, um das Risiko bei Patienten mit Verdacht auf erbliche Prädisposition besser 
einschätzen zu können.





























Darmkanker is een van de belangrijkste doodsoorzaken in de westelijke wereld. In 10 
tot 45% van de darmkanker gevallen wordt een erfelijke aanleg vermoed, maar op dit 
moment kan slechts 5-10% van de gevallen via hoog penetrante kiembaan mutaties 
worden verklaard. Deze mutaties leiden tot familiaire clustering en/of een relatief jonge 
leeftijd waarop de aandoening zich manifesteert. In een additionele 5-10% van de 
darmkanker gevallen werden recent laagpenetrante risicofactoren geïdentificeerd via 
genoomwijde associatiestudies (GWAS). Desondanks blijft vooralsnog een aanzienlijk 
deel van de verwachte erfelijke aanleg onopgehelderd (ook wel “missing hertitability” 
genoemd). In hoofdstuk 1 wordt een overzicht gegeven van de bekende erfelijke 
vormen van darmkanker en worden strategieën geïntroduceerd voor het opsporen van 
nog ontbrekende erfelijke factoren. Een deel van de “missing heritability” zou mogelijk 
verklaard kunnen worden door de aanwezigheid van zeldzame, matig penetrante, 
genomische varianten en mutaties. De introductie van “massively parallel sequencing” 
(MPS) als nieuwe technologie heeft het in kaart brengen van dergelijke varianten en 
mutaties aanzienlijk vereenvoudigd op zowel een genoom-brede schaal (door middel 
van “whole-exome sequencing” (WES)) als gericht in geselecteerde sets van genen 
(bijvoorbeeld via gerichte MPS). In dit proefschrift heb ik mij geconcentreerd op het 
identificeren en categoriseren van matig penetrante genetische risicofactoren, ervan 
uitgaande dat zulke varianten vooral bij patiënten met darmkanker op jonge leeftijd 
een belangrijke rol zouden kunnen spelen.
In hoofdstuk 2 werd WES uitgevoerd op kiembaan DNA van Nederlandse patiënten 
met de diagnose darmkanker voor de leeftijd van 45 jaar met het doel om nieuwe 
risico factoren op te sporen. Hierbij werd vooral gekeken naar zeer zeldzame 
(MAF<0.001) potentieel pathogene varianten. De genen die in darmkanker patiënten 
frequenter aangedaan waren dan in gezonde individuen (controle groep), en die 
functioneel gezien betrokken zouden kunnen zijn bij tumor ontwikkeling, werden 
geselecteerd voor verder onderzoek. Daartoe werden de coderende gebieden van 
de aldus geselecteerde genen gescreend op de aanwezigheid van mutaties in een 
aparte cohort van 181 darmkanker patiënten. Twee genen, LRP6 en PTPN12, bleken 
mutaties te bevatten in drie of meer van de patiënten. Uit functionele analyses bleek 
dat tenminste twee van de drie varianten in LRP6 leidden tot een verhoogde WNT 
activiteit in vitro. Deze resultaten geven aan dat LRP6 en PTPN12 als nieuwe kandidaat 
genen voor darmkanker predispositie in aanmerking komen. Verder onderzoek is 
nodig om de exacte rol van deze genen in de aanleg voor darmkanker vast te stellen.
Aangezien wij met behulp van WES ook twee patiënten met pathogene BLM mutaties 
identificeerden in hoofdstuk 2, hebben wij de frequentie van BLM mutatie dragers 
met darmkanker verder onderzocht in hoofdstuk 3. Middels gerichte verrijking 
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gevolgd door MPS werden de coderende gebieden van het BLM gen in dit hoofdstuk 
gescreend op de aanwezigheid van pathogene mutaties in een cohort van 185 
darmkanker patiënten (gediagnosticeerd voor de leeftijd van 50 jaar) en een cohort 
van 532 qua leeftijd en geslacht overeenkomende gezonde controle personen. In 3 van 
de darmkanker patiënten (1,6%) en in een controle individu (0,2%) werden bekende 
pathogene BLM mutaties aangetroffen. Op basis van deze bevindingen concluderen 
wij dat het dragerschap van pathogene BLM mutaties verrijkt was in de darmkanker 
patiënten groep vergeleken met de controle groep en dus dat dragers van pathogene 
BLM mutaties een verhoogd risico hebben op het ontwikkelen van darmkanker, zij het 
met een matige tot lage penetratie.
In hoofdstuk 4 werd gericht MPS onderzoek toegepast om na te gaan of darmkanker 
gevallen met bi-allelische MUTYH mutaties in ons cohort van jonge patiënten 
gedetecteerd zouden kunnen worden, die eerder niet als zodanig werden herkend 
vanwege het ontbreken van een duidelijk polyposis fenotype. Daartoe werd de 
coderende sequentie van het MUTYH gen gescreend op de aanwezigheid van 
pathogene mutaties in een cohort van 192 geselecteerde darmkanker patiënten. 
Bi-allelische MUTYH mutaties met een bekende pathogeniciteit werden inderdaad 
gedetecteerd in een patiënt. Verder vonden wij een andere patiënt met een pathogene 
variant en een tweede variant, p.D161H, waarvan de pathogeniciteit nog moet worden 
vastgesteld. Uit deze bevinding blijkt dat MUTYH patiënten met onduidelijke fenotypes 
kunnen worden geïdentificeerd met behulp van MPS. MPS kan dus worden gebruikt 
als instrument om patiënten te identificeren met bekende predispositie syndromen in 
een genetisch heterogene aandoeningen zoals darmkanker.
In hoofdstuk 5 hebben we ons gericht op een mogelijke rol van het “spindle 
assembly checkpoint” (SAC) eiwit BUBR1, dat wordt gecodeerd door het BUB1B gen, 
in jonge darmkanker patiënten. Eerder hadden wij en andere onderzoekers kiembaan 
mutaties in verschillende SAC componenten in verband gebracht met de aanleg 
voor tumoren in het maag-darm stelsel. Om te onderzoeken of mutaties in BUB1B 
met enige regelmaat optreden in jonge CRC patiënten hebben wij in deze studie 
een gerichte MPS uitgevoerd, vergelijkbaar met die in hoofdstuk 4. Hierbij vonden 
wij twee zeldzame heterozygote varianten, p.E390del en p.C945Y. Beide varianten 
bleken echter geen invloed te hebben op interacties van BUBR1 met andere SAC 
eiwitten in vitro. Op basis van deze bevindingen nemen wij aan dat BUB1B mutaties 
geen belangrijke rol spelen in jonge darmkanker patiënten.
Tenslotte bespreek ik in hoofdstuk 6 de implicaties van deze resultaten voor de 
genetische aanleg van darmkanker en geef suggesties voor toekomstige onderzoek 
op dit gebied. Op basis van het werk beschreven in dit proefschrift en soortgelijke 




























onderzoek door anderen wordt verwacht dat het ophelderen van de resterende 
“missing heritablity” voor darmkanker een uitdaging zal blijken te zijn. Hoewel dit 
proefschrift illustreert dat MPS een zeer bruikbare methode is voor het opsporen van 
mutaties in bekende predispositie genen, zoals BLM en MUTYH, levert de toepassing 
van MPS ook vele nieuwe kandidaat genen op. Om de rol ven deze kandidaat genen 
te bevestigen in een heterogene aandoening als CRC is een effectief en integratief 
onderzoek een vereiste. In hoofdstuk 6 geef ik een aantal suggesties over hoe dit kan 
worden gerealiseerd, met name op basis van vergelijkingen met andere al dan niet 
Mendeliaanse vormen van kanker predispositie. Uiteindelijk zal meer werk nodig zijn 




Colorectal cancer (CRC) is one of the major causes of death in developed countries. 
Based on twin studies, 10-45% of CRC cases are expected to be heritable. Yet, only in 
5%-10% of these cases highly penetrant germline mutations are found (e.g. mutations 
in the mismatch-repair and APC genes) that result in familial aggregation of cases and/
or a relatively early age of onset of the disease. In another 5-10% of CRC cases, low-
penetrant risk factors have been identified through genome-wide association studies 
(GWAS). Consequently, a large fraction of the expected heritability of CRC still remains 
unexplained (‘missing heritability’). Chapter 1 provides an overview of the known 
heritability of CRC, and outlines strategies for uncovering the as yet missing heritability. 
This missing heritability may result from the presence of rare, moderately penetrant, 
genomic variants/mutations. The introduction of massively parallel sequencing (MPS) 
has facilitated the cataloguing of such variants on a genome-wide scale (e.g. whole-
exome sequencing (WES)) or in a selected set of genes (e.g. targeted MPS). Here, I 
aimed to identify and assess the role of moderately penetrant genetic risk factors under 
the premise that they underlie less common forms of CRC, or predispose patients with 
an early-onset of CRC, even in the absence of a positive family history.
In chapter 2 WES on germline DNA from Dutch CRC patients that were diagnosed 
before the age of 45 was performed to reveal novel CRC risk variants. First, rare (minor 
allele frequency ≤ 0.001) potentially pathogenic variants were prioritized. Based on 
these variants, genes that were more commonly affected in CRC cases than in healthy 
controls, and that were functionally linked to CRC, were selected. The coding regions of 
these genes were screened for the presence of pathogenic mutations in an additional 
cohort of 181 CRC patients. Two genes, LRP6 and PTPN12, were found to be affected 
in at least three individuals. Further functional follow-up analyses revealed that two 
of the three variants that were identified in LRP6 increased WNT signalling activity 
in vitro. Overall, these results suggest that the LRP6 and PTPN12 genes may serve as 
novel candidates for CRC predisposition, albeit that given the genetic heterogeneity 
of this condition, further work is required to firmly establish their contribution to CRC 
development.
Since we also identified two patients with pathogenic BLM mutations by WES 
(chapter 2), the frequency of pathogenic BLM mutation carriers was further evaluated 
in chapter 3. Using targeted enrichment with molecular inversion probes, followed 
by MPS, the coding regions of the BLM locus were screened for the presence of 
pathogenic mutations in an additional cohort of 185 CRC patients (diagnosed before 
50 years of age) and 532 population-matched controls. In total, 3 additional CRC 
patients (1.6%) and one control individual (0.2%) were identified that carried a known 
pathogenic BLM mutation. These mutations were found to be enriched in early-onset 




























CRC patients in comparison to control cohorts. Together, these data indicate that 
carriers of deleterious BLM mutations are at an increased risk to develop CRC, albeit 
with a moderate-to-low penetrance. 
In chapter 4 a targeted MPS approach was employed to investigate whether CRC 
patients with biallelic MUTYH mutations could be identified that were not previously 
recognized due to the absence of a clear MUTYH-associated polyposis phenotype. To 
this end, the coding sequence of MUTYH was screened for the presence of pathogenic 
mutations in a cohort of 192 early-onset CRC patients without a clear suspicion of 
polyposis. Biallelic MUTYH mutations with a known pathogenicity were found in one 
individual, and an additional individual carried one pathogenic variant and a second 
variant, p.D161H, whose pathogenicity still has to be established. This work, among 
others, shows that patients that remain unrecognized in the clinic due to the absence 
of a pronounced polyposis phenotype can be identified by MPS. As such, MPS may be 
used as an unbiased tool to identify patients with known syndromes but ambiguous 
symptoms in heterogeneous disorders such as CRC.
In chapter 5 we focused on a putative role of the spindle assembly checkpoint protein 
BUBR1, which is encoded by BUB1B, in early-onset CRC predisposition. Previously, we 
and others have linked germline mutations in different components of the spindle 
assembly checkpoint to a predisposition to gastrointestinal neoplasms. In order to 
investigate whether mutations in BUB1B recurrently occur in early-onset CRC patients, 
we performed a targeted MPS screen similar to that reported in chapter 4. In doing 
so, two rare potentially damaging heterozygous variants, i.e., p.E390del and p.C945Y, 
were identified. Both variants do, however, not appear to affect interactions of BUBR1 
with other spindle assembly checkpoint proteins in vitro. Together, these data suggest 
that mutations in BUB1B may not play a major role in early-onset CRC.
Finally, in chapter 6 I discuss the implications of these results in CRC predisposition 
and provide suggestions for future work in this field. Based on the work presented in 
this thesis, and similar work reported by others, uncovering the anticipated remaining 
missing CRC heritability will be challenging. While this thesis illustrates the utility of 
MPS for the assessment and identification of mutations in known genes, such as the 
BLM and MUTYH genes, the application of MPS to CRC has also yielded many novel 
candidate gene mutations, and will most likely continue to do so, given the increasing 
efficiency and accessibility of MPS. In order to validate and confirm these candidate 
mutations in a heterogeneous condition such as CRC, an effective and integrative 
effort will be required. In chapter 6 I provide several suggestions on how this may 
be realized, especially based on comparisons with other (Mendelian) forms of cancer 




Here I would like to thank everybody that contributed and supported this work in the 
last 6 years. Having encountered so many people during this time it’s not possible to 
mention everybody that made this time special. Of course some people always remain 
more memorable than others, but should have forgotten to name you in person in 
the remainder of this section, I wish to thank you very much for the all the efforts and 
help you have put into this.
My first and foremost special gratitude go to my promotional team: roland, ad, 
richarda, and Marjolijn. This was by no means an easy undertaking; especially 
towards the end it was quite a struggle. The more I am grateful to you for making this 
promotion possible. Further I feel that you taught me a great deal. Here I also would 
like to thank you nicoline; unfortunately, there are only 4 seats in the promotion 
committee, but for sure all of you contributed a large share in this undertaking as well.
Of course I would also like to thank my colleagues from the tumour genetics research 
group for their support during all the years. Firstly in this respect I would like to thank 
my promotion helpers lilian and Junxiao for their help and collaborations during the 
years. Also Simon and Eveline, many thanks for the technical advice and chats in the 
lab. Surely life in the Nijmegen also would not have been the same without my other 
fellow promovendi robbert, Ingrid, Jiangien and ram- many thanks for the chats 
and all the fun. Stijn, it was great working with you as an intern and I wish you all 
the best with your own PhD. diederick, anke, Helle, armen, renske, Esme and 
Marcel it was great having you around to discuss technicalities and temporary sharing 
(office) spaces.
Futhermore this project would not have been possible without the help of people 
from other groups: Konny, ronny, Bart, Micheal, Hicham, Irene, Petra, Marcel, 
Bastiaan, and arjen- many thanks for all the help setting up the NGS and especially 
Ion torrent experiments- all those technical and related discussions were very helpful. 
Furthermore I would like to thank the BI people, especially Eugene, Christian, nienke, 
Maartje, Joep and Jayne for doing a tremendous job in the analysis of the NGS data. 
Further support essential to achieving this thesis came from Saskia (Cell culturing), 
Monique (Pathology) and neeltje (Diagnostics). Last but not least I would like to 
thank all the other people from Nijmegen for help, input and having a good time: 
including my roommates at the end of my stay in Nijmegen (rocio, Peer, Suzanne 
and the other busy people dropped in occasionally), all my colleagues from the 
genome research sections including Sensory Diseases (Mahesh, anna, Constantine, 
Bjorn, lisette, Stef, Kaman and others), Translational Genomics (lisenka, alex, 
Joris, Thessa and more), Neurobiology our Secretary team (Ineke, domenique and 















Jo, nick and more). Of course with this size of the department it’s impossible to name 
everybody that made Nijmegen a special place in person.
Another big thanks goes to Macrogen-Europe for the last two years. I feel that 
besides finishing a PhD I have learned a great deal at this place. Thanks Jihwang, 
Woon-ah, John and Hyungtae for giving me the opportunity to work with many 
different clients. Also thanks to my brothers and sisters in sales (former and current): 
remig, Svenja, yolanda, Jae-young, Mazen, Matthias, Mauri and Marco for 
making this a special time. Last but not least I would also like to thank my other 
colleagues in Europe: Seongyon, Geunhye, Heeyoung, Mikyung, Marta, yang, 
Gaonan, HeeJin, Maria, SungHee, JiHyun, SeungEun, Jiae, lisa, Goeun and 
Haneul. Likewise I would like to thank my Korean colleagues overseas (ryan, Bellbull, 
youngtae, Jennifer, Stacy, Kate) who I never met in person but who I could always 
bother with my questions.
Also the people that personally encouraged me during the past 6 years- thanks! An 
Tom, amanda, Melanie, Michaela, oma, meinen zwei opa’s, die leider nicht mehr 
hier dabei sein können und den geammten Rest meiner Familier: vielen Dank an dieser 
Stelle für Eure Unterstützung. alex und Sandy- es war toll das ihr auch Interesse an 
dieser Arbeit hattet, ich wünsche euch an dieser Stelle alles Gute für eure gemeinsame 
Zukunft. Ke (el chino) y Fabio gracias por han hecho mi vida un poco mas latino. Last 
but not least also thanks to Kenneth, avanita, dharjath and audrey, for sharing 




Hahn MM, De Voer RM, Hoogerbrugge N, Ligtenberg MJ, Kuiper RP, Geurts van 
Kessel A.
The Genetic Heterogeneity of Colorectal Cancer Predisposition - Guidelines for Gene 
Discovery
Submitted to Cell Oncol (Dordr).
Hahn MM, Vreede L, Bemelmans SASA, van der Looij E, Geurts van Kessel A, Schackert 
HK, Ligtenberg MJ, Hoogerbrugge N, Kuiper RP, De Voer RM.
Prevalence of Germline Mutations in the Spindle Assembly Checkpoint Gene BUB1B in 
Individuals with Early-onset Colorectal Cancer.
Resubmitted after revision to Genes Chromosomes Cancer.
De Voer RM*, Hahn MM*, Weren RD, Mensenkamp AR, Gilissen C, Van Zelst-Stams 
WA, Spruijt L, Kets CM, Zhang J, Venselaar H, Vreede L, Schubert N, Tychon M, Derks 
RC, Schackert HK, Geurts van Kessel A, Hoogerbrugge N, Ligtenberg MJ, Kuiper RP.
Identification of Novel Candidate Genes for Early-onset Colorectal Cancer Susceptibility.
PLoS Genet. 2016 Feb 22;12(2):e1005880.
 
De Voer RM*, Hahn MM*, Mensenkamp AR*, Hoischen A, Gilissen C, Henkes A, 
Spruijt L, van Zelst-Stams WA, Marleen Kets C, Verwiel ET, Nagtegaal ID, Schackert HK, 
van Kessel AG, Hoogerbrugge N, Ligtenberg MJ, Kuiper RP.
Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. 
Sci Rep. 2015 Sep 11;5:14060. 
Zhang JX, Fu L, de Voer RM, Hahn MM, Jin P, Lv CX, Verwiel ET, Ligtenberg MJ, 
Hoogerbrugge N, Kuiper RP, Sheng JQ, Geurts van Kessel A. 
Candidate colorectal cancer predisposing gene variants in Chinese early-onset and 
familial cases.
World J Gastroenterol. 2015 Apr 14;21(14):4136-49. 
De Voer RM, Geurts van Kessel A, Weren RD, Ligtenberg MJ, Smeets D, Fu L, Vreede 
L, Kamping EJ, Verwiel ET, Hahn MM, Ariaans M, Spruijt L, van Essen T, Houge G, 
Schackert HK, Sheng JQ, Venselaar H, van Ravenswaaij-Arts CM, van Krieken JH, 
Hoogerbrugge N, Kuiper RP.
Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are risk 
factors for colorectal cancer.
Gastroenterology. 2013 Sep;145(3):544-7. 
Zoll J, Hahn MM, Gielen P, Heus HA, Melchers WJ, van Kuppeveld FJ.
Unusual loop-sequence flexibility of the proximal RNA replication element in EMCV.
PLoS One. 2011;6(9):e24818. 
Haagsma AC, Driessen NN, Hahn MM, Lill H, Bald D.
ATP synthase in slow- and fast-growing mycobacteria is active in ATP synthesis and 
blocked in ATP hydrolysis direction.
FEMS Microbiol Lett. 2010 Dec;313(1):68-74. doi:10.1111/j.1574-6968.2010.02123.x. 
Epub 2010 Oct 7. 
Venkatachalam R, Ligtenberg MJ, Hoogerbrugge N, Schackert HK, Görgens H, Hahn 
MM, Kamping EJ, Vreede L, Hoenselaar E, van der Looij E, Goossens M, Churchman 
















Germline epigenetic silencing of the tumor suppressor gene PTPRJ in early-onset 
familial colorectal cancer. 
Gastroenterology. 2010 Dec;139(6):2221-4. 




Marc-Manuel Hahn was born on the 11th of July, 1985 in Saarbrücken, Germany. In 
2004 he graduated from high school at the European School in Luxembourg. Shortly 
afterwards he moved to Rheinbach in Germany to start his undergraduate studies at 
the University of Applied Sciences Bonn-Rhein-Sieg. While taking up an international 
double degree program at the Hogeschool of Arnhem and Nijmegen, he first came 
into the Netherlands in 2006. He graduated in 2007 with a BSc of Applied Biology 
from University of Applied Sciences Bonn-Rhein-Sieg and a Bachelor of Life Sciences 
from the Hogeschool Arnhem and Nijmegen. In August 2007 he moved to Amsterdam 
where he started a research master at the VU Amsterdam. He completed his MSc in 
Biomolecular Sciences with cum laude in February 2010. In May 2010 he started to 
pursue a PhD in the Cancer Genomics group at the Department of Human Genetics 
of the Radboud university medical center Nijmegen, The Netherlands. In June 2014 he 
started working as a sequencing application specialist at Macrogen Inc, in Amsterdam.
193
C
u
r
r
IC
u
lu
M
 v
IT
Ea
CurrICuluM vITEa

